DaVita (DVA) 10-K26 Feb 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2014	Jan. 30, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	DVA
Entity Registrant Name	DAVITA HEALTHCARE PARTNERS INC.
Entity Central Index Key	927066
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		215,800,000	214,800,000
Entity Public Float		$16.20	$15.50

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Patient service revenues	$8,868,338	$8,307,195	$7,351,902
Less: Provision for uncollectible accounts	-366,884	-293,546	-235,218
Net patient service revenues	8,501,454	8,013,649	7,116,684
Capitated revenues	3,261,288	2,987,315	481,336
Other revenues	1,032,364	763,086	588,260
Total net revenues	12,795,106	11,764,050	8,186,280
Operating expenses and charges:
Patient care costs and other costs	9,119,305	8,198,377	5,583,549
General and administrative	1,261,506	1,176,485	889,879
Depreciation and amortization	590,935	528,737	341,969
Provision for uncollectible accounts	14,453	4,852	4,339
Equity investment income	-23,234	-34,558	-16,377
Loss contingency reserve and other legal settlements	17,000	397,000	85,837
Contingent earn-out obligation adjustment		-56,977
Total operating expenses and charges	10,979,965	10,213,916	6,889,196
Operating income	1,815,141	1,550,134	1,297,084
Debt expense	-410,294	-429,943	-288,554
Debt refinancing charges	-97,548		-10,963
Other income, net	2,374	4,787	3,737
Income from continuing operations before income taxes	1,309,673	1,124,978	1,001,304
Income tax expense	446,343	381,013	359,845
Income from continuing operations	863,330	743,965	641,459
Discontinued operations:
Loss from operations of discontinued operations, net of tax		-139	-222
Gain on disposal of discontinued operations, net of tax		13,375
Net income	863,330	757,201	641,237
Less: Net income attributable to noncontrolling interests	-140,216	-123,755	-105,220
Net income	723,114	633,446	536,017
Earnings per share:
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$3.41	$2.95	$2.79
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$3.41	$3.02	$2.79
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$3.33	$2.89	$2.74
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$3.33	$2.95	$2.74
Weighted average shares for earnings per share:
Basic	212,301,827	209,939,364	192,035,878
Diluted	216,927,681	214,763,887	195,942,160
Amounts attributable to DaVita HealthCare Partners Inc.:
Income from continuing operations	723,114	620,197	536,236
Discontinued operations		13,249	-219
Net income	$723,114	$633,446	$536,017

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]
Net income	$863,330	$757,201	$641,237
Unrealized (losses) gain on interest rate swap and cap agreements:
Unrealized (losses) gain on interest rate swap and cap agreements	-10,059	169	-6,204
Reclassifications of net swap and cap agreements realized losses into net income	10,608	12,889	10,130
Unrealized gains on investments:
Unrealized gains on investments	238	2,300	1,541
Reclassification of net investment realized gains into net income	-207	-490	-75
Foreign currency translation adjustments	-22,952	-2,216	-1,205
Other comprehensive (losses) income	-22,372	12,652	4,187
Total comprehensive income (losses)	840,958	769,853	645,424
Less: Comprehensive income attributable to noncontrolling interests	-140,216	-123,755	-105,220
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$700,742	$646,098	$540,204

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
ASSETS
Cash and cash equivalents	$965,241	$946,249
Short-term investments	337,399	6,801
Accounts receivable, less allowance of $242,674 and $237,143	1,525,849	1,485,163
Inventories	136,085	88,805
Other receivables	400,916	349,090
Other current assets	186,842	176,414
Income tax receivable	83,839	10,315
Deferred income taxes	240,626	409,441
Total current assets	3,876,797	3,472,278
Property and equipment, net	2,469,099	2,189,411
Intangibles, net	1,949,498	2,024,373
Equity investments	65,637	40,686
Long-term investments	89,389	79,557
Other long-term assets	77,000	79,598
Goodwill	9,415,295	9,212,974
Total assets	17,942,715	17,098,877
LIABILITIES AND EQUITY
Accounts payable	445,453	435,465
Other liabilities	506,579	464,422
Accrued compensation and benefits	698,475	603,013
Medical payables	314,347	287,452
Loss contingency reserve	3,644	397,000
Current portion of long-term debt	120,154	274,697
Total current liabilities	2,088,652	2,462,049
Long-term debt	8,383,280	8,141,231
Other long-term liabilities	389,806	380,337
Deferred income taxes	890,701	812,419
Total liabilities	11,752,439	11,796,036
Commitments and contingencies
Noncontrolling interests subject to put provisions	829,965	697,300
Equity:
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)
Common stock ($0.001 par value, 450,000,000 shares authorized; 215,640,968 and 213,163,248 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively)	216	213
Additional paid-in capital	1,108,211	1,070,922
Retained earnings	4,087,103	3,363,989
Accumulated other comprehensive loss	-25,017	-2,645
Total DaVita HealthCare Partners Inc. shareholders' equity	5,170,513	4,432,479
Noncontrolling interests not subject to put provisions	189,798	173,062
Total equity	5,360,311	4,605,541
Total liabilities and equity	$17,942,715	$17,098,877

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$242,674	$237,143
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	215,640,968	213,163,248
Common stock, shares outstanding	215,640,968	213,163,248

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$863,330	$757,201	$641,237
Adjustments to reconcile net income to cash provided by operating activities:
Loss contingency accrual	17,000	397,000
Depreciation and amortization	590,935	528,119	343,908
Debt refinancing charges	97,548		10,963
Stock-based compensation expense	56,743	59,998	45,384
Tax benefits from stock award exercises	59,119	46,898	88,964
Excess tax benefits from stock award exercises	-45,271	-36,197	-62,036
Deferred income taxes	210,955	-25,380	43,765
Equity investment income, net	10,125	2,872	3,384
Other non-cash charges and losses on disposal of assets	39,274	-31,351	30,390
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable	-40,676	-59,640	-47,673
Inventories	-46,398	-8,971	4,052
Other receivables and other current assets	-61,674	-108,434	51,730
Other long-term assets	2,916	17,731	-1,775
Accounts payable	-2,956	16,666	40,878
Accrued compensation and benefits	97,261	38,368	18,476
Other current liabilities	83,590	78,817	11,083
Loss contingency reserve	-410,356
Income taxes	-60,475	33,499	-129,948
Other long-term liabilities	-1,583	66,145	19,029
Net cash provided by operating activities	1,459,407	1,773,341	1,100,848
Cash flows from investing activities:
Additions of property and equipment, net	-641,330	-617,597	-550,146
Acquisitions	-272,094	-310,394	-4,294,077
Proceeds from asset sales	8,791	62,258	3,559
Purchase of investments available-for-sale	-8,440	-12,445	-3,935
Purchase of investments held-to-maturity	-472,628	-1,039	-7,418
Proceeds from sale of investments available-for-sale	2,475	4,158	7,211
Proceeds from investments held-to-maturity	141,072	1,376	14,530
Purchase of intangible assets	-1,018	-2,391	-830
Purchase of equity investments	-35,382	-1,305	-1,352
Distributions received on equity investments	825	497	8
Net cash used in investing activities	-1,277,729	-876,882	-4,832,450
Cash flows from financing activities:
Borrowings	60,038,508	66,286,097	43,248,175
Payments on long-term debt, contingent earn-out obligations and other financing costs	-60,046,487	-66,723,385	-39,286,027
Deferred financing and debt redemption costs	-122,988	-719	-57,241
Distributions to noncontrolling interests	-149,339	-139,326	-113,504
Stock award exercises and other share issuances, net	19,500	16,423	6,647
Excess tax benefits from stock award exercises	45,271	36,197	62,036
Contributions from noncontrolling interests	64,655	36,996	37,395
Proceeds from sales of additional noncontrolling interests	3,777	8,295	1,664
Purchases from noncontrolling interests	-17,876	-3,569	-26,761
Net cash (used in) provided by financing activities	-164,979	-482,991	3,872,384
Effect of exchange rate changes on cash and cash equivalents	2,293	-967	-786
Net increase in cash and cash equivalents	18,992	412,501	139,996
Cash and cash equivalents at beginning of the year	946,249	533,748	393,752
Cash and cash equivalents at end of the year	$965,241	$946,249	$533,748

CONSOLIDATED_STATEMENTS_OF_EQU

CONSOLIDATED STATEMENTS OF EQUITY (USD $)	Total	Non- controlling Interests subject to put Provisions	Common stock	Additional paid-in capital	Retained earnings	Treasury stock	Accumulated other comprehensive income (loss)	Total	Non-controlling interests not subject to put provisions
In Thousands, except Share data, unless otherwise specified	Total	Non- controlling Interests subject to put Provisions	Common stock	Additional paid-in capital	Retained earnings	Treasury stock	Accumulated other comprehensive income (loss)	Total	Non-controlling interests not subject to put provisions
Beginning Balance at Dec. 31, 2011		$478,216	$270	$596,165	$3,195,818	($1,631,694)	($19,484)	$2,141,075	$127,050
Beginning Balance (in shares) at Dec. 31, 2011			269,725,000			-82,442,000
Comprehensive income:
Net income	641,237	66,456			536,017			536,017	38,764
Other comprehensive income	4,187						4,187	4,187
Stock purchase shares issued				4,311		4,011		8,322
Stock purchase shares issued (in shares)						203,000
Stock unit shares issued				-8,303		8,303
Stock unit shares issued (in shares)						419,000
Stock-settled SAR shares issued				-83,558		85,733		2,175
Stock-settled SAR shares issued (in shares)						4,332,000
Stock-based compensation expense				45,384				45,384
Excess tax benefits from stock awards exercised				62,036				62,036
Issuance of common stock associated with the HCP acquisition				684,161		371,311		1,055,472
Issuance of common stock associated with the HCP acquisition (in shares)						18,760,000
Assumption of noncontrolling interests associated with the HCP acquisition									29,850
Distributions to noncontrolling interests		-70,133							-43,371
Contributions from noncontrolling interests		26,371							11,024
Sales and assumptions of additional noncontrolling interests		20,124		1,064				1,064	2,432
Purchases from noncontrolling interests		-5,229		-20,694				-20,694	-838
Changes in fair value of noncontrolling interests		71,901		-71,901				-71,901
Held for sale reclassification		-7,014
Purchase accounting adjustment									-11,123
Ending Balance at Dec. 31, 2012		580,692	270	1,208,665	3,731,835	-1,162,336	-15,297	3,763,137	153,788
Ending Balance (in shares) at Dec. 31, 2012			269,725,000			-58,728,000
Comprehensive income:
Net income	757,201	78,215			633,446			633,446	45,540
Other comprehensive income	12,652						12,652	12,652
Stock purchase shares issued				12,817				12,817
Stock purchase shares issued (in shares)			238,000
Stock unit shares issued				-3,286		3,247		-39
Stock unit shares issued (in shares)			7,000			164,000
Stock-settled SAR shares issued				-29,025		28,561		-464
Stock-settled SAR shares issued (in shares)			313,000			1,444,000
Stock-based compensation expense				59,998				59,998
Excess tax benefits from stock awards exercised				36,197				36,197
Distributions to noncontrolling interests		-80,353							-58,973
Contributions from noncontrolling interests		22,053							14,943
Sales and assumptions of additional noncontrolling interests		23,642		-1,442				-1,442	10,770
Purchases from noncontrolling interests		-512		-3,119				-3,119	-147
Expiration of put option and other reclassification		-7,141							7,141
Changes in fair value of noncontrolling interests		80,704		-80,704				-80,704
Treasury stock retirement			-57	-129,179	-1,001,292	1,130,528
Treasury stock retirement (Shares)			-57,120,000			57,120,000
Ending Balance at Dec. 31, 2013	4,605,541	697,300	213	1,070,922	3,363,989		-2,645	4,432,479	173,062
Ending Balance (in shares) at Dec. 31, 2013	213,163,248		213,163,000
Comprehensive income:
Net income	863,330	88,425			723,114			723,114	51,791
Other comprehensive income	-22,372						-22,372	-22,372
Stock purchase shares issued				19,010				19,010
Stock purchase shares issued (in shares)			298,000
Stock unit shares issued			1	-28				-27
Stock unit shares issued (in shares)			304,000
Stock-settled SAR shares issued			2	-2
Stock-settled SAR shares issued (in shares)			1,876,000
Stock-based compensation expense				54,969				54,969
Excess tax benefits from stock awards exercised				45,271				45,271
Distributions to noncontrolling interests		-93,884							-55,455
Contributions from noncontrolling interests		41,876							22,779
Sales and assumptions of additional noncontrolling interests		25,220		355				355	4,165
Purchases from noncontrolling interests		-6,111		-5,357				-5,357	-6,544
Changes in fair value of noncontrolling interests		77,139		-77,139				-77,139
Other reclassification				210				210
Ending Balance at Dec. 31, 2014	$5,360,311	$829,965	$216	$1,108,211	$4,087,103		($25,017)	$5,170,513	$189,798
Ending Balance (in shares) at Dec. 31, 2014	215,640,968		215,641,000

Organization_and_summary_of_si

Organization and summary of significant accounting policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and summary of significant accounting policies	1	Organization and summary of significant accounting policies
	Organization
	DaVita HealthCare Partners Inc. operates two major divisions, Kidney Care and HealthCare Partners (HCP). Kidney Care is comprised of the Company’s U.S. dialysis and related lab services, our ancillary services and strategic initiatives, including our international operations, and our corporate support costs. The Company’s largest line of business is its U.S. dialysis and related lab services business, which operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals within the U.S. As of December 31, 2014, the Company operated or provided administrative services through a network of 2,179 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving approximately 173,000 patients. The Company’s HCP division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members primarily through capitation contracts with some of the nation’s leading health plans.
	As of December 31, 2014, the Company operated or provided administrative services to 91 outpatient dialysis centers located in ten countries outside of the U.S.
	The Company’s U.S. dialysis and related lab services business and HCP qualify as separately reportable segments and the Company’s other ancillary services and strategic initiatives, including its international operations, have been combined and disclosed in the other segments category.
	Basis of presentation
	These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita HealthCare Partners Inc. and its subsidiaries, partnerships and other entities in which it maintains a 100% or majority voting interest, another controlling financial interest, or of which it is considered the primary beneficiary (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Non-marketable equity investments are recorded under the equity or cost method of accounting based upon whether the Company has significant influence over the investee. For the Company’s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the Company’s international subsidiaries’ financial statements from their functional currencies into the Company’s reporting currency (USD). Prior year balances and amounts have been reclassified to conform to the current year presentation and retrospectively revised to reflect purchase accounting entries.
	The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary disclosures.
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.
	The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets including goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.
	Patient service net revenues and accounts receivable
	Patient service net revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and ancillary services provided to patients. A usual and customary fee schedule is maintained for the Company’s dialysis treatments and other patient services; however, actual collectible revenue is normally recognized at a discount from the fee schedule.
	Patient service revenues earned by HCP are recognized in the period services are provided, net of an estimated contractual allowance and are mainly attributable to primary care physician services and certain other specialty care services provided to patients.
	Revenues associated with Medicare and Medicaid programs are recognized based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient’s commercial health plan secondary coverage, or the patient. The Company’s reimbursements from Medicare are subject to certain variations under Medicare’s single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. The Company’s revenue recognition will depend upon its ability to effectively capture, document and bill for Medicare’s base payment rate as well as these other variable factors.
	Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company’s billing and collection processes that can result in denied claims for payments, and regulatory compliance matters.
	Commercial revenue recognition also involves significant estimating risks. With many larger, commercial insurers the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company’s centers. It is often not possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company’s usual and customary rates.
	Under Medicare’s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit.
	Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.
	The Company’s range of revenue estimating risk for the dialysis and related lab services segment is generally expected to be within 1% of its revenue. Changes in revenue estimates for prior periods are not material.
	Capitated revenue
	HCP capitated revenue
	The Company’s associated medical groups are licensed to contract with health maintenance organizations (HMOs), to provide physician services in California under capitation contracts, and to provide both hospital and physician services under global risk capitation contracts in Florida, Nevada and Arizona. HCP’s revenues consist primarily of fees for medical services provided by these medical group entities’ payments from capitated contracts with various HMOs and revenues under risk-sharing programs. Capitation revenue under HMO contracts is prepaid monthly based on the number of enrollees electing physicians affiliated with one of the medical group entities as their health care provider, regardless of the level of actual medical services utilized. Capitation revenue is reported as revenue in the month in which enrollees are entitled to receive health care. A portion of the capitation revenue pertaining to Medicare enrollees is subject to possible retroactive premium risk adjustments based on their individual acuity. Due to lack of sufficient data to project the amount of such retroactive adjustments, the Company records any corresponding retroactive revenues in the year of receipt.
	Depending on the applicable state regulation regarding global risk capitation, revenues may be received by the Company or by an independent hospital with which the Company contracts under various managed care-related administrative services agreements. In the Florida, Nevada and Arizona service markets, the global capitation revenue is recorded by the Company with the corresponding cost of medical care reported by the Company as patient care costs. In California, the Company receives professional capitation and either the health plan retains the capitated revenues in a shared risk pool or the independent hospitals receive the institutional capitation revenues. The revenues are used to pay medical claims for the related enrollees. The Company is entitled to any residual amounts and bears the risk of any deficits. In all cases, an estimate is made for the cost of medical services that have been incurred and where no medical claim has been received (IBNR).
	Under risk-sharing programs, the medical groups share in the risk for hospitalization services and earn additional incentive revenues or incur penalties based on the utilization of hospital services. Estimated shared-risk receivables from the HMOs are recorded based upon hospital utilization and associated costs incurred by assigned HMO enrollees, including an estimate of IBNR compared to budgeted funding. Differences between actual contract settlements and estimated receivables or payables are recorded in the year of final settlement. The medical groups also receive other incentive payments from health plans based on specified performance and quality criteria. These amounts are accrued when earned and the amounts can be reasonably estimated, and are included in HCP’s capitated revenues. HCP recently obtained a restricted Knox-Keene license in California, which now permits HCP to enter into contracts with health plans allowing it to recognize revenue in 2014 under global capitation arrangements for both professional and institutional services.
	Other capitated revenues
	One of the Company’s subsidiaries operates a Medicare Advantage ESRD Special Needs Plan in partnership with a payor that works with CMS to provide ESRD patients full service health care. The Company is at risk for all medical costs of the program in excess of the capitation payments.
	Other revenues
	Other revenues consist of the non-patient service revenues associated with the ancillary services and strategic initiatives, management and administrative support services that are provided to outpatient dialysis centers that the Company does not own or in which the Company owns a minority equity interest, retail pharmacies and medical consulting services. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interest. Management fees are principally determined as a percentage of the managed operations’ revenues or cash collections and in some cases an additional component based upon a percentage of operating income. Management fees are included in net revenues when earned and represent less than 1% of total consolidated operating revenues. Revenues related to medical consulting services are recognized in the period services are provided.
	Allowance for uncollectible accounts
	Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters. The Company’s policy is to write off any uncollectible accounts receivable balance only after all collection efforts have been exhausted or when write off is mandated by federal or state policies or required by certain payor contracts. It is also the Company’s policy to write off any accounts receivable balance associated with any payors or patients when the Company receives notification of a bankruptcy filing.
	Other income
	Other income includes interest income on cash investments and other non-operating gains from investment transactions.
	Cash and cash equivalents
	Cash equivalents are short-term highly liquid investments with maturities of three months or less at date of purchase.
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels by the manufacturer and data submission.
	Funds on deposit with a third party
	The Company has established a risk sharing arrangement with a California hospital, wherein the Company shares in any surplus or deficit. One of the terms of this agreement is the establishment of a segregated investment fund to ensure adequate cash to pay IBNR. The Company and the hospital monitor the reserve balance to maintain the adequacy of funds on deposit. The Company has $81,276 in such funds as of December 31, 2014, in other current assets on the consolidated balance sheet.
	Property and equipment
	Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 20 to 40 years; leasehold improvements, the shorter of their economic useful life or the expected lease term; and equipment and information systems, principally three to eight years. Disposition gains and losses are included in current operating expenses.
	Amortizable intangibles
	Amortizable intangible assets and liabilities include customer relationships, trade names, provider networks, supply agreements, practice management tools, non-competition and similar agreements, lease agreements, hospital acute services contracts and deferred debt financing costs, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: customer relationships, ten to twenty years; trade names, provider networks and practice management tools, two to fifteen years; non-competition and similar agreements, two to ten years; the alliance and product supply agreement, ten years; and lease agreements and hospital acute service contracts, over the term of the lease or contract period, respectively. Deferred debt financing costs are amortized to debt expense over the term of the related debt using the effective interest method.
	Investments
	Based upon the Company’s intentions and strategy concerning investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and measures them at amortized cost. The Company classifies equity securities that have readily determinable fair values and certain other debt securities as available for sale and measures them at fair value. Unrealized gains or losses from available for sale investments are recorded in other comprehensive income until realized.
	Goodwill
	Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed for valuation impairment as circumstances may warrant and at least annually. An impairment charge would be recorded to the extent the carrying amount of goodwill exceeds its implied fair value. The Company operates several reporting units for goodwill impairment assessments. See Note 10 to the consolidated financial statements for further details.
	Impairment of long-lived assets
	Long-lived assets, including property and equipment, equity investments in non-consolidated businesses and amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred, including changes in the Company’s business strategy and plans, changes in the quality or structure of its relationships with its partners or deteriorating operating performance of individual outpatient dialysis centers or other operations. An impairment is indicated when the sum of the expected future undiscounted net cash flows identifiable to an asset group is less than its carrying amount. Impairment losses are measured based upon the difference between the actual or estimated fair values, which are based on market values, net realizable values or projections of discounted net cash flows, as appropriate, and the carrying amount of the asset. Impairment charges are included in operating expenses. Indefinite-lived intangible assets are reviewed for possible impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred.
	Self insurance
	The Company’s Kidney Care division maintains insurance reserves for professional and general liability and workers’ compensation in excess of certain individual and or aggregate amounts not covered by third-party carriers. The Company’s Kidney Care division estimates the self-insured retention portion of professional and general liability and workers’ compensation risks using third-party actuarial calculations that are based upon historical claims experience and expectations for future claims. In addition, HCP has purchased its primary professional and general liability insurance from California Medical Group Insurance (CMGI) in which the Company owns an equity interest of 67%.
	Medical liability costs
	The medical groups are responsible for integrated care that the associated physicians and contracted hospitals provide to assigned HMO enrollees. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as patient care costs in the consolidated statements of income. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in patient care costs.
	An estimate of amounts due to contracted physicians, hospitals, and other professional providers for members under global and professional risk arrangements is included in medical payables in the accompanying consolidated balance sheets. Medical payables include claims reported as of the balance sheet date and estimates of IBNR. Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are continually reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. Any adjustments to reserves are reflected in current operations.
	Income taxes
	Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.
	The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.
	Stock-based compensation
	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. Stock-based compensation to be settled in shares is recorded to the Company’s shareholders’ equity, while stock-based compensation to be settled in cash is recorded to a liability.
	Interest rate swap and cap agreements
	The Company has several interest rate swap agreements as a means of hedging its exposure to and volatility from LIBOR variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are designated as cash flow hedges and are not held for trading or speculative purposes. The swap agreements have the economic effect of converting the majority of the LIBOR variable component of the Company’s interest rate to fixed rates on the Company’s Term Loan A outstanding balances. In addition, the Company has several interest rate cap agreements that have the economic effect of capping the Company’s maximum exposure to LIBOR variable interest rate changes on specific portions of the Company’s Term Loan B totaling $2,735,000. The Company also maintains several forward interest rate cap agreements with notional amounts totaling $3,500,000 that will be effective September 30, 2016 and will have economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent of the Company’s debt. See Note 14 to the consolidated financial statements for further details.
	Noncontrolling interests
	Noncontrolling interests represent third-party minority equity ownership interests in consolidated entities which are majority-owned by the Company, as well as the equity ownership interests in entities that are not owned by the Company but which are consolidated for financial statement reporting purposes. As of December 31, 2014, third parties held noncontrolling ownership interests in approximately 380 consolidated legal entities.
	Fair value estimates
The Company currently measures the fair value of certain assets, liabilities (including contingent earn-out consideration) and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable market inputs and assumptions that market participants would use in pricing these assets, liabilities and temporary equity. The Company has also classified its assets, liabilities and temporary equity into the appropriate fair value hierarchy levels as defined by the FASB. See Note 24 to the consolidated financial statements for further details.
New accounting standards
On January 1, 2013, the Company adopted the Financial Accounting Standards Boards (FASB) ASU No. 2013-02 Comprehensive Income. This standard requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. See Note 20 to the consolidated financial statements for further details.
In July 2013, the FASB issued ASU No. 2013-10, Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. This standard amends the acceptable benchmark interest rates to permit the inclusion of the Fed Funds Effective Swap Rate (OIS) to be used as a U.S. benchmark interest rate for hedge accounting purposes in addition to U.S. government (UST) and LIBOR. The amendment also removes the restriction on using different benchmark rates for similar hedges. This standard is applied prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements.
In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Earnings_per_share

Earnings per share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings per share	2	Earnings per share
	Basic net income per share is calculated by dividing net income attributable to the Company adjusted for any change in noncontrolling interest redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding, net of shares held in escrow that under certain circumstances may be returned to the Company.
	Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights (SSARs), stock options and unvested stock units (under the treasury stock method) as well as shares held in escrow that the Company expects will remain outstanding.
	The reconciliations of the numerators and denominators used to calculate basic and diluted net income per share are as follows:

			Year ended December 31,
			2014			2013			2012
			(shares in thousands)
	Basic:
	Income from continuing operations attributable to DaVita HealthCare		$	723,114		$	620,197		$	536,236
	Partners Inc.
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			13,249			(219	)
	Net income attributable to DaVita HealthCare Partners Inc. for basic		$	723,114		$	633,446		$	536,017
	earnings per share calculation
	Weighted average shares outstanding during the period			214,496			212,128			192,396
	Vested stock units			—			5			6
	Contingently returnable shares held in escrow for the DaVita HealthCare			(2,194	)		(2,194	)		(366	)
	Partners merger
	Weighted average shares for basic earnings per share calculation			212,302			209,939			192,036
	Basic income from continuing operations per share attributable to		$	3.41		$	2.95		$	2.79
	DaVita HealthCare Partners Inc.
	Basic income from discontinued operations per share attributable			—			0.07			—
	to DaVita HealthCare Partners Inc.
	Basic net income per share attributable to DaVita HealthCare		$	3.41		$	3.02		$	2.79
	Partners Inc.
	Diluted:
	Income from continuing operations attributable to DaVita		$	723,114		$	620,197		$	536,236
	HealthCare Partners Inc.
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			13,249			(219	)
	Net income attributable to DaVita HealthCare Partners Inc. for		$	723,114		$	633,446		$	536,017
	diluted earnings per share calculation
	Weighted average shares outstanding during the period			214,496			212,128			192,396
	Vested stock units			—			5			6
	Assumed incremental shares from stock plans			2,432			2,631			3,540
	Weighted average shares for diluted earnings per share calculation			216,928			214,764			195,942
	Diluted income from continuing operations per share attributable		$	3.33		$	2.89		$	2.74
	to DaVita HealthCare Partners Inc.
	Diluted income from discontinued operations per share attributable to			—			0.06			—
	DaVita HealthCare Partners Inc.
	Diluted net income per share attributable to DaVita HealthCare		$	3.33		$	2.95		$	2.74
	Partners Inc.
	Anti-dilutive stock-settled awards excluded from calculation(1)			1,715			4,194			2,616

	-1	Shares associated with stock-settled stock appreciation rights and stock options excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts_receivable

Accounts receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable	3	Accounts receivable
	Approximately 12% and 14% of the Company’s accounts receivable balances as of December 31, 2014 and 2013, respectively, were more than six months old, and there were no significant balances over one year old. Accounts receivable are principally from Medicare and Medicaid programs and commercial insurance plans.
	Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of its accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to it to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1% of the Company’s net accounts receivable are associated with patient pay and it is the Company’s policy to reserve 100% of the outstanding accounts receivable balances for dialysis services when those amounts due are outstanding for more than four months.
	During the year ended December 31, 2014, the Company’s allowance for doubtful accounts increased by $5,531. The increase in 2014 was primarily due to an increase in the provision for uncollectible accounts due to an increase in the write-offs of Medicare secondary billings. During the year ended December 31, 2013, the Company’s allowance for doubtful accounts decreased by $7,979. The decrease in 2013 was primarily due to an increase in the timing of non-covered Medicare write-offs during the period in the Company’s U.S. dialysis business. There were no unusual non-acquisition transactions impacting the allowance for doubtful accounts.

Other_receivables

Other receivables	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Other receivables	4	Other receivables
	Other receivables were comprised of the following:

			December 31,
			2014		2013
	Supplier rebates and non-trade receivables		$	265,693	$	217,100
	Medicare bad debt claims			118,504		110,825
	Operating advances under management and administrative			16,719		21,165
	services agreements
			$	400,916	$	349,090

	Operating advances under management and administrative services agreements are generally unsecured.

Other_current_assets

Other current assets	12 Months Ended
Other current assets	Dec. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other current assets	5	Other current assets
	Other current assets consist principally of prepaid expenses and funds on deposit with third parties.

			December 31,
			2014		2013
	Prepaid expenses		$	102,466	$	93,877
	Funds on deposit with third parties			81,276		79,317
	Other			3,100		3,220
			$	186,842	$	176,414

Property_and_equipment

Property and equipment	12 Months Ended
Property and equipment	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property and equipment	6	Property and equipment
	Property and equipment were comprised of the following:

			December 31,
			2014			2013
	Land		$	35,885		$	34,960
	Buildings			157,550			157,998
	Leasehold improvements			2,002,735			1,762,470
	Equipment and information systems			2,066,775			1,839,981
	New center and capital asset projects in progress			235,660			172,261
				4,498,605			3,967,670
	Less accumulated depreciation			(2,029,506	)		(1,778,259	)
			$	2,469,099		$	2,189,411

	Depreciation expense on property and equipment was $428,309, $373,107 and $299,810 for 2014, 2013 and 2012, respectively.
	Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $7,888, $6,408 and $8,126 for 2014, 2013 and 2012, respectively.

Intangibles

Intangibles	12 Months Ended
Intangibles	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Intangibles	7	Intangibles
	Intangible assets were comprised of the following:

			December 31,
			2014			2013
	Customer relationships		$	1,575,865		$	1,503,426
	Trade names			171,168			170,994
	Provider network and practice management tools			183,688			184,558
	Noncompetition and other agreements			506,867			495,475
	Lease agreements			7,982			8,889
	Deferred debt financing costs			101,001			121,872
	Indefinite-lived assets			24,818			22,932
				2,571,389			2,508,146
	Less accumulated amortization			(621,891	)		(483,773	)
	Total intangible assets		$	1,949,498		$	2,024,373

	Amortization expense from amortizable intangible assets, other than lease agreements and deferred debt financing costs, was $167,956, $160,960 and $47,489 for 2014, 2013 and 2012, respectively. Deferred debt financing costs were amortized to debt expense as described in Note 14 to these consolidated financial statements. Lease agreement intangible assets and liabilities were amortized to rent expense in the amounts of $(1,798), $(1,447) and $103 for 2014, 2013 and 2012, respectively.
	Amortizable intangible liabilities were comprised of the following:

			December 31,
			2014			2013
	Alliance and product supply agreement commitment		$	68,200		$	68,200
	(See Note 18)		$	68,200		$	68,200
	Less accumulated amortization			(64,203	)		(58,873	)
	Net Alliance and product supply agreement			3,997			9,327
	Lease agreements (net of accumulated amortization of $4,785			10,407			12,563
	and $2,628)			10,407			12,563
			$	14,404		$	21,890

	Amortization benefit recognized from the alliance and product supply agreement was $5,330 each for 2014, 2013 and 2012, respectively. Lease agreement intangible liabilities are classified in other long-term liabilities and amortized to rent expense.
	Scheduled amortization charges from amortizable intangible assets and liabilities as of December 31, 2014 were as follows:

			Customer			Trade			Provider		Noncompetition		Lease			Deferred		Alliance and
			relationships			names			network and		and other		agreements, net			debt		product
									practice		agreements					financing		supply
									management							costs		agreement
									tools									liability
	2015			82,619			16,429			26,229		40,482		(2,107	)		13,279		(3,997	)
	2016			82,704			16,429			26,179		30,172		(1,506	)		13,129		—
	2017			82,686			16,418			26,243		28,563		(1,185	)		12,976		—
	2018			82,640			16,364			26,266		18,429		(849	)		12,683		—
	2019			82,407			16,364			22,542		13,984		(789	)		10,636		—
	Thereafter			991,862			53,961			526		39,242		(3,971	)		22,237		—

Equity_investments_and_other_i

Equity investments and other investments	12 Months Ended
	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Equity investments and other investments	8	Equity investments and other investments
	Equity investments in non-consolidated businesses were $65,637 and $40,686 at December 31, 2014 and 2013, respectively. During 2014, 2013 and 2012, the Company recognized income of $23,234, $34,558 and $16,377, respectively, relating to equity investments in non-consolidated businesses under the equity method of accounting. In 2014 and 2013, the Company’s equity method investment income included $9,480 and $22,758, respectively, of equity income from HCP’s equity investments. During 2013, the Company purchased $5,000 of preferred stock in a privately held company that is accounted for under the cost method as this investment does not have a readily determinable fair value.

Investments_in_debt_and_equity

Investments in debt and equity securities	12 Months Ended
Investments in debt and equity securities	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Investments in debt and equity securities	9	Investments in debt and equity securities
	Based on the Company’s intentions and strategy concerning investments in debt securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values including those of mutual funds and other debt securities are classified as available for sale and recorded at fair value.
	The Company’s investments in securities consist of the following:

			31-Dec-14						31-Dec-13
			Held to		Available		Total		Held to		Available		Total
			maturity		for sale		Total		maturity		for sale		Total
	Certificates of deposit and money market funds due		$	335,975	$	—	$	335,975	$	5,601	$	—	$	5,601
	within one year		$	335,975	$	—	$	335,975	$	5,601	$	—	$	5,601
	Investments in mutual funds and common stock			—		28,123		28,123		—		19,421		19,421
			$	335,975	$	28,123	$	364,098	$	5,601	$	19,421	$	25,022
	Short-term investments		$	335,975	$	1,424	$	337,399	$	5,601	$	1,200	$	6,801
	Long-term investments			—		26,699		26,699		—		18,221		18,221
			$	335,975	$	28,123	$	364,098	$	5,601	$	19,421	$	25,022

	The cost of certificates of deposit and money market funds at December 31, 2014 and 2013 approximate their fair value. As of December 31, 2014 and 2013, available for sale investments included $5,181 and $5,096, respectively, of gross pre-tax unrealized gains. During 2014 and 2013 the Company recorded gross pre-tax unrealized gains of $425 and $3,752, respectively, in other comprehensive income associated with changes in the fair value of these investments. During 2014, the Company sold investments in mutual funds for net proceeds of $1,262, and recognized a pre-tax gain of $340, or $207 after tax, that was previously recorded in other comprehensive income. During 2013, the Company sold investments in mutual funds for net proceeds of $4,158, and recognized a pre-tax gain of $802, or $490 after tax, that was previously recorded in other comprehensive income.
	Investments in mutual funds classified as available for sale are held within a trust to fund existing obligations associated with several of the Company’s non-qualified deferred compensation plans.

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	10	Goodwill
	Changes in the value of goodwill by reportable segments were as follows:

			U.S. dialysis and			HCP			Other ancillary			Consolidated total
			related lab services						services and
									strategic initiatives
	Balance at January 1, 2013		$	5,309,152		$	3,506,571		$	137,027		$	8,952,750
	Acquisitions			163,037			17,833			90,397		$	271,267
	Divestitures			(2,728	)		—			—		$	(2,728	)
	Other adjustments			12			(8,242	)		(85	)	$	(8,315	)
	Balance at December 31, 2013		$	5,469,473		$	3,516,162		$	227,339		$	9,212,974
	Acquisitions			143,021			48,649			29,844		$	221,514
	Divestitures			(1,851	)		—			—		$	(1,851	)
	Foreign currency and other adjustments			—			(2,277	)		(15,065	)	$	(17,342	)
	Balance at December 31, 2014		$	5,610,643		$	3,562,534		$	242,118		$	9,415,295

	Each of the Company’s operating segments described in Note 25 to these consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within our international operating segments is considered a separate reporting unit.
	Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.
	The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company’s additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units.
	HCP’s current and expected future operating results have eroded, primarily as a result of recent reductions in its Medicare Advantage reimbursement rates. As a result, the Company has determined that three of HCP’s reporting units, HCP California, HCP Nevada and HCP New Mexico, continue to be at risk of a goodwill impairment. HCP California, HCP Nevada and HCP New Mexico have goodwill of $2,511,477, $517,618, and $72,130, respectively.
	The Company’s annual goodwill impairment assessment date for its HCP reporting units is November 1. The Company obtained third-party valuations of these three businesses as of November 1, 2014, noting that the estimated fair values of HCP California, HCP Nevada and HCP New Mexico exceeded their total carrying values by approximately 5.6%, 12.4% and 9.7%, respectively. There were no major changes in the business, prospects, or expected future results of these HCP reporting units from November 1 to December 31, 2014. Further reductions in HCP’s reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future.
	For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 2.5%, 2.8% and 3.0%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 5.3%, 5.9% and 6.3%, respectively.
	During 2014, the Company recorded an immaterial goodwill impairment charge related to its international operations. During 2013, the Company did not record any goodwill impairment charges. Except as described above, none of the goodwill associated with the Company’s various other reporting units was considered at risk of impairment as of December 31, 2014. Since the dates of the Company’s last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company’s businesses. However, these did not cause management to believe it is more likely than not that the fair value of any of its reporting units would be less than its carrying amount.

Other_liabilities

Other liabilities	12 Months Ended
Other liabilities	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Other liabilities	11	Other liabilities
	Other liabilities were comprised of the following:

			December 31,
			2014		2013
	Payor refunds and retractions		$	125,435	$	169,480
	Contingent earn-out consideration			15,614		6,577
	Insurance and self-insurance accruals			92,928		84,882
	Accrued interest			87,224		45,662
	Other medical payables			39,867		31,219
	Accrued non-income tax liabilities			25,909		18,366
	Interest rate swap agreements			1,457		12,069
	Other			118,145		96,167
			$	506,579	$	464,422

Medical_payables

Medical payables	12 Months Ended
Medical payables	Dec. 31, 2014
Health Care Organizations [Abstract]
Medical payables	12	Medical payables
	The health care costs shown in the following table include estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs for all markets, other than California, where state regulation allows for the assumption of global risk. Health care costs payable are included in medical payables.
	The following table shows the components of changes in the health care costs payable for the year ended December 31, 2014 and 2013:

			December 31,
			2014		2013
	Health care costs payable, beginning of the year		$	172,310	$	119,512
	Acquisitions and other adjustments			—		26,575
	Add: Components of incurred health care costs
	Current year			1,572,723		1,329,887
	Prior years			3,429		(16,587	)
	Total incurred health care costs			1,576,152		1,313,300
	Less: Claims paid
	Current year			1,378,137		1,169,455
	Prior years			155,920		117,622
	Total claims paid			1,534,057		1,287,077
	Health care costs payable, end of the year		$	214,405	$	172,310

	The Company’s prior year estimates of health care costs payable increased (decreased) by $3,429 in 2014 and $(16,587) in 2013, respectively. The increase in 2014 resulted from certain medical claims being settled for amounts more than originally estimated. When significant (decreases) increases in prior-year health care cost estimates occur that the Company believes significantly impacts its current year operating results, the Company discloses that amount as (favorable) unfavorable development of prior-year’s health care cost estimates. Actual claim payments for prior year services have not been materially different from the Company’s year-end estimates.

Income_taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income taxes	13	Income taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
	Income tax expense (benefit) consisted of the following:

			Year ended December 31,
			2014				2013			2012
	Current:
	Federal		$	188,302			$	334,258		$	239,232
	State			30,789				68,715			49,178
	International			1,687				1,764			660
	Total current income tax		$	220,778			$	404,737		$	289,070
	Deferred:
	Federal			192,267				(6,695	)		64,195
	State			32,360				(8,941	)		6,498
	International			938				746			—
	Total deferred income tax		$	225,565			$	(14,890	)	$	70,693
			$	446,343			$	389,847		$	359,763

	The allocation of income tax expense (benefit) was as follows:

			Year ended December 31,
			2014				2013			2012
	Continuing operations		$	446,343			$	381,013		$	359,845
	Discontinued operations			—				(84	)		(82	)
	Gain on discontinued operations			—				8,918			—
			$	446,343			$	389,847		$	359,763

	The reconciliation between the Company’s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:

			Year ended December 31,
			2014				2013			2012
	Federal income tax rate			35	%			35	%		35	%
	State income taxes, net of federal benefit			3.5				3.8			4
	International rate differential			(0.2	)			0.1			—
	Changes in deferred tax valuation allowances			0.6				0.3			—
	Contingent earn-out adjustments			—				(2.6	)		—
	Other			(0.8	)			1.4			1.1
	Impact of noncontrolling interests primarily attributable to non-tax paying entities			(4.0	)			(4.1	)		(4.2	)
	Effective tax rate			34.1	%			33.9	%		35.9	%

	The Company has not recognized any deferred taxes for the undistributed earnings of its foreign subsidiaries because the Company currently expects those earnings to be permanently reinvested. Determination of the amount of unrecognized deferred taxes related to undistributed earnings of foreign subsidiaries is not practicable because such liability, if any, is dependent on circumstances that will exist if and when remittance occurs.
	Deferred tax assets and liabilities arising from temporary differences associated with continuing operations were as follows:

			December 31,
			2014				2013
	Receivables		$	42,973			$	49,667
	Accrued liabilities			253,158				252,008
	Loss contingency reserve			1,423				139,844
	Net operating loss carryforwards			100,768				96,212
	Other			88,435				67,882
	Deferred tax assets			486,757				605,613
	Valuation allowance			(26,667	)			(13,860	)
	Net deferred tax assets			460,090				591,753
	Intangible assets			(835,816	)			(752,838	)
	Property and equipment			(187,054	)			(183,059	)
	Investments in partnerships			(78,618	)			(51,921	)
	Other			(8,677	)			(6,913	)
	Deferred tax liabilities			(1,110,165	)			(994,731	)
	Net deferred tax liabilities		$	(650,075	)		$	(402,978	)

	At December 31, 2014, the Company had federal net operating loss carryforwards of approximately $203,282 that expire through 2034, although a substantial amount expire by 2028. The Company also had state net operating loss carryforwards of $568,286 that expire through 2034 and international net operating loss carryforwards of $55,436, some of which have an indefinite life. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. The valuation allowance increase of $12,807 is primarily due to the realizability of losses in certain foreign and state jurisdictions.
	Unrecognized tax benefits
	A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold were as follows:

		Year ended December 31,
			2014				2013
Balance beginning		$	60,538			$	67,546
Additions for tax positions related to current year			914				6,005
Reductions for tax positions related to prior years			(27,312	)			(3,901	)
Reductions related to lapse of applicable statute			(2,077	)			(8,480	)
Reductions related to settlements with taxing authorities			(186	)			(632	)
Balance ending		$	31,877			$	60,538

As of December 31, 2014, the Company’s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $31,877, all of which would impact the Company’s effective tax rate if recognized. This balance represents a decrease of $28,661 from the December 31, 2013 balance of $60,538, of which $27,427 is due to a change of accounting method for income tax reporting and did not impact the Company’s effective tax rate.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At December 31, 2014 and 2013, the Company had approximately $10,123 and $10,742, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.
The Company and its subsidiaries file U.S. federal and state income tax returns and various international income tax returns. The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2011 and 2008, respectively.

Longterm_debt

Long-term debt	12 Months Ended
Long-term debt	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term debt	14	Long-term debt
	Long-term debt was comprised of the following:

			December 31,
			2014				2013
	Senior Secured Credit Facilities:
	Term Loan A		$	975,000			$	800,000
	Term Loan A-3			—				1,282,500
	Term Loan B			3,482,500				1,697,500
	Term Loan B-2			—				1,633,500
	Senior notes			3,775,000				2,800,000
	Acquisition obligations and other notes payable			69,045				67,352
	Capital lease obligations			218,097				152,751
	Total debt principal outstanding			8,519,642				8,433,603
	Discount on long-term debt			(16,208	)			(17,675	)
				8,503,434				8,415,928
	Less current portion			(120,154	)			(274,697	)
			$	8,383,280			$	8,141,231

	Scheduled maturities of long-term debt at December 31, 2014 were as follows:

	2015			120,154
	2016			117,193
	2017			144,161
	2018			155,750
	2019			730,084
	Thereafter			7,252,300

	Term Loans
	Total outstanding borrowings under Term Loan A and Term Loan B can consist of various individual tranches that can range in maturity from one month to twelve months (currently all tranches are one month in duration). Each tranche for the Term Loan A bears interest at a London Interbank Offered Rate (LIBOR) rate determined by the duration of such tranche plus an interest rate margin, currently 1.75%. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. At December 31, 2014, the overall weighted average interest rate for the Term Loan A was determined based upon the LIBOR interest rates in effect for all of the individual tranches plus the interest rate margin. The Company has several interest rate swap agreements that have the economic effect of fixing the majority of the Term Loan A LIBOR variable component of the Company’s interest rate, as described below. At December 31, 2014, the Term Loan B bears interest at LIBOR (floor of 0.75%) plus a margin of 2.75%. The Company is subject to a LIBOR-based floor until such time as the LIBOR-based component of the interest rate exceeds 0.75% on the Term Loan B. At such time, the Company will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of its interest rate and the overall weighted average interest rate for the Term Loan B will then be determined based upon the LIBOR interest rates in effect for all individual tranches plus the interest rate margin. The Company has several interest rate cap agreements that have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 2.50% on $2,735,000 of outstanding principal debt. The remaining $747,500 outstanding principal balance of the Term Loan B would still be subject to LIBOR-based interest rate volatility above a floor of 0.75%. In addition, the Company maintains several forward interest rate cap agreements with notional amounts totaling $3,500,000 that will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of the Company’s debt. See below for further details.
	During the year ended December 31, 2014, the Company made mandatory principal payments under its then existing Senior Secured Credit Facilities (before entering into a new senior secured credit agreement and repaying all outstanding amounts under the then existing Senior Secured Credit Facilities, as discussed below) totaling $37,500 on the Term Loan A, $16,875 on the Term Loan A-3, $4,375 on the Term Loan B and $4,125 on the Term Loan B-2. During the third and fourth quarters of 2014, the Company made mandatory principal payments under its New Senior Secured Credit Facility (the New Credit Agreement), as described below, totaling $25,000 on the New Term Loan A and $17,500 on the New Term Loan B.
	In 2013, the Company made principal payments totaling $100,000 on the Term Loan A, $67,500 on the Term Loan A-3, $17,500 on the Term Loan B and $16,500 on the Term Loan B-2.
	Revolving lines of credit
	The Company has an undrawn revolving line under the Senior Secured Credit Facilities totaling $1,000,000, of which approximately $95,000 was committed for outstanding letters of credit. In addition, the Company has approximately $1,000 of committed outstanding letters of credit related to HCP, which is backed by a certificate of deposit.
	Senior Notes
	The Company’s senior notes as of December 31, 2014 , consisted of $1,750,000 5 1/8% senior notes due 2024, as described below, $775,000 of 6 5/8% senior notes due 2020 and $1,250,000 of 5 3/4% senior notes due 2022.
	In addition, the $775,000 6⅝% senior notes and the $1,250,000 5¾% senior notes are also unsecured obligations and will rank equally in right of payment with the Company’s existing and future unsecured senior indebtedness. These senior notes are guaranteed by substantially all of the Company’s direct and indirect wholly-owned domestic subsidiaries and require semi-annual interest payments. The Company may redeem some or all of the senior notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement.
	Senior Secured Credit Facility, 51/8% Senior Notes and 6 ⅜% Senior Notes
	In June 2014, the Company entered into a $5,500,000 senior secured credit agreement. The New Credit Agreement consists of a five year Revolving Credit Facility in the aggregate principal amount of $1,000,000 (the New Revolver), a five year Term Loan A facility in the aggregate principal amount of $1,000,000 (the New Term Loan A) and a seven year Term Loan B facility in the aggregate principal amount of $3,500,000 (the New Term Loan B and collectively with the New Revolver and the New Term Loan A, the New Loans). In addition, the Company can increase the existing revolving commitments and enter into one or more incremental term loan facilities in an amount not to exceed the sum of $1,500,000 (less the amount of other permitted indebtedness incurred or issued in reliance on such amount), plus an amount of indebtedness such that the senior secured leverage ratio is not in excess of 3.50 to 1.00 after giving effect to such borrowings. The New Revolver and the New Term Loan A initially bear interest at LIBOR plus an interest rate margin of 1.75% which is subject to adjustment depending upon the Company’s leverage ratio and can range from 1.50% to 2.00%. The New Term Loan A requires annual principal payments which began on September 30, 2014 of $25,000 in 2014, $50,000 in 2015, $62,500 in 2016, $87,500 in 2017, and $100,000 in 2018 with the balance of $675,000 due in 2019. The New Term Loan B bears interest at LIBOR (Floor of 0.75%) plus an interest rate margin of 2.75%. The New Term Loan B requires annual principal payments of $17,500 in 2014, and $35,000 for each year from 2015 through 2020, with the balance of $3,272,500 due in 2021. These New Loans under the New Credit Agreement are guaranteed by certain of the Company’s direct and indirect wholly-owned domestic subsidiaries holding most of the Company’s domestic assets and are secured by substantially all of DaVita HealthCare Partners Inc.’s and the guarantors’ assets. The New Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on the amount of investments, acquisitions, the payment of dividends and redemptions and the incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company’s leverage ratio is below 3.50 to 1.00. In addition, the New Credit Agreement places limitations on the amount of tangible net assets of the non-guarantor subsidiaries and also requires compliance with a maximum leverage ratio covenant.
	In addition, in June 2014, the Company issued $1,750,000 5 1/8% Senior Notes due 2024 (the 5 1/8% Senior Notes). The 5 1/8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015. The 5 1/8% Senior Notes are unsecured obligations and will rank equally in right of payment with our existing and future unsecured senior indebtedness. The 5 1/8% Senior Notes are guaranteed by each of the Company’s domestic subsidiaries that guarantees our New Credit Agreement. The Company may redeem up to 35% of the 5 1/8% Senior Notes at any time prior to July 15, 2017 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem the 5 1/8% Senior Notes at any time prior to July 15, 2019 at make whole redemption prices and after such date at certain specified redemption prices.
	The Company received total proceeds from these borrowings of $6,250,000, $4,500,000 from the issuance of the New Term Loans and $1,750,000 from the issuance of the 5 1/8% Senior Notes. The Company used a portion of the proceeds to pay off the total outstanding principal balances under the Company’s then existing Senior Secured Credit Facilities plus accrued interest totaling $5,362,400 and in addition, to purchase pursuant to a cash tender offer $483,100 of the outstanding principal balances of the Company’s $775,000 6 3/8% Senior Notes plus accrued interest and cash tender premium totaling $512,400. The total amount paid for the 6 3/8% Senior Notes from the cash tender offer was $1,051.25 per 1,000 of principal amount which resulted in the Company paying a cash tender premium of $24,800 for the redemption of this portion of the 6 3/8% Senior Notes. The Company also incurred an additional $81,600 in fees, discounts and other professional expenses associated with these transactions.
	In July 2014, the Company also purchased an additional $188 principal amount of the 6 3/8% Senior Notes plus accrued interest totaling $194 pursuant to the cash tender offer at a price of $1,021.25 per 1,000 of principal amount of the 6 3/8% Senior Notes, which resulted in the Company paying an additional cash tender premium of $4.
	In addition, in July 2014, the Company redeemed the remaining outstanding principal balance of the 6 3/8% Senior Notes of $291,719 at a redemption price of $1,047.81 per 1,000 of principal amount of the 6 3/8% Senior Notes plus accrued interest and a redemption premium which totaled $309,954. This resulted in an additional redemption premium of $13,947 being recorded as debt refinancing charges.
	In addition, the Company terminated $1,137,500 notional amounts of amortizing swaps and also terminated $600,000 of forward swaps during June 2014, that resulted in the Company recognizing a loss of $3,100, of which $3,000 was previously recorded in other comprehensive income due to our previously outstanding principal debt being paid-off as described above, and as a result of future forecasted transactions that are no longer probable. The loss is included as a component of the Company’s debt refinancing charges. During the year ended December 31, 2014, the Company recognized debt expense of $6,100 from these swaps.
	As a result of these transactions, the Company recorded debt refinancing charges of $97,500 that consist of the cash tender premiums, the redemption premium, the write-off of existing deferred financing costs, the write-off of certain new refinancing costs, other professional fees and losses associated with the termination of several of the Company’s interest rate swap agreements.
	Interest rate swaps and caps
	The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company’s interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as the hedged forecasted cash flows occur, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, the Company has entered into several interest rate cap agreements and several forward interest rate cap agreements that have the economic effect of capping the Company’s maximum exposure to LIBOR variable interest rate changes on specific portions of the Company’s floating rate debt, as described below. Certain cap agreements are also designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.
	As of December 31, 2014, the Company maintains several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling $855,000. These agreements have the economic effect of modifying the LIBOR variable component of the Company’s interest rate on an equivalent amount of the Company’s New Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the New Term Loan A margin of 1.75%. The overall weighted average effective interest rate also includes the effects of $120,000 of unhedged New Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 1.75%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the year ended December 31, 2014, the Company recognized debt expense of $3,170 from these swaps. As of December 31, 2014, the total fair value of these swap agreements was a net asset of approximately $1,824. The Company estimates that approximately $1,457 of existing unrealized pre-tax losses in other comprehensive income at December 31, 2014 will be reclassified into income over the next twelve months.
	As of December 31, 2014, the Company maintained several forward interest rate cap agreements that were entered into in November 2014 with notional amounts totaling $3,500,000. These forward cap agreements will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 3.50% on an equivalent amount of our debt. The cap agreements expire on June 30, 2018. As of December 31, 2014, the total fair value of these cap agreements was an asset of approximately $12,340. During the fourth quarter of 2014, the Company recorded a loss of $2,147 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.
	As of December 31, 2014, the Company also maintains several interest rate cap agreements that were entered into in March 2013 with notional amounts totaling $2,735,000 on the Company’s New Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 2.50% on an equivalent amount of the Company’s New Term Loan B. During the year ended December 31, 2014, the Company recognized debt expense of $2,439 from these caps. The cap agreements expire on September 30, 2016. As of December 31, 2014, the total fair value of these cap agreements was an asset of approximately $1,594. During the year ended December 31, 2014, the Company recorded a loss of $5,972 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.
	Previously, the Company maintained five other interest rate cap agreements with notional amounts totaling $1,250,000. These agreements had the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our New Term Loan B debt. However, these interest rate cap agreements expired on September 30, 2014. During the year ended December 31, 2014, the Company recognized $2,691 of debt expense related to these cap agreements.

	The following table summarizes the Company’s derivative instruments as of December 31, 2014 and 2013:

			Interest rate swap and cap agreements (liabilities and assets)
			31-Dec-14						31-Dec-13
	Derivatives designated as hedging instruments		Balance sheet		Fair value				Balance sheet		Fair value
	Derivatives designated as hedging instruments		location		Fair value				location		Fair value
	Interest rate swap agreements		Other short-		$	1,457			Other short-		$	12,069
	Interest rate swap agreements		term liabilities		$	1,457			term liabilities		$	12,069
	Interest rate swap agreements		Other long-		$	3,281			Other long-		$	10,004
	Interest rate swap agreements		term assets		$	3,281			term assets		$	10,004
	Interest rate cap agreements		Other long-		$	13,934			Other long-		$	7,567
	Interest rate cap agreements		term assets		$	13,934			term assets		$	7,567

The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the years ended December 31, 2014, 2013 and 2012:

		Amount of gains (losses)											Location of (losses) gains reclassified from	Amount of gains (losses)
		recognized in OCI												reclassified from accumulated
		on interest rate swap												OCI into income
		and cap agreements
		Years ended December 31,											accumulated	Years ended December 31,
Derivatives designated as cash flow hedges		2014				2013				2012			OCI into	2014			2013			2012
Derivatives designated as cash flow hedges		2014				2013				2012			income	2014			2013			2012
Interest rate swap agreements		$	(8,390	)		$	1,251			$	(8,838	)	Debt expense	$	12,279		$	15,678		$	(12,989	)
Interest rate cap agreements			(8,119	)			(974	)			(1,316	)	Debt expense		5,130			5,418			(3,589	)
Tax (expense) benefit			6,450				(108	)			3,950				(6,801	)		(8,207	)		6,448
Total		$	(10,059	)		$	169			$	(6,204	)		$	10,608		$	12,889		$	(10,130	)

As of December 31, 2014, the interest rate on the Company’s Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date and the New Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. See above for further details. Interest rates on the Company’s senior notes are fixed by their terms. The majority of the LIBOR variable component of the Company’s interest rates on the Company’s Term Loan A are economically fixed as a result of interest rate swaps.
As a result of embedded LIBOR floors in some of the Company’s debt agreements and the swap and cap agreements, the Company’s overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.43%, based upon the current margins in effect of 1.75% for the Term Loan A and 2.75% for the Term Loan B, as of December 31, 2014.
The Company’s overall weighted average effective interest rate for the year ended December 31, 2014 was 4.68% and as of December 31, 2014 was 4.46%.
Debt expense
Debt expense consisted of interest expense of $385,750, $401,140 and $270,107, and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs and the amortization of interest rate cap agreements of $24,544, $28,803 and $18,447 for 2014, 2013 and 2012, respectively. The interest expense amounts are net of capitalized interest.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2014
Leases [Abstract]
Leases	15	Leases
	The majority of the Company’s facilities are leased under non-cancelable operating leases, ranging in terms from five to fifteen years, which contain renewal options of five to ten years at the fair rental value at the time of renewal. The Company’s leases are generally subject to periodic consumer price index increases or contain fixed escalation clauses. The Company also leases certain facilities and equipment under capital leases.
	Future minimum lease payments under non-cancelable operating leases and capital leases are as follows:

			Operating		Capital
			leases		leases
	2015		$	395,862	$	21,011
	2016			370,920		21,277
	2017			344,232		21,552
	2018			302,752		21,961
	2019			262,645		22,615
	Thereafter			901,792		202,245
			$	2,578,203		310,661
	Less portion representing interest					(92,564	)
	Total capital lease obligations, including current portion				$	218,097

	Rent expense under all operating leases for 2014, 2013, and 2012 was $460,093, $424,096 and $345,066, respectively. Rent expense is recorded on a straight-line basis, over the term of the lease, for leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives are deferred and amortized to rent expense over the term of the lease. The net book value of property and equipment under capital leases was $197,344 and $145,615 at December 31, 2014 and 2013, respectively. Capital lease obligations are included in long-term debt. See Note 14 to the consolidated financial statements.

Employee_benefit_plans

Employee benefit plans	12 Months Ended
	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Employee benefit plans	16	Employee benefit plans
	The Company has a savings plan for substantially all of its non-HCP employees which has been established pursuant to the provisions of Section 401(k) of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company does not provide any matching contributions.
	The Company also has various savings plans covering substantially all of its HCP employees which have been established pursuant to the provisions of Section 401(k) of the IRC. These plans provide for multiple employer matching contributions ranging from 0% to 6% of employee contributions. For the year ended December 31, 2014, the Company made matching contributions totaling approximately $7,400.
	The Company also maintains a voluntary compensation deferral plan, the DaVita Voluntary Deferral Plan. This plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2014, 2013 and 2012 were $3,772, $4,089 and $3,935, respectively. Deferred amounts are generally paid out in cash at the participant’s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2014, 2013 and 2012 the Company distributed $1,111, $4,158 and $1,324, respectively, to participants in this plan. Participants are credited with their proportional amount of annual earnings from the plan. The assets of this plan are held in a rabbi trust and as such are subject to the claims of the Company’s general creditors in the event of its bankruptcy. As of December 31, 2014 and 2013, the total fair value of assets held in this plan’s trust were $21,208 and $17,419, respectively. In addition, the Company maintains a non-qualified voluntary compensation deferral plan, the HealthCare Partners, LLC Deferred Compensation Plan. As of December 31, 2014 and 2013, the total fair value of the assets held in this plan’s trust were $5,347 and $572, respectively.
	The Company maintains an Executive Retirement Plan for certain members of management. This plan is non-qualified and contributions to the plan were made at the discretion of DVA Renal Healthcare based upon a pre-determined percentage of a participant’s base salary. Effective November 2005, all contributions to this plan were discontinued and the balance of the plan assets will be paid out upon termination or retirement of each individual participant. During 2014 and 2012 the Company distributed $152 and $226, respectively, to participants in this plan. During 2013 the Company did not make any distributions to participants under this plan. As of December 31, 2014 and 2013, the total fair value of assets held under this plan’s trust was $1,344 and $1,430, respectively.
	The Company also maintains a non-qualified deferred compensation program for certain key employees of HCP. Under the program, the employees can defer a portion of their salary which is invested at the direction of the employee into certain phantom investments as offered by the program. A portion of the amount deferred by the employees is used to purchase life insurance policies on each of the participating employees, with the Company named as beneficiary of the policies. The total cash surrender value of all of the life insurance policies totaled approximately $57,700 and $56,300 at December 31, 2014 and 2013, respectively, and is included in long-term investments. In addition, the total deferred compensation liabilities owed to the participants totaled approximately $60,400 and $62,000 at December 31, 2014 and 2013, respectively, and are included in other long-term liabilities. During 2014, the Company did not make any contributions on behalf of its participants. During the year ended December 31, 2013, the Company contributed a total of approximately $4,658 into the deferred compensation program on behalf of its participants.
	The fair value of all of the assets held in plan trusts as of December 31, 2014, and 2013 totaled $27,899 and $19,421, respectively. These assets are available for sale and as such are recorded at fair market value with changes in the fair market values being recorded in other comprehensive income. Any fair market value changes to the corresponding liability balance are recorded as compensation expense. See Note 9 to the consolidated financial statements.
	Most of the Company’s outstanding employee stock plan awards include a provision accelerating the vesting of the award in the event of a change of control. The Company also maintains a change of control protection program for its employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to employees in the event of a change of control. Based on the market price of the Company’s common stock and shares outstanding on December 31, 2014, these cash bonuses would total approximately $646,000 if a change of control transaction occurred at that price and the Company’s Board of Directors did not modify the program. This amount has not been accrued at December 31, 2014, and would only be accrued upon a change of control. These change of control provisions may affect the price an acquirer would be willing to pay for the Company.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Contingencies	17	Contingencies
	The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.
	Inquiries by the Federal Government and Certain Related Civil Proceedings
	Vainer Private Civil Suit: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for HHS relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company was advised by the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the qui tam provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended civil complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The amended complaint alleges that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. The amended complaint seeks monetary damages and civil penalties as well as costs and expenses. The parties completed discovery in early 2014; however in August 2014, the Court granted relators’ motion for sanctions and reopened discovery on a limited basis. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation. The Company cannot predict the ultimate outcome of this case, but if the case is resolved in favor of the plaintiffs, its resolution could have a material adverse effect on our earnings and cash flows.
	2010 U.S. Attorney Physician Relationship Investigation: As previously disclosed, the U.S. Attorney’s Office for the District of Colorado and the OIG investigated, among other things, the Company’s financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. This investigation has been described in the Company’s prior Reports on Forms 10-K and 10-Q and referred to as the 2010 U.S. Attorney Physician Relationship Investigation. This investigation overlapped substantially with the investigation described below under the caption 2011 U.S. Attorney Physician Relationship Investigation. The Company disclosed in early 2014 that it had reached an agreement in principle with the government to resolve these matters.
	As described more fully in the Company’s current report on Form 8-K filed on October 23, 2014, and as also disclosed in the Company’s prior report on Form 10-Q for the quarter ended September 30, 2014 that was filed with the SEC on November 6, 2014, the Company entered into a final settlement agreement on October 22, 2014 (the Settlement Agreement) with the United States of America, acting through the United States Department of Justice and on behalf of the OIG, the Defense Health Agency on behalf of TRICARE, through its General Counsel (collectively, the United States) and relator David Barbetta, to resolve the 2010 and 2011 U.S. Attorney Physician Relationship Investigations. In connection with the resolution of these matters, the Company agreed to pay and has now paid to the United States $350,000 plus accrued interest from the date of the Company’s agreement in principle with the United States, plus a civil forfeiture of $39,000. In addition, the Company agreed to and has paid a settlement of certain state Medicaid claims in the amount of $11,500 plus interest. Under the Settlement Agreement, among other things, the United States agrees to release the Company from any civil or administrative monetary liability arising from allegations that the Company caused the submission of claims to the federal health care programs that were ineligible for reimbursement due to certain violations of the federal anti-kickback statute in connection with certain of its dialysis center joint venture arrangements, and the United States and the relator agree to dismissal of the civil action filed by the relator under the qui tam provisions of the federal False Claims Act. The Company also has entered into a five-year corporate integrity agreement (the CIA) with the OIG. The CIA, among other things, (i) requires that the Company maintain certain elements of its compliance programs, (ii) imposes certain expanded compliance-related requirements during the term of the CIA, (iii) requires ongoing monitoring, reporting, certification, records retention and training obligations, the formal allocation of certain oversight responsibility to the Board’s Compliance Committee, the creation of a Management Compliance Committee and the retention of an independent compliance advisor to the Board, and (iv) contains certain business restrictions related to a subset of the Company’s joint venture arrangements, including the Company’s agreeing to: (1) unwind 11 joint venture transactions that were created through partial divestitures to or partial acquisitions from nephrologists and that cover 26 of the Company’s 2,119 clinics that existed at the time the Company entered into the Settlement Agreement; (2) not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the CIA; and (3) certain other restrictions. In the event of a breach of the CIA, the Company could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The costs associated with compliance with the CIA could be substantial and may be greater than the Company currently anticipates. In 2013, the Company accrued a loss contingency reserve of $397,000 related to this matter. In the third quarter of 2014, the Company accrued an additional $17,000 related to this matter which resulted in an increase in the reserve from $397,000 to $414,000.
	2011 U.S. Attorney Physician Relationship Investigation: In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation related to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlapped substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As also described above, both the 2010 and 2011 U.S. Attorney Physician Relationship Investigations have now been resolved. The United States has informed the Company that it has declined to proceed with any criminal charges in connection with this matter.
	2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle to resolve this matter. The specific terms of a settlement have not been finalized.
	Swoben Private Civil Suit: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the qui tam provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a qui tam action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.
	2015 U.S. Attorney Transportation Investigation: In February 2015, the Company announced that it received six subpoenas from the OIG for medical records from six different dialysis centers in Southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of the respective dialysis center. The Company has been advised by an attorney with the Civil Division of the United States Attorney’s Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation. The Company does not provide transportation or bill for the transport of its dialysis patients. The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.
	Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.

	Shareholder Derivative Claims
	In re DaVita HealthCare Partners Inc. Derivative Litigation: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. The Company has entered into a settlement with the lead plaintiff, subject to court approval. The terms of the settlement, which were described in a court-ordered notice sent to shareholders in late January 2015, include enhancements to the Company’s corporate governance practices and provides that the Company will not oppose the derivative plaintiff’s application for an award of fees and expenses, the dollar amount of which is not material to the Company. On January 8, 2015, the Court entered an order preliminarily approving the settlement, directing that the notice to shareholders be provided as described above and setting a settlement fairness hearing on May 1, 2015.
	Other
	The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.
	A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company’s consolidated financial statements.
	In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

Noncontrolling_interests_subje

Noncontrolling interests subject to put provisions and other commitments	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Noncontrolling interests subject to put provisions and other commitments	18	Noncontrolling interests subject to put provisions and other commitments
	Noncontrolling interests subject to put provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners’ noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company’s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers’ access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners’ noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial.
	Additionally, the Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative service agreements of approximately $1,000.
	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.
	Other commitments
	In November 2011, the Company entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. (Amgen) that expires on December 31, 2018. Under terms of the agreement, the Company will purchase EPO in amounts necessary to meet no less than 90% of its requirements for ESAs. The actual amount of EPO that the Company will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that the Company serves.
	In December 2012, the Company entered into an amendment to its agreement with Amgen that made non-material changes to certain terms of the agreement for the period from January 1, 2013 through December 31, 2013. Under the terms of the original agreement before the amendment, the Company was required to purchase EPO in amounts necessary to meet no less than 90% of its requirements of ESAs and is still required to do so after 2013. In addition, all of the other conditions as specified in the original agreement entered into in November 2011 still apply.
	In January 2010, the Company entered into an agreement with Fresenius which committed the Company to purchase a certain amount of dialysis equipment, parts and supplies from Fresenius through 2013. However, this agreement has been extended through 2015. During 2014, 2013 and 2012, the Company purchased $154,266 and $144,030 and $138,450, respectively, of certain equipment, parts and supplies from Fresenius.
	In conjunction with its acquisition of DVA Renal Healthcare, Inc., formerly known as Gambro Healthcare, Inc. in October 2005, the Company entered into an Alliance and Product Supply Agreement (the Product Supply Agreement) with Gambro AB and Gambro. Because the Amended Product Supply Agreement results in higher costs for most of the products covered by the Product Supply Agreement than would otherwise be available, the Company recorded an intangible liability at the time of the acquisition
	The Product Supply Agreement committed the Company to purchase a significant majority of its hemodialysis products, supplies and equipment at fixed prices through 2015. The agreement was amended in 2006 (the Amended Product Supply Agreement) to reduce the Company’s purchase obligations for certain hemodialysis product supplies and equipment, and in 2007, the Company terminated its obligation to purchase certain dialysis machines under the Amended Product Supply Agreement. However, the Company continues to be subject to the Product Supply Agreement’s requirements to purchase a majority of its hemodialysis non-equipment product supplies, such as dialyzers, from Gambro at fixed prices.
	During 2014, 2013 and 2012, the Company purchased $112,645, $124,555 and $147,639 of hemodialysis product supplies from Gambro.
	Certain HCP entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of December 31, 2014, this minimum cash balance was approximately $65,400.
	Other than operating leases disclosed in Note 15 to the consolidated financial statements, the letters of credit disclosed in Note 14 to the consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December 31, 2014.

Longterm_incentive_compensatio

Long-term incentive compensation and shareholders' equity	12 Months Ended
Long-term incentive compensation and shareholders' equity	Dec. 31, 2014
Equity [Abstract]
Long-term incentive compensation and shareholders' equity	19	Long-term incentive compensation and shareholders’ equity
	Long-term incentive compensation
	Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the dialysis and related lab services business, the HCP business, corporate support costs, and the ancillary services and strategic initiatives.
	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.
	Stock-based compensation to be settled in shares is recorded to the Company’s shareholders’ equity, while stock-based compensation to be settled in cash is recorded to a liability. Shares issued upon exercise of stock awards are generally issued from authorized but unissued shares.
	Stock split
	In the third quarter of 2013, the Board of Directors approved a two-for-one stock split of the Company’s common stock in the form of a stock dividend payable on September 6, 2013 to stockholders of record on August 23, 2013. The Company’s common stock began trading on a post-split basis on September 9, 2013. All share and per share data for all periods presented have been adjusted to reflect the effects of the stock split.
	Long-term incentive compensation plans
	On June 17, 2013, the stockholders of the Company approved an amendment to the DaVita HealthCare Partners Inc. 2011 Incentive Award Plan to increase the number of shares of common stock available for issuance under the Plan by 17,000,000 shares.
	On June 11, 2012, the Company’s stockholders approved an amendment to the Company’s 2011 Incentive Award Plan (the 2011 Plan) to increase the number of shares of common stock available for issuance under the plan by 9,000,000 shares and to increase the amount by which share reserves under the plan are reduced by grants of full value share awards to 3.5 times from 3.0 times the number of shares subject to the award.
	The Company’s 2011 Incentive Award Plan is the Company’s omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2011 Plan authorizes the Company to award stock options, stock appreciation rights, restricted stock units, restricted stock, and other stock-based or performance-based awards, and is designed to enable the Company to grant equity and cash awards that qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code. The 2011 Plan mandates a maximum award term of five years and stipulates that stock appreciation rights and stock options be granted with prices not less than fair market value on the date of grant. The 2011 Plan also requires that full value share awards such as restricted stock units reduce shares available under the Plan at a ratio of 3.5:1. The Company’s nonqualified stock appreciation rights and stock units awarded under the Plan generally vest over 36 to 48 months from the date of grant. At December 31, 2014, there were 10,585,172 stock-settled stock appreciation rights, 921,898 stock-settled stock units, 65,000 cash-settled stock appreciation rights and 7,734 cash-settled stock units outstanding, and 33,687,881 shares available for future grants, under the Plan.
	A combined summary of the status of the Company’s stock-settled awards under the 2011 Plan, including base shares for stock-settled stock appreciation rights and stock-settled stock unit awards is as follows:

			Year ended December 31, 2014
			Stock appreciation rights											Stock units
							Weighted				Weighted						Weighted
							average				average						average
							exercise				remaining						remaining
			Awards				price				contractual life			Awards			contractual life
	Outstanding at beginning of year			12,956,094			$	45.44							966,596
	Granted			1,553,829				70.15							332,007
	Exercised			(3,473,804	)			32.05							(303,970	)
	Cancelled			(450,947	)			51.49							(72,735	)
	Outstanding at end of period			10,585,172			$	53.21				2.7			921,898			1.5
	Exercisable at end of period			2,541,397			$	42.79				1.6			496			0.3
	Weighted-average fair value of grants in 2014		$	16.41										$	72.24
	Weighted-average fair value of grants in 2013		$	13.47										$	58.9
	Weighted-average fair value of grants in 2012		$	11.28										$	54.85

			Awards				Weighted average				Awards			Weighted average
	Range of SSAR base prices		outstanding				exercise price				exercisable			exercise price
	$20.01–$30.00			9,000				29.9				9,000			29.9
	$30.01–$40.00			893,976				34.92				710,869			34.65
	$40.01–$50.00			3,230,512				43.02				1,545,204			42.86
	$50.01–$60.00			4,577,354				57.49				36,324			55.03
	$60.01–$70.00			1,470,547				68.06				240,000			65.08
	$70.01–$80.00			403,783				73.07				—			—
	Total			10,585,172			$	53.21				2,541,397		$	42.79

	Liability-classified awards contributed $1,774, $338 and $175 to stock-based compensation expense for the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014 the Company had 72,734 liability-classified share awards outstanding, 10,625 of which were vested, and a total stock-based liability balance of $1,242. The Company did not grant any cash-settled stock-based awards during 2014.
	For the years ended December 31, 2014, 2013, and 2012, the aggregate intrinsic value of stock-based awards exercised was $151,342, $120,775 and $228,698, respectively. At December 31, 2014, the aggregate intrinsic value of stock awards outstanding was $310,351 and the aggregate intrinsic value of stock awards exercisable was $84,129.
	Estimated fair value of stock-based compensation awards
	The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant. The following assumptions were used in estimating these values and determining the related stock-based compensation attributable to the current period:
	Expected term of the awards: The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company’s historical exercise and post-vesting termination patterns, and the terms expected by peer companies in near industries.
	Expected volatility: Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatility expectations implied by the market price of its exchange-traded options and the volatilities expected by peer companies in near industries.
	Expected dividend yield: The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.
	Risk-free interest rate: The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.
	A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock-settled stock appreciation rights awards granted in the periods indicated is as follows:

			Year ended December 31,
			2014				2013				2012
	Expected term		4.2 years				4.1 years				3.7 years
	Expected volatility			25.8	%			27.2	%			28	%
	Expected dividend yield			0	%			0	%			0	%
	Risk-free interest rate			1.5	%			0.7	%			0.6	%

	The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.
	Employee stock purchase plan
	The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company’s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of the fair market value on the first day of the purchase right period or 85% of the fair market value on the last day of the purchase right period. Purchase right periods begin on January 1 and July 1, and end on December 31. Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits and used to purchase the Company’s common stock for 2014, 2013 and 2012 participation periods, were $19,010, $12,817 and $8,322, respectively. Shares purchased pursuant to the plan’s 2014, 2013 and 2012 participation periods were 297,954, 237,961and 202,658, respectively. At December 31, 2014, there were 836,421 shares remaining available for future grants under this plan.
	The fair value of employees’ purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2014, 2013 and 2012, respectively: expected volatility of 27%, 28% and 26%; risk-free interest rate of 0.2%, 0.2% and 0.1%, and no dividends. Using these assumptions, the weighted average estimated fair value of these purchase rights was $16.40, $14.24 and $10.05 for 2014, 2013 and 2012, respectively.
	Long-term incentive compensation expense and proceeds
	For the years ended December 31, 2014, 2013 and 2012, the Company recognized $118,970, $84,841 and $45,820, respectively, in total LTIP expense, of which $56,743, $59,998 and $45,384, respectively, was stock-based compensation expense for stock appreciation rights, stock options, stock units and discounted employee stock plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2014, 2013 and 2012 were $20,351, $22,187 and $16,874, respectively. As of December 31, 2014, there was $122,574 total estimated unrecognized compensation cost for outstanding LTIP awards, including $73,585 related to stock-based compensation arrangements under the Company’s equity compensation and stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.0 year and the stock-based component of these LTIP costs over a weighted average remaining period of 1.3 years.
	For the years ended December 31, 2014, 2013 and 2012, the Company received $59,119, $46,898 and $88,964, respectively, in actual tax benefits upon the exercise of stock awards. As a result of the Company issuing SSARs, beginning in 2013, the Company no longer has stock options outstanding and did not receive cash proceeds from stock option exercises during the years ended December 31, 2014 and 2013. During the year ended December 31, 2012, the Company received $2,175 in cash proceeds from legacy stock option exercises.
	Stock repurchases
The Company did not repurchase any of its common stock during 2014, 2013 or 2012. As of December 31, 2014, the total outstanding authorization for share repurchases was approximately $358,200. The Company has not repurchased any additional shares of its common stock from January 1, 2015 through February 26, 2015. This stock repurchase program has no expiration date.
Charter documents & Delaware law
The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.
The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.
Changes in DaVita HealthCare Partners Inc.’s ownership interest in consolidated subsidiaries
The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows:

		Year ended December 31,
		2014				2013				2012
Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	633,446			$	536,017
Increase (decrease) in paid-in capital for sales of			355				(1,442	)			1,064
noncontrolling interest			355				(1,442	)			1,064
Decrease in paid-in capital for the purchase of a			(5,357	)			(3,119	)			(20,694	)
noncontrolling interest			(5,357	)			(3,119	)			(20,694	)
Net transfer to noncontrolling interests			(5,002	)			(4,561	)			(19,630	)
Change from net income attributable to DaVita		$	718,112			$	628,885			$	516,387
HealthCare Partners Inc. and transfers to
noncontrolling interests

During 2014, the Company acquired additional ownership interests in several existing majority-owned joint ventures for $17,876 in cash and deferred purchase price of $136. In 2013, the Company also acquired additional ownership interests in several existing majority-owned joint ventures for $3,569 in cash and deferred purchase price of $209. In 2012, the Company acquired additional ownership interest in several existing majority-owned joint ventures for $26,761.

Other_comprehensive_income_los

Other comprehensive income (loss)	12 Months Ended
Other comprehensive income (loss)	Dec. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Other comprehensive income (loss)	20	Other comprehensive income (loss)
	Charges and credits to other comprehensive income (loss) have been as follows:

			Interest rate			Investment			Foreign			Accumulated
			swap and cap			securities			currency			other
			agreements						translation			comprehensive
									adjustments			income (loss)
	Balance at December 31, 2011		$	(19,328	)	$	(156	)	$	—		$	(19,484	)
	Unrealized (losses) gains			(10,154	)		2,524			(1,205	)		(8,835	)
	Related income tax			3,950			(983	)		—			2,967
				(6,204	)		1,541			(1,205	)		(5,868	)
	Reclassification from accumulated other			16,578			(123	)		—			16,455
	comprehensive losses (income) into net income			16,578			(123	)		—			16,455
	Related income tax			(6,448	)		48			—			(6,400	)
				10,130			(75	)		—			10,055
	Balance at December 31, 2012		$	(15,402	)	$	1,310		$	(1,205	)	$	(15,297	)
	Unrealized gains (losses)			277			3,752			(2,216	)		1,813
	Related income tax			(108	)		(1,452	)		—			(1,560	)
				169			2,300			(2,216	)		253
	Reclassification from accumulated other			21,096			(802	)		—			20,294
	comprehensive losses (income) into net income			21,096			(802	)		—			20,294
	Related income tax			(8,207	)		312			—			(7,895	)
				12,889			(490	)		—			12,399
	Balance at December 31, 2013		$	(2,344	)	$	3,120		$	(3,421	)	$	(2,645	)
	Unrealized (losses) gains			(16,509	)		425			(22,952	)		(39,036	)
	Related income tax			6,450			(187	)		—			6,263
				(10,059	)		238			(22,952	)		(32,773	)
	Reclassification from accumulated other			17,409			(340	)		—			17,069
	comprehensive losses (income) into net income			17,409			(340	)		—			17,069
	Related income tax			(6,801	)		133			—			(6,668	)
				10,608			(207	)		—			10,401
	Balance at December 31, 2014		$	(1,795	)	$	3,151		$	(26,373	)	$	(25,017	)

	The reclassification of net swap and cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 14 to the consolidated financial statements for further details.
	The reclassification of net investment realized gains into income are recorded in other income in the corresponding consolidated statements of income. See Note 9 to the consolidated financial statements for further details.

Acquisitions_and_discontinued_

Acquisitions and discontinued operations	12 Months Ended
Acquisitions and discontinued operations	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions and discontinued operations	21	Acquisitions and discontinued operations
	Routine acquisitions
	During 2014, the Company acquired dialysis-related and other ancillary businesses consisting of 18 dialysis centers in the U.S., 7 dialysis centers outside of the U.S. and other medical businesses for a total of $272,094 in net cash and deferred purchase price and earn-outs of $23,781. During 2013, the Company acquired dialysis-related and other ancillary businesses consisting of 26 dialysis centers in the U.S., 38 dialysis centers outside of the U.S. and other medical businesses for a total of $310,394 in net cash and deferred purchase price of $24,683. During 2012, the Company acquired dialysis-related and other ancillary businesses consisting of 93 dialysis centers in the U.S., 13 dialysis centers outside of the U.S. and other medical businesses for a total of $648,318 in net cash and deferred purchase price of $6,101.
	The assets and liabilities for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company’s financial statements and operating results from the effective dates of the acquisitions. For several of the 2014 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies.
	The following table summarizes the assets acquired and liabilities assumed in the above described transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:

			Year ended December 31,
			2014				2013			2012
	Current assets		$	915			$	7,215		$	18,708
	Property and equipment			5,999				23,760			41,741
	Amortizable intangible and other long-term assets			95,293				80,646			90,296
	Goodwill			221,514				271,267			554,685
	Long-term deferred income taxes			—				(5,666	)		(1,838	)
	Noncontrolling interests assumed			(25,963	)			(22,880	)		(21,962	)
	Liabilities assumed			(1,883	)			(19,265	)		(27,211	)
	Aggregate purchase cost		$	295,875			$	335,077		$	654,419

	Amortizable intangible assets acquired during 2014, 2013 and 2012 had weighted-average estimated useful lives of 10, 14 and 17 years, respectively. The majority of the intangibles assets acquired relate to customer relationships and non-compete agreements. The weighted-average amortization period for customer relationships was 10, 17, and 18 years, respectively. The weighted-average amortization period for non-compete agreements was 8, 9, and 8 years, respectively. The total amount of goodwill deductible for tax purposes associated with these acquisitions for 2014, 2013, and 2012 was approximately $175,247, $221,454 and $491,457, respectively.
	2012 acquisition of HCP
	On November 1, 2012, the Company completed the acquisition of HCP pursuant to an Agreement and Plan of Merger dated May 20, 2012, whereby HCP became a wholly-owned subsidiary of the Company. The operating results of HCP are included in the Company’s consolidated financial results from November 1, 2012.
	The total consideration paid at closing for all of the outstanding common units of HCP was approximately $4,701,231, which consisted of $3,645,759 in cash, net of cash acquired, and 18,760,624 shares of the Company’s common stock valued at approximately $1,055,472. During 2013, the Company paid an additional $5,251 in cash for post-closing working capital adjustments. In addition, the acquisition agreement provides that as further consideration, the Company could have paid the common unit holders of HCP a total of up to an additional $275,000 in cash if certain performance targets were achieved by HCP in 2012 and 2013. These contingent earn-out obligations were settled as discussed below.
	The following table summarizes the initial assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at their estimated fair values at that date:

	Current assets, net of cash acquired		$	321,235
	Property and equipment			102,382
	Intangible assets			1,882,818
	Other long-term assets			100,143
	Goodwill			3,496,713
	Current liabilities assumed			(559,180	)
	Other long-term liabilities			(169,015	)
	Long-term deferred income taxes			(184,015	)
	Noncontrolling interests			(29,850	)
			$	4,961,231

	The initial allocations of purchase price were recorded at the estimated fair values of assets acquired and liabilities assumed based upon the best information available to management. The fair values of property and equipment, intangible assets, and contingent earn-out obligations were estimated by the Company with the assistance of an independent third party. During 2013, the Company completed the final valuations of medical claims reserves, certain noncontrolling interests and certain income tax amounts, including pre-acquisition tax contingencies that were previously unresolved. See below for further details regarding these final adjustments.
	The amortizable intangible assets acquired in this transaction included $1,453,410 for customer relationships, $170,494 for trade names, $74,650 for non-compete agreements and $184,264 for provider network and practice management tools. See Note 7 to the consolidated financial statements. These amortizable intangible assets and liabilities are scheduled to be amortized on a straight-line method over a weighted-average amortization period of 17.2 years. The weighted-average amortization period for customer relationships is 20.0 years, trade names is 10.6 years, non-compete agreements is 5.7 years, and provider network and practice management tools is 7.0 years.
	Of the goodwill recognized in this transaction, approximately $2,426,986 is expected to be deductible for tax purposes over the next 14 years, based on actual earn-out payments and assuming all other escrow release conditions are satisfied.

	Contingent earn-out obligations
	As a result of HCP achieving certain financial performance targets in 2012, the Company made earn-out payments of $136,954 on April 1, 2013 to the common unit holders of HCP. During 2013, the Company also reached an agreement with the representative of the former owners and option holders of HealthCare Partners Holdings, LLC to settle certain post-closing adjustments, including the 2013 contingent earn-out obligation for $68,750, which resulted in the Company recording a contingent earn-out obligation adjustment of $56,977 in operating income.
	The Company has several contingent earn-out obligations associated with other acquisitions that could result in the Company paying the former shareholders of those acquired companies a total of up to approximately $134,321 or a portion of that amount if certain EBITDA performance targets and quality margins are met over the next two years, if certain percentages of operating income are met over the next three years or if certain percentages of other annual EBITDA targets are met. As of December 31, 2014, the Company has estimated the fair value of these contingent earn-out obligations to be $39,129.
	Contingent earn-out obligations will be remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 24 to the consolidated financial statements for further details. Of the total contingent earn-out obligations of $39,129 recognized at December 31, 2014, a total of $15,614 is included in other liabilities and the remaining $23,515 is included in other long-term liabilities in the Company’s consolidated balance sheet.
	The following is a reconciliation of changes in the contingent earn-out obligations for the year ended December 31, 2014:

	Beginning balance, January 1, 2014		$	28,058
	Contingent earn-out obligations associated with acquisitions			18,234
	Remeasurement of fair value			(4,448	)
	Payments of contingent earn-out obligations			(2,715	)
			$	39,129

	Discontinued operations
	Divestiture of HomeChoice Partners, Inc.
	On February 1, 2013, the Company completed the sale of HomeChoice Partners Inc. (HomeChoice) to BioScrip, Inc. pursuant to a stock purchase agreement (the Agreement) dated December 12, 2012 for $70,000 in cash, subject to various post-closing adjustments, of which the Company receives approximately 90% of the proceeds. The stock purchase agreement also provides that as additional consideration the Company could earn up to a total of 90% of $20,000 if certain performance amounts exceed certain thresholds over the next two years. However, HomeChoice performance amounts did not exceed any of the established thresholds in year one, accordingly, the Company now can only receive up to $9,000 of potential additional consideration under the remaining earn-out period. The Company has not yet assigned any value to this contingent receivable and will only recognize the estimated realizable value of this receivable when it becomes probable and reasonably estimable. The Company recorded a gain of approximately $13,375, net of tax, during 2013, related to this divestiture.
	The operating results of HomeChoice have been reported as discontinued operations for all periods presented.
	The results from discontinued operations related to HomeChoice were as follows:

			Year ended December 31,
			2014				2013			2012
	Net revenues			—			$	6,351		$	67,990
	Loss before income taxes			—				(223	)		(304	)
	Income tax benefit			—				(84	)		(82	)
	Loss from discontinued operations		$	—			$	(139	)	$	(222	)

	Net assets of discontinued operations related to HomeChoice as of February 1, 2013, were as follows:

Current assets		$	17,039
Property and equipment, net			2,963
Long-term assets			28
Goodwill			31,853
Liabilities and noncontrolling interests			(8,998	)
Net assets from discontinued operations		$	42,885

Pro forma financial information (unaudited)
The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions and divestitures in 2014 and 2013 had been consummated as of the beginning of 2013, after including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.

		Year ended December 31,
		2014				2013
		(unaudited)
Pro forma net revenues		$	12,887,330			$	12,160,749
Pro forma net income attributable to DaVita HealthCare Partners Inc.			733,490				651,204
Pro forma income from continuing operations attributable to DaVita HealthCare Partners Inc.			733,490				651,204
Pro forma basic net income per share attributable to DaVita HealthCare Partners Inc.			3.45				3.1
Pro forma diluted net income per share attributable to DaVita HealthCare Partners Inc.			3.38				3.03

Variable_interest_entities

Variable interest entities	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable interest entities	22	Variable interest entities
	The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs).
	Under U.S. GAAP, VIEs typically include (i) those for which the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) those for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) those for which the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses.
	Under U.S. GAAP, the Company has determined that substantially all of the entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for the entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee share ownership or share transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases the Company’s management agreements with these entities include both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases the Company has contractual arrangements with its related party nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities.
	The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At December 31, 2014, these consolidated financial statements include total assets of VIEs of $575,074 and total liabilities and noncontrolling interests of VIEs to third parties of $311,148.
	The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 16 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2014
Risks And Uncertainties [Abstract]
Concentrations	23	Concentrations
	Approximately 67%, 66% and 66% of total U.S. dialysis and related lab services net revenues in 2014, 2013 and 2012, respectively, are from government-based programs, principally Medicare and Medicaid. Related accounts receivable and other receivables from Medicare, including Medicare-assigned plans, and Medicaid, including Medicaid-assigned plans, were approximately $705,532 and $679,006, as of December 31, 2014 and 2013, respectively.
	Approximately 71% and 69% of HCP’s revenues in 2014 and 2013, respectively, are from government-based programs, principally Medicare and Medicaid. Approximately 64% and 67% for 2014 and 2013, respectively, of HCP’s capitated and patient services revenues (medical revenues) are associated with three health plans. In addition, approximately 73% and 69% at December 31, 2014 and 2013, respectively, of HCP’s accounts receivables are associated with three health plans.
	There is no single payor that accounted for more than 10% of total consolidated accounts receivable at December 31, 2014 and 2013.
	EPO is a significant physician-prescribed pharmaceutical that is administered during dialysis and is provided by a sole supplier, Amgen. The amount of EPO that is separately billable accounted for approximately 2% of U.S. dialysis and related lab services net revenues in 2014 and 2013. As long as certain conditions are met by the Company, the agreement with Amgen limits their ability to unilaterally decide to increase the price it charges the Company for EPO. See Note 18 of the consolidated financial statements for further details.

Fair_values_of_financial_instr

Fair values of financial instruments	12 Months Ended
Fair values of financial instruments	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair values of financial instruments	24	Fair values of financial instruments
	The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by FASB.
	The following tables summarize the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December 31, 2014 and 2013:

			Total		Quoted prices in		Significant other		Significant
					active markets for		observable inputs		unobservable
					identical assets		(Level 2)		inputs
					(Level 1)				(Level 3)
	31-Dec-14
	Assets
	Available for sale securities		$	28,123	$	28,123	$	—	$	—
	Interest rate cap agreements		$	13,934	$	—	$	13,934	$	—
	Interest rate swap agreements		$	3,281	$	—	$	3,281	$	—
	Funds on deposit with third parties		$	81,276	$	81,276	$	—	$	—
	Liabilities
	Interest rate swap agreements		$	1,457	$	—	$	1,457	$	—
	Contingent earn-out obligations		$	39,129	$	—	$	—	$	39,129
	Temporary equity
	Noncontrolling interests subject to put provisions		$	829,965	$	—	$	—	$	829,965
	31-Dec-13
	Assets
	Available for sale securities		$	19,421	$	19,421	$	—	$	—
	Interest rate cap agreements		$	7,567	$	—	$	7,567	$	—
	Interest rate swap agreements		$	10,004	$	—	$	10,004	$	—
	Funds on deposit with third parties		$	79,317	$	79,317	$	—	$	—
	Liabilities
	Interest rate swap agreements		$	12,069	$	—	$	12,069	$	—
	Contingent earn-out obligations		$	28,058	$	—	$	—	$	28,058
	Temporary equity
	Noncontrolling interests subject to put provisions		$	697,300	$	—	$	—	$	697,300

	The available for sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at fair value based upon quoted prices reported by each mutual fund. See Note 9 to these consolidated financial statements for further discussion.
	The interest rate swap and cap agreements are recorded at fair value based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different from the fair values currently reported. See Note 14 to the consolidated financial statements for further discussion.
	The funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices.
	The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs including projected EBITDA, estimated probabilities of achieving gross margin of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair values of the quality results amounts. The estimated fair value of these contingent earn-out obligations will be remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value.
	See Note 18 to these consolidated financial statements for a discussion of the Company’s methodology for estimating the fair value of noncontrolling interests subject to put obligations.
	Other financial instruments consist primarily of cash, accounts receivable, life insurance contracts, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at December 31, 2014 and 2013 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company’s Senior Secured Credit Facilities totaled $4,441,292 as of December 31, 2014, and the fair value was approximately $4,420,238 based upon quoted market prices. The fair value of the Company’s senior notes was approximately $3,924,715 at December 31, 2014 based upon quoted market prices, as compared to the carrying amount of $3,775,000.

Segment_reporting

Segment reporting	12 Months Ended
Segment reporting	Dec. 31, 2014
Segment Reporting [Abstract]
Segment reporting	25	Segment reporting
	The Company operates two major divisions, Kidney Care and HCP. The Kidney Care division is comprised of the Company’s U.S. dialysis and related lab services business, various other ancillary services and strategic initiatives, including its international dialysis operations, and the Company’s corporate support costs. The Company’s U.S. dialysis and related lab services business is the Company’s largest line of business, and is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. The Company’s HCP division is a patient- and physician-focused integrated health care delivery and management company with nearly three decades of providing coordinated outcomes-based medical care in a cost-effective manner.
	As of December 31, 2014, the ancillary services and strategic initiatives consisted primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and the Company’s international dialysis operations.
	The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker in making decisions about allocating resources to and assessing the financial results of the Company’s different operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.
	The Company’s separate operating segments include its U.S. dialysis and related lab services business, its HCP operations in each region, each of its ancillary services and strategic initiatives, and its international operations in the European and Middle Eastern, Asia Pacific, and Latin American regions. The U.S. dialysis and related lab services business and the HCP business each qualify as separately reportable segments, while all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category.
	The Company’s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial results of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude (i) the HCP contingent earn-out obligation adjustment, (ii) corporate support costs, which consists primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to all of the Company’s different operating lines of business, (iii) the reduction of a tax asset associated with the HCP acquisition escrow provisions, and (iv) transaction expenses in 2012 associated with the HCP acquisition.
	The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

			Year ended December 31,
			2014				2013				2012
	Segment revenues:
	U.S. dialysis and related lab services
	Patient service revenues:
	External sources		$	8,513,089			$	7,998,692			$	7,299,032
	Intersegment revenues			37,112				34,080				17,786
	Total dialysis and related lab services revenues			8,550,201				8,032,772				7,316,818
	Less: Provision for uncollectible accounts			(353,028	)			(281,146	)			(233,580	)
	Net dialysis and related lab services patient			8,197,173				7,751,626				7,083,238
	service revenues			8,197,173				7,751,626				7,083,238
	Other revenues(1)			13,498				12,600				11,447
	Total net dialysis and related lab services			8,210,671				7,764,226				7,094,685
	revenues			8,210,671				7,764,226				7,094,685
	HCP
	HCP revenues:
	Capitated revenues		$	3,190,903			$	2,919,964			$	419,431
	Net patient service revenues			219,306				220,251				34,407
	Other revenues(2)			91,374				55,723				23,552
	Intersegment capitated and other revenues			716				250				—
	Total revenues		$	3,502,299			$	3,196,188			$	477,390
	Other - Ancillary services and strategic initiatives
	Net patient service revenues		$	122,087			$	75,852			$	16,824
	Capitated revenues			70,385				67,351				61,906
	Other external sources			927,492				694,763				553,261
	Intersegment revenues			19,535				13,916				10,481
	Total ancillary services and strategic initiatives			1,139,499				851,882				642,472
	revenues			1,139,499				851,882				642,472
	Total net segment revenues			12,852,469				11,812,296				8,214,547
	Elimination of intersegment revenues			(57,363	)			(48,246	)			(28,267	)
	Consolidated net revenues		$	12,795,106			$	11,764,050			$	8,186,280
	Segment operating margin (loss):(3)
	U.S. dialysis and related lab services		$	1,637,626			$	1,200,198			$	1,372,265
	HCP			214,983				385,253				66,930
	Other——Ancillary services and strategic initiatives			(24,456	)			(38,595	)			(64,877	)
	Total segment margin			1,828,153				1,546,856				1,374,318
	Reconciliation of segment operating margin to
	consolidated income from continuing operations before
	income taxes:
	Contingent earn-out obligation adjustment			—				56,977				—
	Corporate support costs(4)			(13,012	)			(53,699	)			(46,481	)
	Transaction expenses			—				—				(30,753	)
	Consolidated operating income			1,815,141				1,550,134				1,297,084
	Debt expense			(410,294	)			(429,943	)			(288,554	)
	Debt refinancing and redemption charges			(97,548	)			—				(10,963	)
	Other income			2,374				4,787				3,737
	Consolidated income from continuing		$	1,309,673			$	1,124,978			$	1,001,304
	operations before income taxes		$	1,309,673			$	1,124,978			$	1,001,304

	-1	Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.
	-2	Other revenues primarily relate to providing medical consulting services.
	-3	Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.
	-4	Corporate support costs in 2013 also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.
	Depreciation and amortization expense by segment is as follows:

			December 31,
		2014				2013				2012

U.S. dialysis and related lab services		$	402,767			$	355,879			$	310,375
HCP			169,485				158,356				24,544
Other - Ancillary services and strategic initiatives			18,683				14,502				7,050
		$	590,935			$	528,737			$	341,969

Summary of assets by segment is as follows:

		December 31,
		2014				2013
Segment assets
U.S. dialysis and related lab services (including equity investments of $28,138 and $27,009, respectively)		$	10,959,096			$	10,248,993
HCP (including equity investments of $15,393 and $13,677, respectively)			6,285,984				6,265,767
Other - —Ancillary services and strategic initiatives(1) (including equity investments of $22,106 in 2014)			697,635				584,117
Consolidated assets		$	17,942,715			$	17,098,877

-1	Includes approximately $44,000 and $26,000 in 2014 and 2013, respectively, of net property and equipment related to the Company’s international operations.
Expenditures for property and equipment by segment is as follows:

		December 31,
		2014				2013				2012

U.S. dialysis and related lab services		$	560,610			$	554,345			$	524,180
HCP			27,885				31,582				7,464
Other - Ancillary services and strategic initiatives			52,835				31,670				18,502
		$	641,330			$	617,597			$	550,146

Supplemental_cash_flow_informa

Supplemental cash flow information	12 Months Ended
Supplemental cash flow information	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Supplemental cash flow information	26	Supplemental cash flow information
	The table below provides supplemental cash flow information:

			Year ended December 31,
			2014		2013		2012
	Cash paid:
	Income taxes		$	238,615	$	341,426	$	322,018
	Interest			351,967		405,030		257,640
	Non-cash investing and financing activities:
	Fixed assets under capital lease obligations			72,389		60,920		55,813

Selected_quarterly_financial_d

Selected quarterly financial data (unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data (unaudited)	27	Selected quarterly financial data (unaudited)

			2014								2013
			31-Dec		30-Sep		30-Jun		31-Mar		31-Dec		30-Sep		30-Jun		31-Mar
	Net revenues		$	3,328,017	$	3,251,824	$	3,172,489	$	3,042,776	$	3,063,209	$	2,999,586	$	2,871,673	$	2,829,582
	Operating income		$	452,085	$	437,536	$	484,295	$	441,225	$	484,179	$	377,074	$	522,020	$	166,861
	Income from continuing operations		$	354,365	$	336,412	$	282,308	$	336,588	$	380,020	$	270,766	$	412,550	$	61,642
	before income taxes
	Discontinued operations, net of tax.		$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	13,236
	Net income attributable to DaVita		$	208,020	$	184,122	$	147,683	$	183,289	$	212,278	$	136,628	$	254,376	$	30,164
	HealthCare Partners Inc.
	Basic income from continuing		$	0.98	$	0.87	$	0.7	$	0.87	$	1.01	$	0.65	$	1.21	$	0.08
	operations per share attributable
	to DaVita HealthCare Partners Inc.
	Basic net income per share		$	0.98	$	0.87	$	0.7	$	0.87	$	1.01	$	0.65	$	1.21	$	0.14
	attributable to DaVita HealthCare
	Partners Inc.
	Diluted income from continuing		$	0.96	$	0.85	$	0.68	$	0.85	$	0.99	$	0.64	$	1.18	$	0.08
	operations per share attributable
	to DaVita HealthCare Partners Inc.
	Diluted net income per share		$	0.96	$	0.85	$	0.68	$	0.85	$	0.99	$	0.64	$	1.18	$	0.14
	attributable to DaVita HealthCare
	Partners Inc.

Consolidating_financial_statem

Consolidating financial statements	12 Months Ended
Consolidating financial statements	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidating financial statements	28	Consolidating financial statements
	The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company’s consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other services. The Company’s senior notes are guaranteed by substantially all of its domestic subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, including by merger or consolidation or the sale of all equity interests in such subsidiary owned by the Company, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Certain domestic subsidiaries, foreign subsidiaries, joint ventures, partnerships and third parties are not guarantors of the senior notes.
	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2014
	Patient services revenues		$	—			$	6,246,683			$	2,739,996			$	(118,341	)		$	8,868,338
	Less: Provision for uncollectible accounts			—				(238,600	)			(128,284	)			—				(366,884	)
	Net patient service revenues			—				6,008,083				2,611,712				(118,341	)			8,501,454
	Capitated revenues			—				1,689,634				1,579,804				(8,150	)			3,261,288
	Other revenues			684,066				1,639,828				24,155				(1,315,685	)			1,032,364
	Total net revenues			684,066				9,337,545				4,215,671				(1,442,176	)			12,795,106
	Operating expenses and charges			443,951				8,276,991				3,701,199				(1,442,176	)			10,979,965
	Operating income			240,115				1,060,554				514,472				—				1,815,141
	Debt (expense) and refinancing charges			(502,762	)			(363,623	)			(43,449	)			401,992				(507,842	)
	Other income, net			385,532				11,731				7,103				(401,992	)			2,374
	Income tax expense			46,856				397,268				2,219				—				446,343
	Equity earnings in subsidiaries			647,085				335,691				—				(982,776	)			—
	Net income			723,114				647,085				475,907				(982,776	)			863,330
	Less: Net income attributable to noncontrolling interests			—				—				—				(140,216	)			(140,216	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	647,085			$	475,907			$	(1,122,992	)		$	723,114



	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2013
	Patient services revenues		$	—			$	5,989,658			$	2,420,975			$	(103,438	)		$	8,307,195
	Less: Provision for uncollectible accounts			—				(177,415	)			(116,131	)			—				(293,546	)
	Net patient service revenues			—				5,812,243				2,304,844				(103,438	)			8,013,649
	Capitated revenues			—				1,427,321				1,560,244				(250	)			2,987,315
	Other revenues			616,155				1,534,310				17,867				(1,405,246	)			763,086
	Total net revenues			616,155				8,773,874				3,882,955				(1,508,934	)			11,764,050
	Operating expenses and charges			434,776				7,843,476				3,444,598				(1,508,934	)			10,213,916
	Operating income			181,379				930,398				438,357				—				1,550,134
	Debt (expense)			(427,141	)			(366,188	)			(39,413	)			402,799				(429,943	)
	Other income, net			402,910				1,903				2,773				(402,799	)			4,787
	Income tax expense			59,716				303,603				17,694				—				381,013
	Equity earnings in subsidiaries			536,014				260,268				—				(796,282	)			—
	Income from continuing operations			633,446				522,778				384,023				(796,282	)			743,965
	Discontinued operations net of gain on disposal			—				—				13,236				—				13,236
	of discontinued operations			—				—				13,236				—				13,236
	Net income			633,446				522,778				397,259				(796,282	)			757,201
	Less: Net income attributable to noncontrolling interests			—				—				—				(123,755	)			(123,755	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	633,446			$	522,778			$	397,259			$	(920,037	)		$	633,446
	For the year ended December 31, 2012
	Patient services revenues		$	—			$	5,417,800			$	2,005,424			$	(71,322	)		$	7,351,902
	Less: Provision for uncollectible accounts			—				(124,592	)			(110,626	)			—				(235,218	)
	Net patient service revenues			—				5,293,208				1,894,798				(71,322	)			7,116,684
	Capitated revenues			—				232,744				248,592				—				481,336
	Other revenues			514,190				745,920				10,190				(682,040	)			588,260
	Total net revenues			514,190				6,271,872				2,153,580				(753,362	)			8,186,280
	Operating expenses and charges			365,680				5,479,531				1,797,347				(753,362	)			6,889,196
	Operating income			148,510				792,341				356,233				—				1,297,084
	Debt (expense) and refinancing charges			(331,944	)			(207,499	)			(27,193	)			267,119				(299,517	)
	Other income, net			265,508				4,305				1,043				(267,119	)			3,737
	Income tax expense			32,912				320,267				6,666				—				359,845
	Equity earnings in subsidiaries			486,855				218,197				—				(705,052	)			—
	Income from continuing operations			536,017				487,077				323,417				(705,052	)			641,459
Discontinued operations			—				—				(222	)			—				(222	)
Net income			536,017				487,077				323,195				(705,052	)			641,237
Less: Net income attributable to noncontrolling interests			—				—				—				(105,220	)			(105,220	)
Net income attributable to DaVita HealthCare Partners Inc.		$	536,017			$	487,077			$	323,195			$	(810,272	)		$	536,017



Consolidating Statements of Comprehensive Income

		DaVita				Guarantor				Non-				Consolidating				Consolidated
		HealthCare				Subsidiaries				Guarantor				Adjustments				Total
		Partners Inc.								Subsidiaries
For the year ended December 31, 2014
Net income		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
Other comprehensive income (losses)			580				—				(22,952	)			—				(22,372	)
Total comprehensive income			723,694				647,085				452,955				(982,776	)			840,958
Less: Comprehensive income attributable to			—				—				—				(140,216	)			(140,216	)
noncontrolling interest			—				—				—				(140,216	)			(140,216	)
Comprehensive income attributable to DaVita HealthCare		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
Partners Inc.		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
For the year ended December 31, 2013
Net income		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
Other comprehensive income (losses)			14,868				—				(2,216	)			—				12,652
Total comprehensive income			648,314				522,778				395,043				(796,282	)			769,853
Less: Comprehensive income attributable to			—				—				—				(123,755	)			(123,755	)
noncontrolling interest			—				—				—				(123,755	)			(123,755	)
Comprehensive income attributable to DaVita HealthCare		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
Partners Inc.		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
For the year ended December 31, 2012
Net income		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
Other comprehensive income (losses)			5,392				—				(1,205	)			—				4,187
Total comprehensive income			541,409				487,077				321,990				(705,052	)			645,424
Less: Comprehensive income attributable to			—				—				—				(105,220	)			(105,220	)
noncontrolling interest			—				—				—				(105,220	)			(105,220	)
Comprehensive income attributable to DaVita HealthCare		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204
Partners Inc.		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204



Consolidating Balance Sheets

		DaVita				Guarantor				Non-				Consolidating				Consolidated
		HealthCare				Subsidiaries				Guarantor				Adjustments				Total
		Partners Inc.								Subsidiaries
As of December 31, 2014
Cash and cash equivalents		$	698,876			$	77,921			$	188,444			$	—			$	965,241
Accounts receivable, net			—				915,851				609,998				—				1,525,849
Other current assets			362,672				930,093				92,942				—				1,385,707
Total current assets			1,061,548				1,923,865				891,384				—				3,876,797
Property and equipment, net			195,690				1,473,188				800,221				—				2,469,099
Intangible assets, net			85,338				1,811,218				52,942				—				1,949,498
Investments in subsidiaries			8,868,335				1,561,195				—				(10,429,530	)			—
Intercompany receivables			3,723,454				—				564,241				(4,287,695	)			—
Other long-term assets and investments			70,309				60,385				101,332				—				232,026
Goodwill			—				7,958,221				1,457,074				—				9,415,295
Total assets		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
Current liabilities		$	180,977			$	1,493,243			$	414,432			$	—			$	2,088,652
Intercompany payables			—				3,105,173				1,182,522				(4,287,695	)			—
Long-term debt and other long-term liabilities			8,124,863				1,321,321				217,603				—				9,663,787
Noncontrolling interests subject to put provisions			528,321				—				—				301,644				829,965
Total DaVita HealthCare Partners Inc.			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
shareholders’' equity			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
Noncontrolling interests not subject to put provisions			—				—				491,442				(301,644	)			189,798
Total equity			5,170,513				8,868,335				2,052,637				(10,731,174	)			5,360,311
Total liabilities and equity		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
As of December 31, 2013
Cash and cash equivalents		$	602,188			$	175,004			$	169,057			$	—			$	946,249
Accounts receivable, net			—				939,543				545,620				—				1,485,163
Other current assets			27,910				904,852				108,104				—				1,040,866
Total current assets			630,098				2,019,399				822,781				—				3,472,278
Property and equipment, net			177,633				1,378,017				633,761				—				2,189,411
Intangible assets, net			77,531				1,882,685				64,157				—				2,024,373
Investments in subsidiaries			8,231,059				1,391,655				—				(9,622,714	)			—
Intercompany receivables			3,983,214				—				480,993				(4,464,207	)			—
Other long-term assets and investments			61,391				70,728				67,722				—				199,841
Goodwill		—					7,850,910				1,362,064				—				9,212,974
Total assets		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877
Current liabilities		$	328,875			$	1,776,419			$	356,755			$	—			$	2,462,049
Intercompany payables			—				3,426,433				1,037,774				(4,464,207	)			—
Long-term debt and other long-term liabilities			7,948,390				1,159,483				226,114				—				9,333,987
Noncontrolling interests subject to put provisions			451,182				—				—				246,118				697,300
Total DaVita HealthCare Partners Inc.			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
shareholders’' equity			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
Noncontrolling interests not subject to put provisions			—				—				419,180				(246,118	)			173,062
Total equity			4,432,479				8,231,059				1,810,835				(9,868,832	)			4,605,541
Total liabilities and equity		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877



Consolidating Statements of Cash Flows

		DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
		HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
		Partners Inc.
For the year ended December 31, 2014
Cash flows from operating activities:
Net income.		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
Changes in operating assets and liabilities and non cash			(597,992	)			120,772				90,521				982,776				596,077
items included in net income			(597,992	)			120,772				90,521				982,776				596,077
Net cash provided by operating activities			125,122				767,857				566,428				—				1,459,407
Cash flows from investing activities:
Additions of property and equipment, net			(51,374	)			(312,191	)			(277,765	)			—				(641,330	)
Acquisitions			—				(228,569	)			(43,525	)			—				(272,094	)
Proceeds from asset sales			—				8,791				—				—				8,791
Purchase of investments and other items			(333,803	)			(316	)			(38,977	)			—				(373,096	)
Net cash (used in) provided by investing activities			(385,177	)			(532,285	)			(360,267	)			—				(1,277,729	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			4,513				(12,545	)			43				—				(7,989	)
Intercompany borrowing			410,437				(306,011	)			(104,426	)			—				—
Other items			(58,207	)			(14,099	)			(84,684	)			—				(156,990	)
Net cash provided by (used in) financing activities			356,743				(332,655	)			(189,067	)			—				(164,979	)
Effect of exchange rate changes on cash			—				—				2,293				—				2,293
Net increase (decrease) in cash and cash equivalents			96,688				(97,083	)			19,387				—				18,992
Cash and cash equivalents at beginning of the year			602,188				175,004				169,057				—				946,249
Cash and cash equivalents at the end of the year		$	698,876			$	77,921			$	188,444			$	—			$	965,241
For the year ended December 31, 2013
Cash flows from operating activities:
Net income.		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
Changes in operating assets and liabilities and non cash			(443,071	)			652,374				10,555				796,282				1,016,140
items included in net income			(443,071	)			652,374				10,555				796,282				1,016,140
Net cash provided by operating activities			190,375				1,175,152				407,814				—				1,773,341
Cash flows from investing activities:
Additions of property and equipment, net			(55,252	)			(337,042	)			(225,303	)			—				(617,597	)
Acquisitions			—				(156,830	)			(153,564	)			—				(310,394	)
Proceeds from asset sales			60,650				1,608				—				—				62,258
Purchase of investments and other items			(4,944	)			(3,502	)			(2,703	)			—				(11,149	)
Net cash provided by (used in) by investing activities			454				(495,766	)			(381,570	)			—				(876,882	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(421,739	)			(11,061	)			(5,207	)			—				(438,007	)
Intercompany borrowing			585,441				(664,154	)			78,713				—				—
Other items			52,620				4,726				(102,330	)			—				(44,984	)
Net cash provided by (used in) financing activities			216,322				(670,489	)			(28,824	)			—				(482,991	)
Effect of exchange rate changes on cash			—				—				(967	)			—				(967	)
Net increase (decrease) in cash and cash equivalents			407,151				8,897				(3,547	)			—				412,501
Cash and cash equivalents at beginning of the year			195,037				166,107				172,604				—				533,748
Cash and cash equivalents at the end of the year		$	602,188			$	175,004			$	169,057			$	—			$	946,249



Consolidating Statements of Cash Flows

		DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
		HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
		Partners Inc.
For the year ended December 31, 2012
Cash flows from operating activities:
Net income.		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
Changes in operating assets and liabilities and non cash			(383,619	)			15,693				122,485				705,052				459,611
items included in net income			(383,619	)			15,693				122,485				705,052				459,611
Net cash provided by operating activities			152,398				502,770				445,680				—				1,100,848
Cash flows from investing activities:
Additions of property and equipment, net			(72,125	)			(305,885	)			(172,136	)			—				(550,146	)
Acquisitions			(3,645,760	)			(564,499	)			(83,818	)			—				(4,294,077	)
Proceeds from asset sales			—				3,559				—				—				3,559
Proceeds from investment sales and other items			2,841				(1,761	)			7,134				—				8,214
Net cash used in by investing activities			(3,715,044	)			(868,586	)			(248,820	)			—				(4,832,450	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			3,909,760				(23,805	)			18,938				—				3,904,893
Intercompany borrowing			(586,050	)			580,825				5,225			—					—
Other items			68,697				(25,097	)			(76,109	)			—				(32,509	)
Net cash provided by (used in) financing activities			3,392,407				531,923				(51,946	)			—				3,872,384
Effect of exchange rate changes on cash			—				—				(786	)			—				(786	)
Net (decrease) increase in cash and cash equivalents			(170,239	)			166,107				144,128				—				139,996
Cash and cash equivalents at beginning of the year			365,276				—				28,476				—				393,752
Cash and cash equivalents at the end of the year		$	195,037			$	166,107			$	172,604			$	—			$	533,748

Supplemental_data

Supplemental data	12 Months Ended
Supplemental data	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental data (unaudited)	DAVITA HEALTHCARE PARTNERS INC.
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(continued)
	(dollars in thousands, except per share data)

	29. Supplemental data (unaudited)
	The following information is presented as supplemental data as required by the indentures governing our senior notes.
	Condensed Consolidating Statements of Income

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2014
	Patient services revenues		$	8,868,338			$	121,929			$	—			$	8,746,409
	Less: Provision for uncollectible accounts			(366,884	)			(8,534	)			—				(358,350	)
	Net patient service revenues			8,501,454				113,395				—				8,388,059
	Capitated revenues			3,261,288				1,511,000				—				1,750,288
	Other revenues			1,032,364				6,630				—				1,025,734
	Total net revenues			12,795,106				1,631,025				—				11,164,081
	Operating expenses and charges			10,979,965				1,601,027				514				9,378,424
	Operating income			1,815,141				29,998				(514	)			1,785,657
	Debt (expense) and refinancing charges			(507,842	)			(11,113	)			—				(496,729	)
	Other income, net			2,374				238				—				2,136
	Income tax expense			446,343				1,866				(206	)			444,683
	Net income			863,330				17,257				(308	)			846,381
	Less: Net income attributable to noncontrolling interests			(140,216	)			—				—				(140,216	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	17,257			$	(308	)		$	706,165

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2013
	Patient services revenues		$	8,307,195			$	122,873			$	—			$	8,184,322
	Less: Provision for uncollectible accounts			(293,546	)			(6,602	)			—				(286,944	)
	Net patient service revenues			8,013,649				116,271				—				7,897,378
	Capitated revenues			2,987,315				1,560,244				—				1,427,071
	Other revenues			763,086				5,239				—				757,847
	Total net revenues			11,764,050				1,681,754				—				10,082,296
	Operating expenses and charges			10,213,916				1,659,151				457				8,554,308
	Operating income			1,550,134				22,603				(457	)			1,527,988
	Debt (expense)			(429,943	)			(14,605	)			—				(415,338	)
	Other income, net			4,787				6				—				4,781
	Income tax expense			381,013				3,523				(183	)			377,673
	Income from continuing operations			743,965				4,481				(274	)			739,758
	Discontinued operations net of gain on disposal of discontinued			13,236				—				—				13,236
	operations			13,236				—				—				13,236
	Net income			757,201				4,481				(274	)			752,994
	Less: Net income attributable to noncontrolling interests			(123,755	)			—				—				(123,755	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	633,446			$	4,481			$	(274	)		$	629,239
	For the year ended December 31, 2012
	Patient services revenues		$	7,351,902			$	20,052			$	—			$	7,331,850
	Less: Provision for uncollectible accounts			(235,218	)			(686	)			—				(234,532	)
	Net patient service revenues			7,116,684				19,366				—				7,097,318
	Capitated revenues			481,336				248,592				—				232,744
	Other revenues			588,260				487				—				587,773
	Total net revenues			8,186,280				268,445				—				7,917,835
	Operating expenses and charges			6,889,196				268,205				(1,372	)			6,622,363
	Operating income			1,297,084				240				1,372				1,295,472
	Debt (expense) and refinancing charges			(299,517	)			(1,386	)			—				(298,131	)
	Other income, net			3,737				54				—				3,683
	Income tax expense			359,845				—				549				359,296
	Income from continuing operations			641,459				(1,092	)			823				641,728
	Discontinued operations			(222	)			—				—				(222	)
	Net income			641,237				(1,092	)			823				641,506
	Less: Net income attributable to noncontrolling interests			(105,220	)			—				—				(105,220	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	536,017			$	(1,092	)		$	823			$	536,286


	-1	After the elimination of the unrestricted subsidiaries and the physician groups



Condensed Consolidating Statements of Comprehensive Income

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For the year ended December 31, 2014
Net income (losses)		$	863,330			$	17,257			$	(308	)		$	846,381
Other comprehensive losses			(22,372	)			—				—				(22,372	)
Total comprehensive income (losses)			840,958				17,257				(308	)			824,009
Less: Comprehensive income attributable to noncontrolling			(140,216	)			—				—				(140,216	)
interest			(140,216	)			—				—				(140,216	)
Comprehensive income (losses) attributable to DaVita		$	700,742			$	17,257			$	(308	)		$	683,793
HealthCare Partners Inc.		$	700,742			$	17,257			$	(308	)		$	683,793
For the year ended December 31, 2013
Net income (losses)		$	757,201			$	4,481			$	(274	)		$	752,994
Other comprehensive income			12,652				—				—				12,652
Total comprehensive income (losses)			769,853				4,481				(274	)			765,646
Less: Comprehensive income attributable to noncontrolling			(123,755	)			—				—				(123,755	)
interest			(123,755	)			—				—				(123,755	)
Comprehensive income (losses) attributable to DaVita		$	646,098			$	4,481			$	(274	)		$	641,891
HealthCare Partners Inc.		$	646,098			$	4,481			$	(274	)		$	641,891
For the year ended December 31, 2012
Net income (losses)		$	641,237			$	(1,092	)		$	823			$	641,506
Other comprehensive income			4,187				—				—				4,187
Total comprehensive income (losses)			645,424				(1,092	)			823				645,693
Less: Comprehensive income attributable to noncontrolling			(105,220	)			—				—				(105,220	)
interest			(105,220	)			—				—				(105,220	)
Comprehensive income (losses) attributable to DaVita		$	540,204			$	(1,092	)		$	823			$	540,473
HealthCare Partners Inc.		$	540,204			$	(1,092	)		$	823			$	540,473

-1	After the elimination of the unrestricted subsidiaries and the physician groups



Condensed Consolidating Balance Sheets

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
As of December 31, 2014
Cash and cash equivalents		$	965,241			$	112,448			$	—			$	852,793
Accounts receivable, net			1,525,849				255,953				—				1,269,896
Other current assets			1,385,707				18,450				—				1,367,257
Total current assets			3,876,797				386,851				—				3,489,946
Property and equipment, net			2,469,099				2,406				—				2,466,693
Amortizable intangibles, net			1,949,498				6,239				—				1,943,259
Other long-term assets			232,026				66,087				2,811				163,128
Goodwill			9,415,295				9,181				—				9,406,114
Total assets		$	17,942,715			$	470,764			$	2,811			$	17,469,140
Current liabilities		$	2,088,652			$	213,609			$	—			$	1,875,043
Payables to parent			—				178,371				2,811				(181,182	)
Long-term debt and other long-term liabilities			9,663,787				61,895				—				9,601,892
Noncontrolling interests subject to put provisions			829,965				—				—				829,965
Total DaVita HealthCare Partners Inc. shareholders'’ equity			5,170,513				16,889				—				5,153,624
Noncontrolling interests not subject to put provisions			189,798				—				—				189,798
Shareholders' equity			5,360,311				16,889				—				5,343,422
Total liabilities and shareholder's equity		$	17,942,715			$	470,764			$	2,811			$	17,469,140
As of December 31, 2013
Cash and cash equivalents		$	946,249			$	127,309			$	—			$	818,940
Accounts receivable, net			1,485,163				235,463				—				1,249,700
Other current assets			1,040,866				35,640				—				1,005,226
Total current assets			3,472,278				398,412				—				3,073,866
Property and equipment, net			2,189,411				5,541				—				2,183,870
Amortizable intangibles, net			2,024,373				7,283				—				2,017,090
Other long-term assets			199,841				64,013				3,325				132,503
Goodwill			9,212,974				8,981				—				9,203,993
Total assets		$	17,098,877			$	484,230			$	3,325			$	16,611,322
Current liabilities		$	2,462,049			$	193,079			$	—			$	2,268,970
Payables to parent			—				194,958				3,325				(198,283	)
Long-term debt and other long-term liabilities			9,333,987				94,727				—				9,239,260
Noncontrolling interests subject to put provisions			697,300				—				—				697,300
Total DaVita HealthCare Partners Inc. shareholders’' equity			4,432,479				1,466				—				4,431,013
Noncontrolling interests not subject to put provisions			173,062				—				—				173,062
Shareholders' equity			4,605,541				1,466				—				4,604,075
Total liabilities and shareholder's equity		$	17,098,877			$	484,230			$	3,325			$	16,611,322

-1	After the elimination of the unrestricted subsidiaries and the physician groups



Condensed Consolidating Statements of Cash Flows

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For the year ended December 31, 2014
Cash flows from operating activities:
Net income		$	863,330			$	17,257			$	(308	)		$	846,381
Changes in operating and intercompany assets and liabilities and			596,077				1,048				308				594,721
non cash items included in net income			596,077				1,048				308				594,721
Net cash provided by operating activities			1,459,407				18,305				—				1,441,102
Cash flows from investing activities:
Additions of property and equipment			(641,330	)			2,058				—				(643,388	)
Acquisitions and divestitures, net			(272,094	)			—				—				(272,094	)
Proceeds from asset sales			8,791				—				—				8,791
Investments and other items			(373,096	)			(16,745	)			—				(356,351	)
Net cash used in investing activities			(1,277,729	)			(14,687	)			—				(1,263,042	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(7,989	)			—				—				(7,989	)
Intercompany			—				(18,479	)			—				18,479
Other items			(156,990	)			—				—				(156,990	)
Net cash used in financing activities			(164,979	)			(18,479	)			—				(146,500	)
Effect of exchange rate changes on cash			2,293				—				—				2,293
Net increase (decrease) in cash			18,992				(14,861	)			—				33,853
Cash at beginning of the year			946,249				127,309				—				818,940
Cash at the end of the year		$	965,241			$	112,448			$	—			$	852,793
For the year ended December 31, 2013
Cash flows from operating activities:
Net income		$	757,201			$	4,481			$	(274	)		$	752,994
Changes in operating and intercompany assets and liabilities and			1,016,140				4,343				274				1,011,523
non cash items included in net income			1,016,140				4,343				274				1,011,523
Net cash provided by operating activities			1,773,341				8,824				—				1,764,517
Cash flows from investing activities:
Additions of property and equipment			(617,597	)			(2,262	)			—				(615,335	)
Acquisitions and divestitures, net			(310,394	)			—				—				(310,394	)
Proceeds from discontinued operations			62,258				—				—				62,258
Investments and other items			(11,149	)			—				—				(11,149	)
Net cash used in investing activities			(876,882	)			(2,262	)			—				(874,620	)
Cash flows from financing activities:
Long-term debt			(438,007	)			—				—				(438,007	)
Intercompany			—				(11,615	)			—				11,615
Other items			(44,984	)			—				—				(44,984	)
Net cash used in financing activities			(482,991	)			(11,615	)			—				(471,376	)
Effect of exchange rate changes on cash			(967	)			—				—				(967	)
Net increase (decrease) in cash			412,501				(5,053	)			—				417,554
Cash at beginning of the year			533,748				132,362				—				401,386
Cash at the end of the year		$	946,249			$	127,309			$	—			$	818,940

		Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
For the year ended December 31, 2012
Cash flows from operating activities:
Net income		$	641,237			$	(1,092	)		$	823			$	641,506
Changes in operating and intercompany assets and liabilities and			459,611				(26,549	)			(823	)			486,983
non cash items included in net income			459,611				(26,549	)			(823	)			486,983
Net cash provided by operating activities			1,100,848				(27,641	)			—				1,128,489
Cash flows from investing activities:
Additions of property and equipment			(550,146	)			(4,794	)			—				(545,352	)
Acquisitions and divestitures, net			(4,294,077	)			—				—				(4,294,077	)
Proceeds from discontinued operations			3,559				—				—				3,559
Investments and other items			8,214				—				—				8,214
Net cash used in investing activities			(4,832,450	)			(4,794	)			—				(4,827,656	)
Cash flows from financing activities:
Long-term debt			3,904,893				—				—				3,904,893
Intercompany			—				164,797				—				(164,797	)
Other items			(32,509	)			—				—				(32,509	)
Net cash provided by financing activities			3,872,384				164,797				—				3,707,587
Effect of exchange rate changes on cash			(786	)			—				—				(786	)
Net increase in cash			139,996				132,362				—				7,634
Cash at beginning of the year			393,752				—				—				393,752
Cash at the end of the year		$	533,748			$	132,362			$	—			$	401,386


-1	After the elimination of the unrestricted subsidiaries and the physician groups

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2014
Valuation And Qualifying Accounts [Abstract]
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	DAVITA HEALTHCARE PARTNERS INC.
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

	Description	Balance at		Acquisitions		Amounts		Amounts		Balance
		beginning				charged		written off		at end of
		of year				to income				year
				(in thousands)
	Allowance for uncollectible accounts:
	Year ended December 31, 2012	$	250,343	$	7,752	$	243,377	$	256,350	$	245,122
	Year ended December 31, 2013	$	245,122	$	—	$	298,711	$	306,690	$	237,143
	Year ended December 31, 2014	$	237,143	$	—	$	381,337	$	375,806	$	242,674

Organization_and_summary_of_si1

Organization and summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization	Organization
	DaVita HealthCare Partners Inc. operates two major divisions, Kidney Care and HealthCare Partners (HCP). Kidney Care is comprised of the Company’s U.S. dialysis and related lab services, our ancillary services and strategic initiatives, including our international operations, and our corporate support costs. The Company’s largest line of business is its U.S. dialysis and related lab services business, which operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals within the U.S. As of December 31, 2014, the Company operated or provided administrative services through a network of 2,179 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving approximately 173,000 patients. The Company’s HCP division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members primarily through capitation contracts with some of the nation’s leading health plans.
	As of December 31, 2014, the Company operated or provided administrative services to 91 outpatient dialysis centers located in ten countries outside of the U.S.
	The Company’s U.S. dialysis and related lab services business and HCP qualify as separately reportable segments and the Company’s other ancillary services and strategic initiatives, including its international operations, have been combined and disclosed in the other segments category.
Basis of presentation	Basis of presentation
	These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita HealthCare Partners Inc. and its subsidiaries, partnerships and other entities in which it maintains a 100% or majority voting interest, another controlling financial interest, or of which it is considered the primary beneficiary (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Non-marketable equity investments are recorded under the equity or cost method of accounting based upon whether the Company has significant influence over the investee. For the Company’s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the Company’s international subsidiaries’ financial statements from their functional currencies into the Company’s reporting currency (USD). Prior year balances and amounts have been reclassified to conform to the current year presentation and retrospectively revised to reflect purchase accounting entries.
	The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary disclosures.
Use of estimates	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.
	The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets including goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.
Patient service net revenues and accounts receivable	Patient service net revenues and accounts receivable
	Patient service net revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and ancillary services provided to patients. A usual and customary fee schedule is maintained for the Company’s dialysis treatments and other patient services; however, actual collectible revenue is normally recognized at a discount from the fee schedule.
	Patient service revenues earned by HCP are recognized in the period services are provided, net of an estimated contractual allowance and are mainly attributable to primary care physician services and certain other specialty care services provided to patients.
	Revenues associated with Medicare and Medicaid programs are recognized based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient’s commercial health plan secondary coverage, or the patient. The Company’s reimbursements from Medicare are subject to certain variations under Medicare’s single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. The Company’s revenue recognition will depend upon its ability to effectively capture, document and bill for Medicare’s base payment rate as well as these other variable factors.
	Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company’s billing and collection processes that can result in denied claims for payments, and regulatory compliance matters.
	Commercial revenue recognition also involves significant estimating risks. With many larger, commercial insurers the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company’s centers. It is often not possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company’s usual and customary rates.
	Under Medicare’s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit.
	Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.
	The Company’s range of revenue estimating risk for the dialysis and related lab services segment is generally expected to be within 1% of its revenue. Changes in revenue estimates for prior periods are not material.
	Capitated revenue
	HCP capitated revenue
	The Company’s associated medical groups are licensed to contract with health maintenance organizations (HMOs), to provide physician services in California under capitation contracts, and to provide both hospital and physician services under global risk capitation contracts in Florida, Nevada and Arizona. HCP’s revenues consist primarily of fees for medical services provided by these medical group entities’ payments from capitated contracts with various HMOs and revenues under risk-sharing programs. Capitation revenue under HMO contracts is prepaid monthly based on the number of enrollees electing physicians affiliated with one of the medical group entities as their health care provider, regardless of the level of actual medical services utilized. Capitation revenue is reported as revenue in the month in which enrollees are entitled to receive health care. A portion of the capitation revenue pertaining to Medicare enrollees is subject to possible retroactive premium risk adjustments based on their individual acuity. Due to lack of sufficient data to project the amount of such retroactive adjustments, the Company records any corresponding retroactive revenues in the year of receipt.
	Depending on the applicable state regulation regarding global risk capitation, revenues may be received by the Company or by an independent hospital with which the Company contracts under various managed care-related administrative services agreements. In the Florida, Nevada and Arizona service markets, the global capitation revenue is recorded by the Company with the corresponding cost of medical care reported by the Company as patient care costs. In California, the Company receives professional capitation and either the health plan retains the capitated revenues in a shared risk pool or the independent hospitals receive the institutional capitation revenues. The revenues are used to pay medical claims for the related enrollees. The Company is entitled to any residual amounts and bears the risk of any deficits. In all cases, an estimate is made for the cost of medical services that have been incurred and where no medical claim has been received (IBNR).
	Under risk-sharing programs, the medical groups share in the risk for hospitalization services and earn additional incentive revenues or incur penalties based on the utilization of hospital services. Estimated shared-risk receivables from the HMOs are recorded based upon hospital utilization and associated costs incurred by assigned HMO enrollees, including an estimate of IBNR compared to budgeted funding. Differences between actual contract settlements and estimated receivables or payables are recorded in the year of final settlement. The medical groups also receive other incentive payments from health plans based on specified performance and quality criteria. These amounts are accrued when earned and the amounts can be reasonably estimated, and are included in HCP’s capitated revenues. HCP recently obtained a restricted Knox-Keene license in California, which now permits HCP to enter into contracts with health plans allowing it to recognize revenue in 2014 under global capitation arrangements for both professional and institutional services.
	Other capitated revenues
	One of the Company’s subsidiaries operates a Medicare Advantage ESRD Special Needs Plan in partnership with a payor that works with CMS to provide ESRD patients full service health care. The Company is at risk for all medical costs of the program in excess of the capitation payments.
	Other revenues
	Other revenues consist of the non-patient service revenues associated with the ancillary services and strategic initiatives, management and administrative support services that are provided to outpatient dialysis centers that the Company does not own or in which the Company owns a minority equity interest, retail pharmacies and medical consulting services. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interest. Management fees are principally determined as a percentage of the managed operations’ revenues or cash collections and in some cases an additional component based upon a percentage of operating income. Management fees are included in net revenues when earned and represent less than 1% of total consolidated operating revenues. Revenues related to medical consulting services are recognized in the period services are provided.
Allowance for uncollectible accounts	Allowance for uncollectible accounts
Allowance for uncollectible accounts	Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters. The Company’s policy is to write off any uncollectible accounts receivable balance only after all collection efforts have been exhausted or when write off is mandated by federal or state policies or required by certain payor contracts. It is also the Company’s policy to write off any accounts receivable balance associated with any payors or patients when the Company receives notification of a bankruptcy filing.
Other income	Other income
Other income	Other income includes interest income on cash investments and other non-operating gains from investment transactions.
Cash and cash equivalents	Cash and cash equivalents
Cash and cash equivalents	Cash equivalents are short-term highly liquid investments with maturities of three months or less at date of purchase.
Inventories	Inventories
Inventories	Inventories are stated at the lower of cost (first-in, first-out) or market and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels by the manufacturer and data submission.
Funds on deposit with a third party	Funds on deposit with a third party
Funds on deposit with a third party	The Company has established a risk sharing arrangement with a California hospital, wherein the Company shares in any surplus or deficit. One of the terms of this agreement is the establishment of a segregated investment fund to ensure adequate cash to pay IBNR. The Company and the hospital monitor the reserve balance to maintain the adequacy of funds on deposit. The Company has $81,276 in such funds as of December 31, 2014, in other current assets on the consolidated balance sheet.
Property and equipment	Property and equipment
Property and equipment	Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 20 to 40 years; leasehold improvements, the shorter of their economic useful life or the expected lease term; and equipment and information systems, principally three to eight years. Disposition gains and losses are included in current operating expenses.
Amortizable intangibles	Amortizable intangibles
Amortizable intangibles	Amortizable intangible assets and liabilities include customer relationships, trade names, provider networks, supply agreements, practice management tools, non-competition and similar agreements, lease agreements, hospital acute services contracts and deferred debt financing costs, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: customer relationships, ten to twenty years; trade names, provider networks and practice management tools, two to fifteen years; non-competition and similar agreements, two to ten years; the alliance and product supply agreement, ten years; and lease agreements and hospital acute service contracts, over the term of the lease or contract period, respectively. Deferred debt financing costs are amortized to debt expense over the term of the related debt using the effective interest method.
Investments	Investments
Investments	Based upon the Company’s intentions and strategy concerning investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and measures them at amortized cost. The Company classifies equity securities that have readily determinable fair values and certain other debt securities as available for sale and measures them at fair value. Unrealized gains or losses from available for sale investments are recorded in other comprehensive income until realized.
Goodwill	Goodwill
Goodwill	Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed for valuation impairment as circumstances may warrant and at least annually. An impairment charge would be recorded to the extent the carrying amount of goodwill exceeds its implied fair value. The Company operates several reporting units for goodwill impairment assessments. See Note 10 to the consolidated financial statements for further details.
Impairment of long-lived assets	Impairment of long-lived assets
Impairment of long-lived assets	Long-lived assets, including property and equipment, equity investments in non-consolidated businesses and amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred, including changes in the Company’s business strategy and plans, changes in the quality or structure of its relationships with its partners or deteriorating operating performance of individual outpatient dialysis centers or other operations. An impairment is indicated when the sum of the expected future undiscounted net cash flows identifiable to an asset group is less than its carrying amount. Impairment losses are measured based upon the difference between the actual or estimated fair values, which are based on market values, net realizable values or projections of discounted net cash flows, as appropriate, and the carrying amount of the asset. Impairment charges are included in operating expenses. Indefinite-lived intangible assets are reviewed for possible impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred.
Self insurance	Self insurance
Self insurance	The Company’s Kidney Care division maintains insurance reserves for professional and general liability and workers’ compensation in excess of certain individual and or aggregate amounts not covered by third-party carriers. The Company’s Kidney Care division estimates the self-insured retention portion of professional and general liability and workers’ compensation risks using third-party actuarial calculations that are based upon historical claims experience and expectations for future claims. In addition, HCP has purchased its primary professional and general liability insurance from California Medical Group Insurance (CMGI) in which the Company owns an equity interest of 67%.
Medical liability costs	Medical liability costs
	The medical groups are responsible for integrated care that the associated physicians and contracted hospitals provide to assigned HMO enrollees. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as patient care costs in the consolidated statements of income. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in patient care costs.
	An estimate of amounts due to contracted physicians, hospitals, and other professional providers for members under global and professional risk arrangements is included in medical payables in the accompanying consolidated balance sheets. Medical payables include claims reported as of the balance sheet date and estimates of IBNR. Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are continually reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. Any adjustments to reserves are reflected in current operations.
Income taxes	Income taxes
	Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.
	The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.
Stock-based compensation	Stock-based compensation
Stock-based compensation	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. Stock-based compensation to be settled in shares is recorded to the Company’s shareholders’ equity, while stock-based compensation to be settled in cash is recorded to a liability.
Interest rate swap and cap agreements	Interest rate swap and cap agreements
Interest rate swap and cap agreements	The Company has several interest rate swap agreements as a means of hedging its exposure to and volatility from LIBOR variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are designated as cash flow hedges and are not held for trading or speculative purposes. The swap agreements have the economic effect of converting the majority of the LIBOR variable component of the Company’s interest rate to fixed rates on the Company’s Term Loan A outstanding balances. In addition, the Company has several interest rate cap agreements that have the economic effect of capping the Company’s maximum exposure to LIBOR variable interest rate changes on specific portions of the Company’s Term Loan B totaling $2,735,000. The Company also maintains several forward interest rate cap agreements with notional amounts totaling $3,500,000 that will be effective September 30, 2016 and will have economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent of the Company’s debt. See Note 14 to the consolidated financial statements for further details.
Noncontrolling interests	Noncontrolling interests
Noncontrolling interests	Noncontrolling interests represent third-party minority equity ownership interests in consolidated entities which are majority-owned by the Company, as well as the equity ownership interests in entities that are not owned by the Company but which are consolidated for financial statement reporting purposes. As of December 31, 2014, third parties held noncontrolling ownership interests in approximately 380 consolidated legal entities.
Fair value estimates	Fair value estimates
Fair value estimates	The Company currently measures the fair value of certain assets, liabilities (including contingent earn-out consideration) and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable market inputs and assumptions that market participants would use in pricing these assets, liabilities and temporary equity. The Company has also classified its assets, liabilities and temporary equity into the appropriate fair value hierarchy levels as defined by the FASB. See Note 24 to the consolidated financial statements for further details.
New accounting standards	New accounting standards
	On January 1, 2013, the Company adopted the Financial Accounting Standards Boards (FASB) ASU No. 2013-02 Comprehensive Income. This standard requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. See Note 20 to the consolidated financial statements for further details.
	In July 2013, the FASB issued ASU No. 2013-10, Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. This standard amends the acceptable benchmark interest rates to permit the inclusion of the Fed Funds Effective Swap Rate (OIS) to be used as a U.S. benchmark interest rate for hedge accounting purposes in addition to U.S. government (UST) and LIBOR. The amendment also removes the restriction on using different benchmark rates for similar hedges. This standard is applied prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Earnings_per_share_Tables

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share	The reconciliations of the numerators and denominators used to calculate basic and diluted net income per share are as follows:

			Year ended December 31,
			2014			2013			2012
			(shares in thousands)
	Basic:
	Income from continuing operations attributable to DaVita HealthCare		$	723,114		$	620,197		$	536,236
	Partners Inc.
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			13,249			(219	)
	Net income attributable to DaVita HealthCare Partners Inc. for basic		$	723,114		$	633,446		$	536,017
	earnings per share calculation
	Weighted average shares outstanding during the period			214,496			212,128			192,396
	Vested stock units			—			5			6
	Contingently returnable shares held in escrow for the DaVita HealthCare			(2,194	)		(2,194	)		(366	)
	Partners merger
	Weighted average shares for basic earnings per share calculation			212,302			209,939			192,036
	Basic income from continuing operations per share attributable to		$	3.41		$	2.95		$	2.79
	DaVita HealthCare Partners Inc.
	Basic income from discontinued operations per share attributable			—			0.07			—
	to DaVita HealthCare Partners Inc.
	Basic net income per share attributable to DaVita HealthCare		$	3.41		$	3.02		$	2.79
	Partners Inc.
	Diluted:
	Income from continuing operations attributable to DaVita		$	723,114		$	620,197		$	536,236
	HealthCare Partners Inc.
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			13,249			(219	)
	Net income attributable to DaVita HealthCare Partners Inc. for		$	723,114		$	633,446		$	536,017
	diluted earnings per share calculation
	Weighted average shares outstanding during the period			214,496			212,128			192,396
	Vested stock units			—			5			6
	Assumed incremental shares from stock plans			2,432			2,631			3,540
	Weighted average shares for diluted earnings per share calculation			216,928			214,764			195,942
	Diluted income from continuing operations per share attributable		$	3.33		$	2.89		$	2.74
	to DaVita HealthCare Partners Inc.
	Diluted income from discontinued operations per share attributable to			—			0.06			—
	DaVita HealthCare Partners Inc.
	Diluted net income per share attributable to DaVita HealthCare		$	3.33		$	2.95		$	2.74
	Partners Inc.
	Anti-dilutive stock-settled awards excluded from calculation(1)			1,715			4,194			2,616

	-1	Shares associated with stock-settled stock appreciation rights and stock options excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Other_receivables_Tables

Other receivables (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Other Receivables	Other receivables were comprised of the following:

		December 31,
		2014		2013
	Supplier rebates and non-trade receivables	$	265,693	$	217,100
	Medicare bad debt claims		118,504		110,825
	Operating advances under management and administrative		16,719		21,165
	services agreements
		$	400,916	$	349,090

Other_current_assets_Tables

Other current assets (Tables)	12 Months Ended
Other current assets (Tables)	Dec. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Current Assets	Other current assets consist principally of prepaid expenses and funds on deposit with third parties.

		December 31,
		2014		2013
	Prepaid expenses	$	102,466	$	93,877
	Funds on deposit with third parties		81,276		79,317
	Other		3,100		3,220
		$	186,842	$	176,414

Property_and_equipment_Tables

Property and equipment (Tables)	12 Months Ended
Property and equipment (Tables)	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property and Equipment	Property and equipment were comprised of the following:

		December 31,
		2014			2013
	Land	$	35,885		$	34,960
	Buildings		157,550			157,998
	Leasehold improvements		2,002,735			1,762,470
	Equipment and information systems		2,066,775			1,839,981
	New center and capital asset projects in progress		235,660			172,261
			4,498,605			3,967,670
	Less accumulated depreciation		(2,029,506	)		(1,778,259	)
		$	2,469,099		$	2,189,411

Intangibles_Tables

Intangibles (Tables)	12 Months Ended
Intangibles (Tables)	Dec. 31, 2014
Intangible Assets Gross Excluding Goodwill [Abstract]
Amortizable intangible assets	Intangible assets were comprised of the following:

		December 31,
		2014			2013
	Customer relationships	$	1,575,865		$	1,503,426
	Trade names		171,168			170,994
	Provider network and practice management tools		183,688			184,558
	Noncompetition and other agreements		506,867			495,475
	Lease agreements		7,982			8,889
	Deferred debt financing costs		101,001			121,872
	Indefinite-lived assets		24,818			22,932
			2,571,389			2,508,146
	Less accumulated amortization		(621,891	)		(483,773	)
	Total intangible assets	$	1,949,498		$	2,024,373

Amortizable Intangible Liabilities	Amortizable intangible liabilities were comprised of the following:

		December 31,
		2014			2013
	Alliance and product supply agreement commitment	$	68,200		$	68,200
	(See Note 18)	$	68,200		$	68,200
	Less accumulated amortization		(64,203	)		(58,873	)
	Net Alliance and product supply agreement		3,997			9,327
	Lease agreements (net of accumulated amortization of $4,785		10,407			12,563
	and $2,628)		10,407			12,563
		$	14,404		$	21,890

Scheduled Amortization Charges from Intangible Assets and Liabilities	Scheduled amortization charges from amortizable intangible assets and liabilities as of December 31, 2014 were as follows:

		Customer			Trade			Provider		Noncompetition		Lease			Deferred		Alliance and
		relationships			names			network and		and other		agreements, net			debt		product
								practice		agreements					financing		supply
								management							costs		agreement
								tools									liability
	2015		82,619			16,429			26,229		40,482		(2,107	)		13,279		(3,997	)
	2016		82,704			16,429			26,179		30,172		(1,506	)		13,129		—
	2017		82,686			16,418			26,243		28,563		(1,185	)		12,976		—
	2018		82,640			16,364			26,266		18,429		(849	)		12,683		—
	2019		82,407			16,364			22,542		13,984		(789	)		10,636		—
	Thereafter		991,862			53,961			526		39,242		(3,971	)		22,237		—

Investments_in_debt_and_equity1

Investments in debt and equity securities (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Investments	The Company’s investments in securities consist of the following:

		31-Dec-14						31-Dec-13
		Held to		Available		Total		Held to		Available		Total
		maturity		for sale				maturity		for sale
	Certificates of deposit and money market funds due	$	335,975	$	—	$	335,975	$	5,601	$	—	$	5,601
	within one year
	Investments in mutual funds and common stock		—		28,123		28,123		—		19,421		19,421
		$	335,975	$	28,123	$	364,098	$	5,601	$	19,421	$	25,022
	Short-term investments	$	335,975	$	1,424	$	337,399	$	5,601	$	1,200	$	6,801
	Long-term investments		—		26,699		26,699		—		18,221		18,221
		$	335,975	$	28,123	$	364,098	$	5,601	$	19,421	$	25,022

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Goodwill by Reportable Segments	Changes in the value of goodwill by reportable segments were as follows:

		U.S. dialysis and			HCP			Other ancillary			Consolidated total
		related lab services						services and
								strategic initiatives
	Balance at January 1, 2013	$	5,309,152		$	3,506,571		$	137,027		$	8,952,750
	Acquisitions		163,037			17,833			90,397		$	271,267
	Divestitures		(2,728	)		—			—		$	(2,728	)
	Other adjustments		12			(8,242	)		(85	)	$	(8,315	)
	Balance at December 31, 2013	$	5,469,473		$	3,516,162		$	227,339		$	9,212,974
	Acquisitions		143,021			48,649			29,844		$	221,514
	Divestitures		(1,851	)		—			—		$	(1,851	)
	Foreign currency and other adjustments		—			(2,277	)		(15,065	)	$	(17,342	)
	Balance at December 31, 2014	$	5,610,643		$	3,562,534		$	242,118		$	9,415,295

Other_liabilities_Tables

Other liabilities (Tables)	12 Months Ended
Other liabilities (Tables)	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Other Liabilities	Other liabilities were comprised of the following:

		December 31,
		2014		2013
	Payor refunds and retractions	$	125,435	$	169,480
	Contingent earn-out consideration		15,614		6,577
	Insurance and self-insurance accruals		92,928		84,882
	Accrued interest		87,224		45,662
	Other medical payables		39,867		31,219
	Accrued non-income tax liabilities		25,909		18,366
	Interest rate swap agreements		1,457		12,069
	Other		118,145		96,167
		$	506,579	$	464,422

Medical_payables_Tables

Medical payables (Tables)	12 Months Ended
Medical payables (Tables)	Dec. 31, 2014
Health Care Organizations [Abstract]
Components of Changes in Health Care Costs Payable	The following table shows the components of changes in the health care costs payable for the year ended December 31, 2014 and 2013:

		December 31,
		2014		2013
	Health care costs payable, beginning of the year	$	172,310	$	119,512
	Acquisitions and other adjustments		—		26,575
	Add: Components of incurred health care costs
	Current year		1,572,723		1,329,887
	Prior years		3,429		(16,587	)
	Total incurred health care costs		1,576,152		1,313,300
	Less: Claims paid
	Current year		1,378,137		1,169,455
	Prior years		155,920		117,622
	Total claims paid		1,534,057		1,287,077
	Health care costs payable, end of the year	$	214,405	$	172,310

Income_taxes_Tables

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Income Tax Expense (benefit)	Income tax expense (benefit) consisted of the following:

		Year ended December 31,
		2014			2013			2012
	Current:
	Federal	$	188,302		$	334,258		$	239,232
	State		30,789			68,715			49,178
	International		1,687			1,764			660
	Total current income tax	$	220,778		$	404,737		$	289,070
	Deferred:
	Federal		192,267			(6,695	)		64,195
	State		32,360			(8,941	)		6,498
	International		938			746			—
	Total deferred income tax	$	225,565		$	(14,890	)	$	70,693
		$	446,343		$	389,847		$	359,763

Allocation of Income Tax Expense (Benefit)	The allocation of income tax expense (benefit) was as follows:

		Year ended December 31,
		2014			2013			2012
	Continuing operations	$	446,343		$	381,013		$	359,845
	Discontinued operations		—			(84	)		(82	)
	Gain on discontinued operations		—			8,918			—
		$	446,343		$	389,847		$	359,763

Reconciliation between our Effective Tax Rate from Continuing Operations and the U.S. Federal Income Tax Rate	The reconciliation between the Company’s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:

		Year ended December 31,
		2014			2013			2012
	Federal income tax rate		35	%		35	%		35	%
	State income taxes, net of federal benefit		3.5			3.8			4
	International rate differential		(0.2	)		0.1			—
	Changes in deferred tax valuation allowances		0.6			0.3			—
	Contingent earn-out adjustments		—			(2.6	)		—
	Other		(0.8	)		1.4			1.1
	Impact of noncontrolling interests primarily attributable to non-tax paying entities		(4.0	)		(4.1	)		(4.2	)
	Effective tax rate		34.1	%		33.9	%		35.9	%

Deferred Tax Assets and Liabilities Arising from Temporary Differences	Deferred tax assets and liabilities arising from temporary differences associated with continuing operations were as follows:

		December 31,
		2014			2013
	Receivables	$	42,973		$	49,667
	Accrued liabilities		253,158			252,008
	Loss contingency reserve		1,423			139,844
	Net operating loss carryforwards		100,768			96,212
	Other		88,435			67,882
	Deferred tax assets		486,757			605,613
	Valuation allowance		(26,667	)		(13,860	)
	Net deferred tax assets		460,090			591,753
	Intangible assets		(835,816	)		(752,838	)
	Property and equipment		(187,054	)		(183,059	)
	Investments in partnerships		(78,618	)		(51,921	)
	Other		(8,677	)		(6,913	)
	Deferred tax liabilities		(1,110,165	)		(994,731	)
	Net deferred tax liabilities	$	(650,075	)	$	(402,978	)

Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-than-not Threshold	A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold were as follows:

		Year ended December 31,
			2014			2013
	Balance beginning	$	60,538		$	67,546
	Additions for tax positions related to current year		914			6,005
	Reductions for tax positions related to prior years		(27,312	)		(3,901	)
	Reductions related to lapse of applicable statute		(2,077	)		(8,480	)
	Reductions related to settlements with taxing authorities		(186	)		(632	)
	Balance ending	$	31,877		$	60,538

Longterm_debt_Tables

Long-term debt (Tables)	12 Months Ended
Long-term debt (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Long Term Debt	Long-term debt was comprised of the following:

		December 31,
		2014				2013
	Senior Secured Credit Facilities:
	Term Loan A	$	975,000			$	800,000
	Term Loan A-3		—				1,282,500
	Term Loan B		3,482,500				1,697,500
	Term Loan B-2		—				1,633,500
	Senior notes		3,775,000				2,800,000
	Acquisition obligations and other notes payable		69,045				67,352
	Capital lease obligations		218,097				152,751
	Total debt principal outstanding		8,519,642				8,433,603
	Discount on long-term debt		(16,208	)			(17,675	)
			8,503,434				8,415,928
	Less current portion		(120,154	)			(274,697	)
		$	8,383,280			$	8,141,231

Scheduled Maturities of Long-term Debt	Scheduled maturities of long-term debt at December 31, 2014 were as follows:

	2015		120,154
	2016		117,193
	2017		144,161
	2018		155,750
	2019		730,084
	Thereafter		7,252,300

Derivative Instruments	The following table summarizes the Company’s derivative instruments as of December 31, 2014 and 2013:

		Interest rate swap and cap agreements (liabilities and assets)
		31-Dec-14						31-Dec-13
	Derivatives designated as hedging instruments	Balance sheet		Fair value				Balance sheet	Fair value
	Derivatives designated as hedging instruments	location		Fair value				location	Fair value
	Interest rate swap agreements	Other short-		$	1,457			Other short-	$	12,069
	Interest rate swap agreements	term liabilities		$	1,457			term liabilities	$	12,069
	Interest rate swap agreements	Other long-		$	3,281			Other long-	$	10,004
	Interest rate swap agreements	term assets		$	3,281			term assets	$	10,004
	Interest rate cap agreements	Other long-		$	13,934			Other long-	$	7,567
	Interest rate cap agreements	term assets		$	13,934			term assets	$	7,567

Effects of Interest Rate Swap Agreements	The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the years ended December 31, 2014, 2013 and 2012:

		Amount of gains (losses)										Location of (losses) gains reclassified from	Amount of gains (losses)
		recognized in OCI											reclassified from accumulated
		on interest rate swap											OCI into income
		and cap agreements
		Years ended December 31,										accumulated	Years ended December 31,
	Derivatives designated as cash flow hedges	2014				2013			2012			OCI into	2014			2013			2012
	Derivatives designated as cash flow hedges	2014				2013			2012			income	2014			2013			2012
	Interest rate swap agreements	$	(8,390	)		$	1,251		$	(8,838	)	Debt expense	$	12,279		$	15,678		$	(12,989	)
	Interest rate cap agreements		(8,119	)			(974	)		(1,316	)	Debt expense		5,130			5,418			(3,589	)
	Tax (expense) benefit		6,450				(108	)		3,950				(6,801	)		(8,207	)		6,448
	Total	$	(10,059	)		$	169		$	(6,204	)		$	10,608		$	12,889		$	(10,130	)

Leases_Tables

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2014
Leases [Abstract]
Future Minimum Lease Payments Under Non-cancelable Operating Leases and Capital Leases	Future minimum lease payments under non-cancelable operating leases and capital leases are as follows:

		Operating		Capital
		leases		leases
	2015	$	395,862	$	21,011
	2016		370,920		21,277
	2017		344,232		21,552
	2018		302,752		21,961
	2019		262,645		22,615
	Thereafter		901,792		202,245
		$	2,578,203		310,661
	Less portion representing interest				(92,564	)
	Total capital lease obligations, including current portion			$	218,097

Longterm_incentive_compensatio1

Long-term incentive compensation and shareholders' equity (Tables)	12 Months Ended
	Dec. 31, 2014
Share Based Compensation [Abstract]
Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements	A combined summary of the status of the Company’s stock-settled awards under the 2011 Plan, including base shares for stock-settled stock appreciation rights and stock-settled stock unit awards is as follows:

		Year ended December 31, 2014
		Stock appreciation rights									Stock units
					Weighted			Weighted						Weighted
					average			average						average
					exercise			remaining						remaining
		Awards			price			contractual life			Awards			contractual life
	Outstanding at beginning of year		12,956,094		$	45.44						966,596
	Granted		1,553,829			70.15						332,007
	Exercised		(3,473,804	)		32.05						(303,970	)
	Cancelled		(450,947	)		51.49						(72,735	)
	Outstanding at end of period		10,585,172		$	53.21			2.7			921,898			1.5
	Exercisable at end of period		2,541,397		$	42.79			1.6			496			0.3
	Weighted-average fair value of grants in 2014	$	16.41								$	72.24
	Weighted-average fair value of grants in 2013	$	13.47								$	58.9
	Weighted-average fair value of grants in 2012	$	11.28								$	54.85

Summary of Range of Exercise Prices
		Awards			Weighted average			Awards			Weighted average
	Range of SSAR base prices	outstanding			exercise price			exercisable			exercise price
	$20.01–$30.00		9,000			29.9			9,000			29.9
	$30.01–$40.00		893,976			34.92			710,869			34.65
	$40.01–$50.00		3,230,512			43.02			1,545,204			42.86
	$50.01–$60.00		4,577,354			57.49			36,324			55.03
	$60.01–$70.00		1,470,547			68.06			240,000			65.08
	$70.01–$80.00		403,783			73.07			—			—
	Total		10,585,172		$	53.21			2,541,397		$	42.79

Summary of Weighted Average Valuation Inputs	A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock-settled stock appreciation rights awards granted in the periods indicated is as follows:

		Year ended December 31,
		2014			2013			2012
	Expected term	4.2 years			4.1 years			3.7 years
	Expected volatility		25.8	%		27.2	%		28	%
	Expected dividend yield		0	%		0	%		0	%
	Risk-free interest rate		1.5	%		0.7	%		0.6	%

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity	The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows:

		Year ended December 31,
		2014			2013			2012
	Net income attributable to DaVita HealthCare Partners Inc.	$	723,114		$	633,446		$	536,017
	Increase (decrease) in paid-in capital for sales of		355			(1,442	)		1,064
	noncontrolling interest		355			(1,442	)		1,064
	Decrease in paid-in capital for the purchase of a		(5,357	)		(3,119	)		(20,694	)
	noncontrolling interest		(5,357	)		(3,119	)		(20,694	)
	Net transfer to noncontrolling interests		(5,002	)		(4,561	)		(19,630	)
	Change from net income attributable to DaVita	$	718,112		$	628,885		$	516,387
	HealthCare Partners Inc. and transfers to
	noncontrolling interests

Other_comprehensive_income_los1

Other comprehensive income (loss) (Tables)	12 Months Ended
Other comprehensive income (loss) (Tables)	Dec. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income (Loss)	Charges and credits to other comprehensive income (loss) have been as follows:

		Interest rate			Investment			Foreign			Accumulated
		swap and cap			securities			currency			other
		agreements						translation			comprehensive
								adjustments			income (loss)
	Balance at December 31, 2011	$	(19,328	)	$	(156	)	$	—		$	(19,484	)
	Unrealized (losses) gains		(10,154	)		2,524			(1,205	)		(8,835	)
	Related income tax		3,950			(983	)		—			2,967
			(6,204	)		1,541			(1,205	)		(5,868	)
	Reclassification from accumulated other		16,578			(123	)		—			16,455
	comprehensive losses (income) into net income		16,578			(123	)		—			16,455
	Related income tax		(6,448	)		48			—			(6,400	)
			10,130			(75	)		—			10,055
	Balance at December 31, 2012	$	(15,402	)	$	1,310		$	(1,205	)	$	(15,297	)
	Unrealized gains (losses)		277			3,752			(2,216	)		1,813
	Related income tax		(108	)		(1,452	)		—			(1,560	)
			169			2,300			(2,216	)		253
	Reclassification from accumulated other		21,096			(802	)		—			20,294
	comprehensive losses (income) into net income		21,096			(802	)		—			20,294
	Related income tax		(8,207	)		312			—			(7,895	)
			12,889			(490	)		—			12,399
	Balance at December 31, 2013	$	(2,344	)	$	3,120		$	(3,421	)	$	(2,645	)
	Unrealized (losses) gains		(16,509	)		425			(22,952	)		(39,036	)
	Related income tax		6,450			(187	)		—			6,263
			(10,059	)		238			(22,952	)		(32,773	)
	Reclassification from accumulated other		17,409			(340	)		—			17,069
	comprehensive losses (income) into net income		17,409			(340	)		—			17,069
	Related income tax		(6,801	)		133			—			(6,668	)
			10,608			(207	)		—			10,401
	Balance at December 31, 2014	$	(1,795	)	$	3,151		$	(26,373	)	$	(25,017	)

Acquisitions_and_discontinued_1

Acquisitions and discontinued operations (Tables)	12 Months Ended
Acquisitions and discontinued operations (Tables)	Dec. 31, 2014
Business Acquisition [Line Items]
Reconciliation of Changes in Contingent Earn-Out Obligations	The following is a reconciliation of changes in the contingent earn-out obligations for the year ended December 31, 2014:

	Beginning balance, January 1, 2014	$	28,058
	Contingent earn-out obligations associated with acquisitions		18,234
	Remeasurement of fair value		(4,448	)
	Payments of contingent earn-out obligations		(2,715	)
		$	39,129

Pro Forma Summary of Results of Operations	The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions and divestitures in 2014 and 2013 had been consummated as of the beginning of 2013, after including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.

		Year ended December 31,
		2014			2013
		(unaudited)
	Pro forma net revenues	$	12,887,330		$	12,160,749
	Pro forma net income attributable to DaVita HealthCare Partners Inc.		733,490			651,204
	Pro forma income from continuing operations attributable to DaVita HealthCare Partners Inc.		733,490			651,204
	Pro forma basic net income per share attributable to DaVita HealthCare Partners Inc.		3.45			3.1
	Pro forma diluted net income per share attributable to DaVita HealthCare Partners Inc.		3.38			3.03

HomeChoice Partners
Business Acquisition [Line Items]
Results from Discontinued Operations	The results from discontinued operations related to HomeChoice were as follows:

		Year ended December 31,
		2014			2013			2012
	Net revenues		—		$	6,351		$	67,990
	Loss before income taxes		—			(223	)		(304	)
	Income tax benefit		—			(84	)		(82	)
	Loss from discontinued operations	$	—		$	(139	)	$	(222	)

Net Assets of Discontinued Operations	Net assets of discontinued operations related to HomeChoice as of February 1, 2013, were as follows:

	Current assets	$	17,039
	Property and equipment, net		2,963
	Long-term assets		28
	Goodwill		31,853
	Liabilities and noncontrolling interests		(8,998	)
	Net assets from discontinued operations	$	42,885

Other dialysis acquisitions
Business Acquisition [Line Items]
Aggregate Purchase Cost Allocations	The following table summarizes the assets acquired and liabilities assumed in the above described transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:

		Year ended December 31,
		2014			2013			2012
	Current assets	$	915		$	7,215		$	18,708
	Property and equipment		5,999			23,760			41,741
	Amortizable intangible and other long-term assets		95,293			80,646			90,296
	Goodwill		221,514			271,267			554,685
	Long-term deferred income taxes		—			(5,666	)		(1,838	)
	Noncontrolling interests assumed		(25,963	)		(22,880	)		(21,962	)
	Liabilities assumed		(1,883	)		(19,265	)		(27,211	)
	Aggregate purchase cost	$	295,875		$	335,077		$	654,419

HealthCare Partners (HCP)
Business Acquisition [Line Items]
Aggregate Purchase Cost Allocations	The following table summarizes the initial assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at their estimated fair values at that date:

	Current assets, net of cash acquired	$	321,235
	Property and equipment		102,382
	Intangible assets		1,882,818
	Other long-term assets		100,143
	Goodwill		3,496,713
	Current liabilities assumed		(559,180	)
	Other long-term liabilities		(169,015	)
	Long-term deferred income taxes		(184,015	)
	Noncontrolling interests		(29,850	)
		$	4,961,231

Fair_values_of_financial_instr1

Fair values of financial instruments (Tables)	12 Months Ended
Fair values of financial instruments (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis	The following tables summarize the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December 31, 2014 and 2013:

		Total		Quoted prices in		Significant other		Significant
				active markets for		observable inputs		unobservable
				identical assets		(Level 2)		inputs
				(Level 1)				(Level 3)
	31-Dec-14
	Assets
	Available for sale securities	$	28,123	$	28,123	$	—	$	—
	Interest rate cap agreements	$	13,934	$	—	$	13,934	$	—
	Interest rate swap agreements	$	3,281	$	—	$	3,281	$	—
	Funds on deposit with third parties	$	81,276	$	81,276	$	—	$	—
	Liabilities
	Interest rate swap agreements	$	1,457	$	—	$	1,457	$	—
	Contingent earn-out obligations	$	39,129	$	—	$	—	$	39,129
	Temporary equity
	Noncontrolling interests subject to put provisions	$	829,965	$	—	$	—	$	829,965
	31-Dec-13
	Assets
	Available for sale securities	$	19,421	$	19,421	$	—	$	—
	Interest rate cap agreements	$	7,567	$	—	$	7,567	$	—
	Interest rate swap agreements	$	10,004	$	—	$	10,004	$	—
	Funds on deposit with third parties	$	79,317	$	79,317	$	—	$	—
	Liabilities
	Interest rate swap agreements	$	12,069	$	—	$	12,069	$	—
	Contingent earn-out obligations	$	28,058	$	—	$	—	$	28,058
	Temporary equity
	Noncontrolling interests subject to put provisions	$	697,300	$	—	$	—	$	697,300

Segment_reporting_Tables

Segment reporting (Tables)	12 Months Ended
Segment reporting (Tables)	Dec. 31, 2014
Segment Reporting [Abstract]
Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes	The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

			Year ended December 31,
			2014			2013			2012
	Segment revenues:
	U.S. dialysis and related lab services
	Patient service revenues:
	External sources		$	8,513,089		$	7,998,692		$	7,299,032
	Intersegment revenues			37,112			34,080			17,786
	Total dialysis and related lab services revenues			8,550,201			8,032,772			7,316,818
	Less: Provision for uncollectible accounts			(353,028	)		(281,146	)		(233,580	)
	Net dialysis and related lab services patient			8,197,173			7,751,626			7,083,238
	service revenues			8,197,173			7,751,626			7,083,238
	Other revenues(1)			13,498			12,600			11,447
	Total net dialysis and related lab services			8,210,671			7,764,226			7,094,685
	revenues			8,210,671			7,764,226			7,094,685
	HCP
	HCP revenues:
	Capitated revenues		$	3,190,903		$	2,919,964		$	419,431
	Net patient service revenues			219,306			220,251			34,407
	Other revenues(2)			91,374			55,723			23,552
	Intersegment capitated and other revenues			716			250			—
	Total revenues		$	3,502,299		$	3,196,188		$	477,390
	Other - Ancillary services and strategic initiatives
	Net patient service revenues		$	122,087		$	75,852		$	16,824
	Capitated revenues			70,385			67,351			61,906
	Other external sources			927,492			694,763			553,261
	Intersegment revenues			19,535			13,916			10,481
	Total ancillary services and strategic initiatives			1,139,499			851,882			642,472
	revenues			1,139,499			851,882			642,472
	Total net segment revenues			12,852,469			11,812,296			8,214,547
	Elimination of intersegment revenues			(57,363	)		(48,246	)		(28,267	)
	Consolidated net revenues		$	12,795,106		$	11,764,050		$	8,186,280
	Segment operating margin (loss):(3)
	U.S. dialysis and related lab services		$	1,637,626		$	1,200,198		$	1,372,265
	HCP			214,983			385,253			66,930
	Other——Ancillary services and strategic initiatives			(24,456	)		(38,595	)		(64,877	)
	Total segment margin			1,828,153			1,546,856			1,374,318
	Reconciliation of segment operating margin to
	consolidated income from continuing operations before
	income taxes:
	Contingent earn-out obligation adjustment			—			56,977			—
	Corporate support costs(4)			(13,012	)		(53,699	)		(46,481	)
	Transaction expenses			—			—			(30,753	)
	Consolidated operating income			1,815,141			1,550,134			1,297,084
	Debt expense			(410,294	)		(429,943	)		(288,554	)
	Debt refinancing and redemption charges			(97,548	)		—			(10,963	)
	Other income			2,374			4,787			3,737
	Consolidated income from continuing		$	1,309,673		$	1,124,978		$	1,001,304
	operations before income taxes		$	1,309,673		$	1,124,978		$	1,001,304

	-1	Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.
	-2	Other revenues primarily relate to providing medical consulting services.
	-3	Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.
	-4	Corporate support costs in 2013 also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.
Summary of Depreciation and Amortization Expense by Segment	Depreciation and amortization expense by segment is as follows:

			December 31,
			2014			2013			2012

	U.S. dialysis and related lab services		$	402,767		$	355,879		$	310,375
	HCP			169,485			158,356			24,544
	Other - Ancillary services and strategic initiatives			18,683			14,502			7,050
			$	590,935		$	528,737		$	341,969

Summary of Assets by Segment	Summary of assets by segment is as follows:

			December 31,
			2014			2013
	Segment assets
	U.S. dialysis and related lab services (including equity investments of $28,138 and $27,009, respectively)		$	10,959,096		$	10,248,993
	HCP (including equity investments of $15,393 and $13,677, respectively)			6,285,984			6,265,767
	Other - —Ancillary services and strategic initiatives(1) (including equity investments of $22,106 in 2014)			697,635			584,117
	Consolidated assets		$	17,942,715		$	17,098,877

	-1	Includes approximately $44,000 and $26,000 in 2014 and 2013, respectively, of net property and equipment related to the Company’s international operations.
Summary of Expenditures for Property and Equipment by Segment	Expenditures for property and equipment by segment is as follows:

			December 31,
			2014			2013			2012

	U.S. dialysis and related lab services		$	560,610		$	554,345		$	524,180
	HCP			27,885			31,582			7,464
	Other - Ancillary services and strategic initiatives			52,835			31,670			18,502
			$	641,330		$	617,597		$	550,146

Supplemental_cash_flow_informa1

Supplemental cash flow information (Tables)	12 Months Ended
Supplemental cash flow information (Tables)	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	The table below provides supplemental cash flow information:

		Year ended December 31,
		2014		2013		2012
	Cash paid:
	Income taxes	$	238,615	$	341,426	$	322,018
	Interest		351,967		405,030		257,640
	Non-cash investing and financing activities:
	Fixed assets under capital lease obligations		72,389		60,920		55,813

Selected_quarterly_financial_d1

Selected quarterly financial data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data (unaudited)
		2014								2013
		31-Dec		30-Sep		30-Jun		31-Mar		31-Dec		30-Sep		30-Jun		31-Mar
	Net revenues	$	3,328,017	$	3,251,824	$	3,172,489	$	3,042,776	$	3,063,209	$	2,999,586	$	2,871,673	$	2,829,582
	Operating income	$	452,085	$	437,536	$	484,295	$	441,225	$	484,179	$	377,074	$	522,020	$	166,861
	Income from continuing operations	$	354,365	$	336,412	$	282,308	$	336,588	$	380,020	$	270,766	$	412,550	$	61,642
	before income taxes
	Discontinued operations, net of tax.	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	13,236
	Net income attributable to DaVita	$	208,020	$	184,122	$	147,683	$	183,289	$	212,278	$	136,628	$	254,376	$	30,164
	HealthCare Partners Inc.
	Basic income from continuing	$	0.98	$	0.87	$	0.7	$	0.87	$	1.01	$	0.65	$	1.21	$	0.08
	operations per share attributable
	to DaVita HealthCare Partners Inc.
	Basic net income per share	$	0.98	$	0.87	$	0.7	$	0.87	$	1.01	$	0.65	$	1.21	$	0.14
	attributable to DaVita HealthCare
	Partners Inc.
	Diluted income from continuing	$	0.96	$	0.85	$	0.68	$	0.85	$	0.99	$	0.64	$	1.18	$	0.08
	operations per share attributable
	to DaVita HealthCare Partners Inc.
	Diluted net income per share	$	0.96	$	0.85	$	0.68	$	0.85	$	0.99	$	0.64	$	1.18	$	0.14
	attributable to DaVita HealthCare
	Partners Inc.

Consolidating_financial_statem1

Consolidating financial statements (Tables)	12 Months Ended
Consolidating financial statements (Tables)	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidating Statements of Income	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2014
	Patient services revenues		$	—			$	6,246,683			$	2,739,996			$	(118,341	)		$	8,868,338
	Less: Provision for uncollectible accounts			—				(238,600	)			(128,284	)			—				(366,884	)
	Net patient service revenues			—				6,008,083				2,611,712				(118,341	)			8,501,454
	Capitated revenues			—				1,689,634				1,579,804				(8,150	)			3,261,288
	Other revenues			684,066				1,639,828				24,155				(1,315,685	)			1,032,364
	Total net revenues			684,066				9,337,545				4,215,671				(1,442,176	)			12,795,106
	Operating expenses and charges			443,951				8,276,991				3,701,199				(1,442,176	)			10,979,965
	Operating income			240,115				1,060,554				514,472				—				1,815,141
	Debt (expense) and refinancing charges			(502,762	)			(363,623	)			(43,449	)			401,992				(507,842	)
	Other income, net			385,532				11,731				7,103				(401,992	)			2,374
	Income tax expense			46,856				397,268				2,219				—				446,343
	Equity earnings in subsidiaries			647,085				335,691				—				(982,776	)			—
	Net income			723,114				647,085				475,907				(982,776	)			863,330
	Less: Net income attributable to noncontrolling interests			—				—				—				(140,216	)			(140,216	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	647,085			$	475,907			$	(1,122,992	)		$	723,114

	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2013
	Patient services revenues		$	—			$	5,989,658			$	2,420,975			$	(103,438	)		$	8,307,195
	Less: Provision for uncollectible accounts			—				(177,415	)			(116,131	)			—				(293,546	)
	Net patient service revenues			—				5,812,243				2,304,844				(103,438	)			8,013,649
	Capitated revenues			—				1,427,321				1,560,244				(250	)			2,987,315
	Other revenues			616,155				1,534,310				17,867				(1,405,246	)			763,086
	Total net revenues			616,155				8,773,874				3,882,955				(1,508,934	)			11,764,050
	Operating expenses and charges			434,776				7,843,476				3,444,598				(1,508,934	)			10,213,916
	Operating income			181,379				930,398				438,357				—				1,550,134
	Debt (expense)			(427,141	)			(366,188	)			(39,413	)			402,799				(429,943	)
	Other income, net			402,910				1,903				2,773				(402,799	)			4,787
	Income tax expense			59,716				303,603				17,694				—				381,013
	Equity earnings in subsidiaries			536,014				260,268				—				(796,282	)			—
	Income from continuing operations			633,446				522,778				384,023				(796,282	)			743,965
	Discontinued operations net of gain on disposal			—				—				13,236				—				13,236
	of discontinued operations			—				—				13,236				—				13,236
	Net income			633,446				522,778				397,259				(796,282	)			757,201
	Less: Net income attributable to noncontrolling interests			—				—				—				(123,755	)			(123,755	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	633,446			$	522,778			$	397,259			$	(920,037	)		$	633,446
	For the year ended December 31, 2012
	Patient services revenues		$	—			$	5,417,800			$	2,005,424			$	(71,322	)		$	7,351,902
	Less: Provision for uncollectible accounts			—				(124,592	)			(110,626	)			—				(235,218	)
	Net patient service revenues			—				5,293,208				1,894,798				(71,322	)			7,116,684
	Capitated revenues			—				232,744				248,592				—				481,336
	Other revenues			514,190				745,920				10,190				(682,040	)			588,260
	Total net revenues			514,190				6,271,872				2,153,580				(753,362	)			8,186,280
	Operating expenses and charges			365,680				5,479,531				1,797,347				(753,362	)			6,889,196
	Operating income			148,510				792,341				356,233				—				1,297,084
	Debt (expense) and refinancing charges			(331,944	)			(207,499	)			(27,193	)			267,119				(299,517	)
	Other income, net			265,508				4,305				1,043				(267,119	)			3,737
	Income tax expense			32,912				320,267				6,666				—				359,845
	Equity earnings in subsidiaries			486,855				218,197				—				(705,052	)			—
	Income from continuing operations			536,017				487,077				323,417				(705,052	)			641,459
	Discontinued operations			—				—				(222	)			—				(222	)
	Net income			536,017				487,077				323,195				(705,052	)			641,237
	Less: Net income attributable to noncontrolling interests			—				—				—				(105,220	)			(105,220	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	536,017			$	487,077			$	323,195			$	(810,272	)		$	536,017

Consolidating Statements of Comprehensive Income	Consolidating Statements of Comprehensive Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2014
	Net income		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
	Other comprehensive income (losses)			580				—				(22,952	)			—				(22,372	)
	Total comprehensive income			723,694				647,085				452,955				(982,776	)			840,958
	Less: Comprehensive income attributable to			—				—				—				(140,216	)			(140,216	)
	noncontrolling interest			—				—				—				(140,216	)			(140,216	)
	Comprehensive income attributable to DaVita HealthCare		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
	Partners Inc.		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
	For the year ended December 31, 2013
	Net income		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
	Other comprehensive income (losses)			14,868				—				(2,216	)			—				12,652
	Total comprehensive income			648,314				522,778				395,043				(796,282	)			769,853
	Less: Comprehensive income attributable to			—				—				—				(123,755	)			(123,755	)
	noncontrolling interest			—				—				—				(123,755	)			(123,755	)
	Comprehensive income attributable to DaVita HealthCare		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
	Partners Inc.		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
	For the year ended December 31, 2012
	Net income		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
	Other comprehensive income (losses)			5,392				—				(1,205	)			—				4,187
	Total comprehensive income			541,409				487,077				321,990				(705,052	)			645,424
	Less: Comprehensive income attributable to			—				—				—				(105,220	)			(105,220	)
	noncontrolling interest			—				—				—				(105,220	)			(105,220	)
	Comprehensive income attributable to DaVita HealthCare		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204
	Partners Inc.		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204

Consolidating Balance Sheets	Consolidating Balance Sheets

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	As of December 31, 2014
	Cash and cash equivalents		$	698,876			$	77,921			$	188,444			$	—			$	965,241
	Accounts receivable, net			—				915,851				609,998				—				1,525,849
	Other current assets			362,672				930,093				92,942				—				1,385,707
	Total current assets			1,061,548				1,923,865				891,384				—				3,876,797
	Property and equipment, net			195,690				1,473,188				800,221				—				2,469,099
	Intangible assets, net			85,338				1,811,218				52,942				—				1,949,498
	Investments in subsidiaries			8,868,335				1,561,195				—				(10,429,530	)			—
	Intercompany receivables			3,723,454				—				564,241				(4,287,695	)			—
	Other long-term assets and investments			70,309				60,385				101,332				—				232,026
	Goodwill			—				7,958,221				1,457,074				—				9,415,295
	Total assets		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
	Current liabilities		$	180,977			$	1,493,243			$	414,432			$	—			$	2,088,652
	Intercompany payables			—				3,105,173				1,182,522				(4,287,695	)			—
	Long-term debt and other long-term liabilities			8,124,863				1,321,321				217,603				—				9,663,787
	Noncontrolling interests subject to put provisions			528,321				—				—				301,644				829,965
	Total DaVita HealthCare Partners Inc.			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
	shareholders’' equity			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
	Noncontrolling interests not subject to put provisions			—				—				491,442				(301,644	)			189,798
	Total equity			5,170,513				8,868,335				2,052,637				(10,731,174	)			5,360,311
	Total liabilities and equity		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
	As of December 31, 2013
	Cash and cash equivalents		$	602,188			$	175,004			$	169,057			$	—			$	946,249
	Accounts receivable, net			—				939,543				545,620				—				1,485,163
	Other current assets			27,910				904,852				108,104				—				1,040,866
	Total current assets			630,098				2,019,399				822,781				—				3,472,278
	Property and equipment, net			177,633				1,378,017				633,761				—				2,189,411
	Intangible assets, net			77,531				1,882,685				64,157				—				2,024,373
	Investments in subsidiaries			8,231,059				1,391,655				—				(9,622,714	)			—
	Intercompany receivables			3,983,214				—				480,993				(4,464,207	)			—
	Other long-term assets and investments			61,391				70,728				67,722				—				199,841
	Goodwill		—					7,850,910				1,362,064				—				9,212,974
	Total assets		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877
	Current liabilities		$	328,875			$	1,776,419			$	356,755			$	—			$	2,462,049
	Intercompany payables			—				3,426,433				1,037,774				(4,464,207	)			—
	Long-term debt and other long-term liabilities			7,948,390				1,159,483				226,114				—				9,333,987
	Noncontrolling interests subject to put provisions			451,182				—				—				246,118				697,300
	Total DaVita HealthCare Partners Inc.			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
	shareholders’' equity			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
	Noncontrolling interests not subject to put provisions			—				—				419,180				(246,118	)			173,062
	Total equity			4,432,479				8,231,059				1,810,835				(9,868,832	)			4,605,541
	Total liabilities and equity		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877


Consolidating Statements of Cash Flows	Consolidating Statements of Cash Flows

			DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
			HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
			Partners Inc.
	For the year ended December 31, 2014
	Cash flows from operating activities:
	Net income.		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
	Changes in operating assets and liabilities and non cash			(597,992	)			120,772				90,521				982,776				596,077
	items included in net income			(597,992	)			120,772				90,521				982,776				596,077
	Net cash provided by operating activities			125,122				767,857				566,428				—				1,459,407
	Cash flows from investing activities:
	Additions of property and equipment, net			(51,374	)			(312,191	)			(277,765	)			—				(641,330	)
	Acquisitions			—				(228,569	)			(43,525	)			—				(272,094	)
	Proceeds from asset sales			—				8,791				—				—				8,791
	Purchase of investments and other items			(333,803	)			(316	)			(38,977	)			—				(373,096	)
	Net cash (used in) provided by investing activities			(385,177	)			(532,285	)			(360,267	)			—				(1,277,729	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			4,513				(12,545	)			43				—				(7,989	)
	Intercompany borrowing			410,437				(306,011	)			(104,426	)			—				—
	Other items			(58,207	)			(14,099	)			(84,684	)			—				(156,990	)
	Net cash provided by (used in) financing activities			356,743				(332,655	)			(189,067	)			—				(164,979	)
	Effect of exchange rate changes on cash			—				—				2,293				—				2,293
	Net increase (decrease) in cash and cash equivalents			96,688				(97,083	)			19,387				—				18,992
	Cash and cash equivalents at beginning of the year			602,188				175,004				169,057				—				946,249
	Cash and cash equivalents at the end of the year		$	698,876			$	77,921			$	188,444			$	—			$	965,241
	For the year ended December 31, 2013
	Cash flows from operating activities:
	Net income.		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
	Changes in operating assets and liabilities and non cash			(443,071	)			652,374				10,555				796,282				1,016,140
	items included in net income			(443,071	)			652,374				10,555				796,282				1,016,140
	Net cash provided by operating activities			190,375				1,175,152				407,814				—				1,773,341
	Cash flows from investing activities:
	Additions of property and equipment, net			(55,252	)			(337,042	)			(225,303	)			—				(617,597	)
	Acquisitions			—				(156,830	)			(153,564	)			—				(310,394	)
	Proceeds from asset sales			60,650				1,608				—				—				62,258
	Purchase of investments and other items			(4,944	)			(3,502	)			(2,703	)			—				(11,149	)
	Net cash provided by (used in) by investing activities			454				(495,766	)			(381,570	)			—				(876,882	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			(421,739	)			(11,061	)			(5,207	)			—				(438,007	)
	Intercompany borrowing			585,441				(664,154	)			78,713				—				—
	Other items			52,620				4,726				(102,330	)			—				(44,984	)
	Net cash provided by (used in) financing activities			216,322				(670,489	)			(28,824	)			—				(482,991	)
	Effect of exchange rate changes on cash			—				—				(967	)			—				(967	)
	Net increase (decrease) in cash and cash equivalents			407,151				8,897				(3,547	)			—				412,501
	Cash and cash equivalents at beginning of the year			195,037				166,107				172,604				—				533,748
	Cash and cash equivalents at the end of the year		$	602,188			$	175,004			$	169,057			$	—			$	946,249



	Consolidating Statements of Cash Flows

			DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
			HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
			Partners Inc.
	For the year ended December 31, 2012
	Cash flows from operating activities:
	Net income.		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
	Changes in operating assets and liabilities and non cash			(383,619	)			15,693				122,485				705,052				459,611
	items included in net income			(383,619	)			15,693				122,485				705,052				459,611
	Net cash provided by operating activities			152,398				502,770				445,680				—				1,100,848
	Cash flows from investing activities:
	Additions of property and equipment, net			(72,125	)			(305,885	)			(172,136	)			—				(550,146	)
	Acquisitions			(3,645,760	)			(564,499	)			(83,818	)			—				(4,294,077	)
Proceeds from asset sales			—				3,559				—				—				3,559
Proceeds from investment sales and other items			2,841				(1,761	)			7,134				—				8,214
Net cash used in by investing activities			(3,715,044	)			(868,586	)			(248,820	)			—				(4,832,450	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			3,909,760				(23,805	)			18,938				—				3,904,893
Intercompany borrowing			(586,050	)			580,825				5,225			—					—
Other items			68,697				(25,097	)			(76,109	)			—				(32,509	)
Net cash provided by (used in) financing activities			3,392,407				531,923				(51,946	)			—				3,872,384
Effect of exchange rate changes on cash			—				—				(786	)			—				(786	)
Net (decrease) increase in cash and cash equivalents			(170,239	)			166,107				144,128				—				139,996
Cash and cash equivalents at beginning of the year			365,276				—				28,476				—				393,752
Cash and cash equivalents at the end of the year		$	195,037			$	166,107			$	172,604			$	—			$	533,748

Supplemental_data_Tables

Supplemental data (Tables)	12 Months Ended
Supplemental data (Tables)	Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Consolidating Statements of Income	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2014
	Patient services revenues		$	—			$	6,246,683			$	2,739,996			$	(118,341	)		$	8,868,338
	Less: Provision for uncollectible accounts			—				(238,600	)			(128,284	)			—				(366,884	)
	Net patient service revenues			—				6,008,083				2,611,712				(118,341	)			8,501,454
	Capitated revenues			—				1,689,634				1,579,804				(8,150	)			3,261,288
	Other revenues			684,066				1,639,828				24,155				(1,315,685	)			1,032,364
	Total net revenues			684,066				9,337,545				4,215,671				(1,442,176	)			12,795,106
	Operating expenses and charges			443,951				8,276,991				3,701,199				(1,442,176	)			10,979,965
	Operating income			240,115				1,060,554				514,472				—				1,815,141
	Debt (expense) and refinancing charges			(502,762	)			(363,623	)			(43,449	)			401,992				(507,842	)
	Other income, net			385,532				11,731				7,103				(401,992	)			2,374
	Income tax expense			46,856				397,268				2,219				—				446,343
	Equity earnings in subsidiaries			647,085				335,691				—				(982,776	)			—
	Net income			723,114				647,085				475,907				(982,776	)			863,330
	Less: Net income attributable to noncontrolling interests			—				—				—				(140,216	)			(140,216	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	647,085			$	475,907			$	(1,122,992	)		$	723,114

	Consolidating Statements of Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2013
	Patient services revenues		$	—			$	5,989,658			$	2,420,975			$	(103,438	)		$	8,307,195
	Less: Provision for uncollectible accounts			—				(177,415	)			(116,131	)			—				(293,546	)
	Net patient service revenues			—				5,812,243				2,304,844				(103,438	)			8,013,649
	Capitated revenues			—				1,427,321				1,560,244				(250	)			2,987,315
	Other revenues			616,155				1,534,310				17,867				(1,405,246	)			763,086
	Total net revenues			616,155				8,773,874				3,882,955				(1,508,934	)			11,764,050
	Operating expenses and charges			434,776				7,843,476				3,444,598				(1,508,934	)			10,213,916
	Operating income			181,379				930,398				438,357				—				1,550,134
	Debt (expense)			(427,141	)			(366,188	)			(39,413	)			402,799				(429,943	)
	Other income, net			402,910				1,903				2,773				(402,799	)			4,787
	Income tax expense			59,716				303,603				17,694				—				381,013
	Equity earnings in subsidiaries			536,014				260,268				—				(796,282	)			—
	Income from continuing operations			633,446				522,778				384,023				(796,282	)			743,965
	Discontinued operations net of gain on disposal			—				—				13,236				—				13,236
	of discontinued operations			—				—				13,236				—				13,236
	Net income			633,446				522,778				397,259				(796,282	)			757,201
	Less: Net income attributable to noncontrolling interests			—				—				—				(123,755	)			(123,755	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	633,446			$	522,778			$	397,259			$	(920,037	)		$	633,446
	For the year ended December 31, 2012
	Patient services revenues		$	—			$	5,417,800			$	2,005,424			$	(71,322	)		$	7,351,902
	Less: Provision for uncollectible accounts			—				(124,592	)			(110,626	)			—				(235,218	)
	Net patient service revenues			—				5,293,208				1,894,798				(71,322	)			7,116,684
	Capitated revenues			—				232,744				248,592				—				481,336
	Other revenues			514,190				745,920				10,190				(682,040	)			588,260
	Total net revenues			514,190				6,271,872				2,153,580				(753,362	)			8,186,280
	Operating expenses and charges			365,680				5,479,531				1,797,347				(753,362	)			6,889,196
	Operating income			148,510				792,341				356,233				—				1,297,084
	Debt (expense) and refinancing charges			(331,944	)			(207,499	)			(27,193	)			267,119				(299,517	)
	Other income, net			265,508				4,305				1,043				(267,119	)			3,737
	Income tax expense			32,912				320,267				6,666				—				359,845
	Equity earnings in subsidiaries			486,855				218,197				—				(705,052	)			—
	Income from continuing operations			536,017				487,077				323,417				(705,052	)			641,459
	Discontinued operations			—				—				(222	)			—				(222	)
	Net income			536,017				487,077				323,195				(705,052	)			641,237
	Less: Net income attributable to noncontrolling interests			—				—				—				(105,220	)			(105,220	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	536,017			$	487,077			$	323,195			$	(810,272	)		$	536,017

Consolidating Statements of Comprehensive Income	Consolidating Statements of Comprehensive Income

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	For the year ended December 31, 2014
	Net income		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
	Other comprehensive income (losses)			580				—				(22,952	)			—				(22,372	)
	Total comprehensive income			723,694				647,085				452,955				(982,776	)			840,958
	Less: Comprehensive income attributable to			—				—				—				(140,216	)			(140,216	)
	noncontrolling interest			—				—				—				(140,216	)			(140,216	)
	Comprehensive income attributable to DaVita HealthCare		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
	Partners Inc.		$	723,694			$	647,085			$	452,955			$	(1,122,992	)		$	700,742
	For the year ended December 31, 2013
	Net income		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
	Other comprehensive income (losses)			14,868				—				(2,216	)			—				12,652
	Total comprehensive income			648,314				522,778				395,043				(796,282	)			769,853
	Less: Comprehensive income attributable to			—				—				—				(123,755	)			(123,755	)
	noncontrolling interest			—				—				—				(123,755	)			(123,755	)
	Comprehensive income attributable to DaVita HealthCare		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
	Partners Inc.		$	648,314			$	522,778			$	395,043			$	(920,037	)		$	646,098
	For the year ended December 31, 2012
	Net income		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
	Other comprehensive income (losses)			5,392				—				(1,205	)			—				4,187
	Total comprehensive income			541,409				487,077				321,990				(705,052	)			645,424
	Less: Comprehensive income attributable to			—				—				—				(105,220	)			(105,220	)
	noncontrolling interest			—				—				—				(105,220	)			(105,220	)
	Comprehensive income attributable to DaVita HealthCare		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204
	Partners Inc.		$	541,409			$	487,077			$	321,990			$	(810,272	)		$	540,204

Consolidating Balance Sheets	Consolidating Balance Sheets

			DaVita				Guarantor				Non-				Consolidating				Consolidated
			HealthCare				Subsidiaries				Guarantor				Adjustments				Total
			Partners Inc.								Subsidiaries
	As of December 31, 2014
	Cash and cash equivalents		$	698,876			$	77,921			$	188,444			$	—			$	965,241
	Accounts receivable, net			—				915,851				609,998				—				1,525,849
	Other current assets			362,672				930,093				92,942				—				1,385,707
	Total current assets			1,061,548				1,923,865				891,384				—				3,876,797
	Property and equipment, net			195,690				1,473,188				800,221				—				2,469,099
	Intangible assets, net			85,338				1,811,218				52,942				—				1,949,498
	Investments in subsidiaries			8,868,335				1,561,195				—				(10,429,530	)			—
	Intercompany receivables			3,723,454				—				564,241				(4,287,695	)			—
	Other long-term assets and investments			70,309				60,385				101,332				—				232,026
	Goodwill			—				7,958,221				1,457,074				—				9,415,295
	Total assets		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
	Current liabilities		$	180,977			$	1,493,243			$	414,432			$	—			$	2,088,652
	Intercompany payables			—				3,105,173				1,182,522				(4,287,695	)			—
	Long-term debt and other long-term liabilities			8,124,863				1,321,321				217,603				—				9,663,787
	Noncontrolling interests subject to put provisions			528,321				—				—				301,644				829,965
	Total DaVita HealthCare Partners Inc.			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
	shareholders’' equity			5,170,513				8,868,335				1,561,195				(10,429,530	)			5,170,513
	Noncontrolling interests not subject to put provisions			—				—				491,442				(301,644	)			189,798
	Total equity			5,170,513				8,868,335				2,052,637				(10,731,174	)			5,360,311
	Total liabilities and equity		$	14,004,674			$	14,788,072			$	3,867,194			$	(14,717,225	)		$	17,942,715
	As of December 31, 2013
	Cash and cash equivalents		$	602,188			$	175,004			$	169,057			$	—			$	946,249
	Accounts receivable, net			—				939,543				545,620				—				1,485,163
	Other current assets			27,910				904,852				108,104				—				1,040,866
	Total current assets			630,098				2,019,399				822,781				—				3,472,278
	Property and equipment, net			177,633				1,378,017				633,761				—				2,189,411
	Intangible assets, net			77,531				1,882,685				64,157				—				2,024,373
	Investments in subsidiaries			8,231,059				1,391,655				—				(9,622,714	)			—
	Intercompany receivables			3,983,214				—				480,993				(4,464,207	)			—
	Other long-term assets and investments			61,391				70,728				67,722				—				199,841
	Goodwill		—					7,850,910				1,362,064				—				9,212,974
	Total assets		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877
	Current liabilities		$	328,875			$	1,776,419			$	356,755			$	—			$	2,462,049
	Intercompany payables			—				3,426,433				1,037,774				(4,464,207	)			—
	Long-term debt and other long-term liabilities			7,948,390				1,159,483				226,114				—				9,333,987
	Noncontrolling interests subject to put provisions			451,182				—				—				246,118				697,300
	Total DaVita HealthCare Partners Inc.			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
	shareholders’' equity			4,432,479				8,231,059				1,391,655				(9,622,714	)			4,432,479
	Noncontrolling interests not subject to put provisions			—				—				419,180				(246,118	)			173,062
	Total equity			4,432,479				8,231,059				1,810,835				(9,868,832	)			4,605,541
	Total liabilities and equity		$	13,160,926			$	14,593,394			$	3,431,478			$	(14,086,921	)		$	17,098,877


Consolidating Statements of Cash Flows	Consolidating Statements of Cash Flows

			DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
			HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
			Partners Inc.
	For the year ended December 31, 2014
	Cash flows from operating activities:
	Net income.		$	723,114			$	647,085			$	475,907			$	(982,776	)		$	863,330
	Changes in operating assets and liabilities and non cash			(597,992	)			120,772				90,521				982,776				596,077
	items included in net income			(597,992	)			120,772				90,521				982,776				596,077
	Net cash provided by operating activities			125,122				767,857				566,428				—				1,459,407
	Cash flows from investing activities:
	Additions of property and equipment, net			(51,374	)			(312,191	)			(277,765	)			—				(641,330	)
	Acquisitions			—				(228,569	)			(43,525	)			—				(272,094	)
	Proceeds from asset sales			—				8,791				—				—				8,791
	Purchase of investments and other items			(333,803	)			(316	)			(38,977	)			—				(373,096	)
	Net cash (used in) provided by investing activities			(385,177	)			(532,285	)			(360,267	)			—				(1,277,729	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			4,513				(12,545	)			43				—				(7,989	)
	Intercompany borrowing			410,437				(306,011	)			(104,426	)			—				—
	Other items			(58,207	)			(14,099	)			(84,684	)			—				(156,990	)
	Net cash provided by (used in) financing activities			356,743				(332,655	)			(189,067	)			—				(164,979	)
	Effect of exchange rate changes on cash			—				—				2,293				—				2,293
	Net increase (decrease) in cash and cash equivalents			96,688				(97,083	)			19,387				—				18,992
	Cash and cash equivalents at beginning of the year			602,188				175,004				169,057				—				946,249
	Cash and cash equivalents at the end of the year		$	698,876			$	77,921			$	188,444			$	—			$	965,241
	For the year ended December 31, 2013
	Cash flows from operating activities:
	Net income.		$	633,446			$	522,778			$	397,259			$	(796,282	)		$	757,201
	Changes in operating assets and liabilities and non cash			(443,071	)			652,374				10,555				796,282				1,016,140
	items included in net income			(443,071	)			652,374				10,555				796,282				1,016,140
	Net cash provided by operating activities			190,375				1,175,152				407,814				—				1,773,341
	Cash flows from investing activities:
	Additions of property and equipment, net			(55,252	)			(337,042	)			(225,303	)			—				(617,597	)
	Acquisitions			—				(156,830	)			(153,564	)			—				(310,394	)
	Proceeds from asset sales			60,650				1,608				—				—				62,258
	Purchase of investments and other items			(4,944	)			(3,502	)			(2,703	)			—				(11,149	)
	Net cash provided by (used in) by investing activities			454				(495,766	)			(381,570	)			—				(876,882	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			(421,739	)			(11,061	)			(5,207	)			—				(438,007	)
	Intercompany borrowing			585,441				(664,154	)			78,713				—				—
	Other items			52,620				4,726				(102,330	)			—				(44,984	)
	Net cash provided by (used in) financing activities			216,322				(670,489	)			(28,824	)			—				(482,991	)
	Effect of exchange rate changes on cash			—				—				(967	)			—				(967	)
	Net increase (decrease) in cash and cash equivalents			407,151				8,897				(3,547	)			—				412,501
	Cash and cash equivalents at beginning of the year			195,037				166,107				172,604				—				533,748
	Cash and cash equivalents at the end of the year		$	602,188			$	175,004			$	169,057			$	—			$	946,249



	Consolidating Statements of Cash Flows

			DaVita				Guarantor				Non-Guarantor				Consolidating				Consolidated
			HealthCare				Subsidiaries				Subsidiaries				Adjustments				Total
			Partners Inc.
	For the year ended December 31, 2012
	Cash flows from operating activities:
	Net income.		$	536,017			$	487,077			$	323,195			$	(705,052	)		$	641,237
	Changes in operating assets and liabilities and non cash			(383,619	)			15,693				122,485				705,052				459,611
	items included in net income			(383,619	)			15,693				122,485				705,052				459,611
	Net cash provided by operating activities			152,398				502,770				445,680				—				1,100,848
	Cash flows from investing activities:
	Additions of property and equipment, net			(72,125	)			(305,885	)			(172,136	)			—				(550,146	)
	Acquisitions			(3,645,760	)			(564,499	)			(83,818	)			—				(4,294,077	)
Proceeds from asset sales			—				3,559				—				—				3,559
Proceeds from investment sales and other items			2,841				(1,761	)			7,134				—				8,214
Net cash used in by investing activities			(3,715,044	)			(868,586	)			(248,820	)			—				(4,832,450	)
Cash flows from financing activities:
Long-term debt and related financing costs, net			3,909,760				(23,805	)			18,938				—				3,904,893
Intercompany borrowing			(586,050	)			580,825				5,225			—					—
Other items			68,697				(25,097	)			(76,109	)			—				(32,509	)
Net cash provided by (used in) financing activities			3,392,407				531,923				(51,946	)			—				3,872,384
Effect of exchange rate changes on cash			—				—				(786	)			—				(786	)
Net (decrease) increase in cash and cash equivalents			(170,239	)			166,107				144,128				—				139,996
Cash and cash equivalents at beginning of the year			365,276				—				28,476				—				393,752
Cash and cash equivalents at the end of the year		$	195,037			$	166,107			$	172,604			$	—			$	533,748

Additional Reporting Entities
Condensed Financial Statements, Captions [Line Items]
Consolidating Statements of Income	Condensed Consolidating Statements of Income

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2014
	Patient services revenues		$	8,868,338			$	121,929			$	—			$	8,746,409
	Less: Provision for uncollectible accounts			(366,884	)			(8,534	)			—				(358,350	)
	Net patient service revenues			8,501,454				113,395				—				8,388,059
	Capitated revenues			3,261,288				1,511,000				—				1,750,288
	Other revenues			1,032,364				6,630				—				1,025,734
	Total net revenues			12,795,106				1,631,025				—				11,164,081
	Operating expenses and charges			10,979,965				1,601,027				514				9,378,424
	Operating income			1,815,141				29,998				(514	)			1,785,657
	Debt (expense) and refinancing charges			(507,842	)			(11,113	)			—				(496,729	)
	Other income, net			2,374				238				—				2,136
	Income tax expense			446,343				1,866				(206	)			444,683
	Net income			863,330				17,257				(308	)			846,381
	Less: Net income attributable to noncontrolling interests			(140,216	)			—				—				(140,216	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	723,114			$	17,257			$	(308	)		$	706,165

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2013
	Patient services revenues		$	8,307,195			$	122,873			$	—			$	8,184,322
	Less: Provision for uncollectible accounts			(293,546	)			(6,602	)			—				(286,944	)
	Net patient service revenues			8,013,649				116,271				—				7,897,378
	Capitated revenues			2,987,315				1,560,244				—				1,427,071
	Other revenues			763,086				5,239				—				757,847
	Total net revenues			11,764,050				1,681,754				—				10,082,296
	Operating expenses and charges			10,213,916				1,659,151				457				8,554,308
	Operating income			1,550,134				22,603				(457	)			1,527,988
	Debt (expense)			(429,943	)			(14,605	)			—				(415,338	)
	Other income, net			4,787				6				—				4,781
	Income tax expense			381,013				3,523				(183	)			377,673
	Income from continuing operations			743,965				4,481				(274	)			739,758
	Discontinued operations net of gain on disposal of discontinued			13,236				—				—				13,236
	operations			13,236				—				—				13,236
	Net income			757,201				4,481				(274	)			752,994
	Less: Net income attributable to noncontrolling interests			(123,755	)			—				—				(123,755	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	633,446			$	4,481			$	(274	)		$	629,239
	For the year ended December 31, 2012
	Patient services revenues		$	7,351,902			$	20,052			$	—			$	7,331,850
	Less: Provision for uncollectible accounts			(235,218	)			(686	)			—				(234,532	)
	Net patient service revenues			7,116,684				19,366				—				7,097,318
	Capitated revenues			481,336				248,592				—				232,744
	Other revenues			588,260				487				—				587,773
	Total net revenues			8,186,280				268,445				—				7,917,835
	Operating expenses and charges			6,889,196				268,205				(1,372	)			6,622,363
	Operating income			1,297,084				240				1,372				1,295,472
	Debt (expense) and refinancing charges			(299,517	)			(1,386	)			—				(298,131	)
	Other income, net			3,737				54				—				3,683
	Income tax expense			359,845				—				549				359,296
	Income from continuing operations			641,459				(1,092	)			823				641,728
	Discontinued operations			(222	)			—				—				(222	)
	Net income			641,237				(1,092	)			823				641,506
	Less: Net income attributable to noncontrolling interests			(105,220	)			—				—				(105,220	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	536,017			$	(1,092	)		$	823			$	536,286


Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2014
	Net income (losses)		$	863,330			$	17,257			$	(308	)		$	846,381
	Other comprehensive losses			(22,372	)			—				—				(22,372	)
	Total comprehensive income (losses)			840,958				17,257				(308	)			824,009
	Less: Comprehensive income attributable to noncontrolling			(140,216	)			—				—				(140,216	)
	interest			(140,216	)			—				—				(140,216	)
	Comprehensive income (losses) attributable to DaVita		$	700,742			$	17,257			$	(308	)		$	683,793
	HealthCare Partners Inc.		$	700,742			$	17,257			$	(308	)		$	683,793
	For the year ended December 31, 2013
	Net income (losses)		$	757,201			$	4,481			$	(274	)		$	752,994
	Other comprehensive income			12,652				—				—				12,652
	Total comprehensive income (losses)			769,853				4,481				(274	)			765,646
	Less: Comprehensive income attributable to noncontrolling			(123,755	)			—				—				(123,755	)
	interest			(123,755	)			—				—				(123,755	)
	Comprehensive income (losses) attributable to DaVita		$	646,098			$	4,481			$	(274	)		$	641,891
	HealthCare Partners Inc.		$	646,098			$	4,481			$	(274	)		$	641,891
	For the year ended December 31, 2012
	Net income (losses)		$	641,237			$	(1,092	)		$	823			$	641,506
	Other comprehensive income			4,187				—				—				4,187
	Total comprehensive income (losses)			645,424				(1,092	)			823				645,693
	Less: Comprehensive income attributable to noncontrolling			(105,220	)			—				—				(105,220	)
	interest			(105,220	)			—				—				(105,220	)
	Comprehensive income (losses) attributable to DaVita		$	540,204			$	(1,092	)		$	823			$	540,473
	HealthCare Partners Inc.		$	540,204			$	(1,092	)		$	823			$	540,473

Consolidating Balance Sheets	Condensed Consolidating Balance Sheets

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	As of December 31, 2014
	Cash and cash equivalents		$	965,241			$	112,448			$	—			$	852,793
	Accounts receivable, net			1,525,849				255,953				—				1,269,896
	Other current assets			1,385,707				18,450				—				1,367,257
	Total current assets			3,876,797				386,851				—				3,489,946
	Property and equipment, net			2,469,099				2,406				—				2,466,693
	Amortizable intangibles, net			1,949,498				6,239				—				1,943,259
	Other long-term assets			232,026				66,087				2,811				163,128
	Goodwill			9,415,295				9,181				—				9,406,114
	Total assets		$	17,942,715			$	470,764			$	2,811			$	17,469,140
	Current liabilities		$	2,088,652			$	213,609			$	—			$	1,875,043
	Payables to parent			—				178,371				2,811				(181,182	)
	Long-term debt and other long-term liabilities			9,663,787				61,895				—				9,601,892
	Noncontrolling interests subject to put provisions			829,965				—				—				829,965
	Total DaVita HealthCare Partners Inc. shareholders'’ equity			5,170,513				16,889				—				5,153,624
	Noncontrolling interests not subject to put provisions			189,798				—				—				189,798
	Shareholders' equity			5,360,311				16,889				—				5,343,422
	Total liabilities and shareholder's equity		$	17,942,715			$	470,764			$	2,811			$	17,469,140
	As of December 31, 2013
	Cash and cash equivalents		$	946,249			$	127,309			$	—			$	818,940
	Accounts receivable, net			1,485,163				235,463				—				1,249,700
	Other current assets			1,040,866				35,640				—				1,005,226
	Total current assets			3,472,278				398,412				—				3,073,866
	Property and equipment, net			2,189,411				5,541				—				2,183,870
	Amortizable intangibles, net			2,024,373				7,283				—				2,017,090
	Other long-term assets			199,841				64,013				3,325				132,503
	Goodwill			9,212,974				8,981				—				9,203,993
	Total assets		$	17,098,877			$	484,230			$	3,325			$	16,611,322
	Current liabilities		$	2,462,049			$	193,079			$	—			$	2,268,970
	Payables to parent			—				194,958				3,325				(198,283	)
	Long-term debt and other long-term liabilities			9,333,987				94,727				—				9,239,260
	Noncontrolling interests subject to put provisions			697,300				—				—				697,300
	Total DaVita HealthCare Partners Inc. shareholders’' equity			4,432,479				1,466				—				4,431,013
	Noncontrolling interests not subject to put provisions			173,062				—				—				173,062
	Shareholders' equity			4,605,541				1,466				—				4,604,075
	Total liabilities and shareholder's equity		$	17,098,877			$	484,230			$	3,325			$	16,611,322

Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2014
	Cash flows from operating activities:
	Net income		$	863,330			$	17,257			$	(308	)		$	846,381
	Changes in operating and intercompany assets and liabilities and			596,077				1,048				308				594,721
	non cash items included in net income			596,077				1,048				308				594,721
	Net cash provided by operating activities			1,459,407				18,305				—				1,441,102
	Cash flows from investing activities:
	Additions of property and equipment			(641,330	)			2,058				—				(643,388	)
	Acquisitions and divestitures, net			(272,094	)			—				—				(272,094	)
	Proceeds from asset sales			8,791				—				—				8,791
	Investments and other items			(373,096	)			(16,745	)			—				(356,351	)
	Net cash used in investing activities			(1,277,729	)			(14,687	)			—				(1,263,042	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			(7,989	)			—				—				(7,989	)
	Intercompany			—				(18,479	)			—				18,479
	Other items			(156,990	)			—				—				(156,990	)
	Net cash used in financing activities			(164,979	)			(18,479	)			—				(146,500	)
	Effect of exchange rate changes on cash			2,293				—				—				2,293
	Net increase (decrease) in cash			18,992				(14,861	)			—				33,853
	Cash at beginning of the year			946,249				127,309				—				818,940
	Cash at the end of the year		$	965,241			$	112,448			$	—			$	852,793
	For the year ended December 31, 2013
	Cash flows from operating activities:
	Net income		$	757,201			$	4,481			$	(274	)		$	752,994
	Changes in operating and intercompany assets and liabilities and			1,016,140				4,343				274				1,011,523
	non cash items included in net income			1,016,140				4,343				274				1,011,523
	Net cash provided by operating activities			1,773,341				8,824				—				1,764,517
	Cash flows from investing activities:
	Additions of property and equipment			(617,597	)			(2,262	)			—				(615,335	)
	Acquisitions and divestitures, net			(310,394	)			—				—				(310,394	)
	Proceeds from discontinued operations			62,258				—				—				62,258
	Investments and other items			(11,149	)			—				—				(11,149	)
	Net cash used in investing activities			(876,882	)			(2,262	)			—				(874,620	)
	Cash flows from financing activities:
	Long-term debt			(438,007	)			—				—				(438,007	)
	Intercompany			—				(11,615	)			—				11,615
	Other items			(44,984	)			—				—				(44,984	)
	Net cash used in financing activities			(482,991	)			(11,615	)			—				(471,376	)
	Effect of exchange rate changes on cash			(967	)			—				—				(967	)
	Net increase (decrease) in cash			412,501				(5,053	)			—				417,554
	Cash at beginning of the year			533,748				132,362				—				401,386
	Cash at the end of the year		$	946,249			$	127,309			$	—			$	818,940

			Consolidated Total				Physician Groups				Unrestricted Subsidiaries				Company and Restricted Subsidiaries(1)
	For the year ended December 31, 2012
	Cash flows from operating activities:
	Net income		$	641,237			$	(1,092	)		$	823			$	641,506
	Changes in operating and intercompany assets and liabilities and			459,611				(26,549	)			(823	)			486,983
	non cash items included in net income			459,611				(26,549	)			(823	)			486,983
	Net cash provided by operating activities			1,100,848				(27,641	)			—				1,128,489
	Cash flows from investing activities:
	Additions of property and equipment			(550,146	)			(4,794	)			—				(545,352	)
	Acquisitions and divestitures, net			(4,294,077	)			—				—				(4,294,077	)
	Proceeds from discontinued operations			3,559				—				—				3,559
	Investments and other items			8,214				—				—				8,214
	Net cash used in investing activities			(4,832,450	)			(4,794	)			—				(4,827,656	)
	Cash flows from financing activities:
	Long-term debt			3,904,893				—				—				3,904,893
	Intercompany			—				164,797				—				(164,797	)
	Other items			(32,509	)			—				—				(32,509	)
	Net cash provided by financing activities			3,872,384				164,797				—				3,707,587
Effect of exchange rate changes on cash			(786	)			—				—				(786	)
Net increase in cash			139,996				132,362				—				7,634
Cash at beginning of the year			393,752				—				—				393,752
Cash at the end of the year		$	533,748			$	132,362			$	—			$	401,386

Recovered_Sheet1

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
	Segment
	Entity
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Number of Operating Segments	2
Ownership in joint venture	50.00%
Other current assets	$186,842	$176,414
Number of legal entities that third parties held noncontrolling ownership	380
Interest rate cap agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Interest rate agreements, notional amount	3,500,000
Debt instrument, description of variable rate basis	LIBOR
Derivative, effective date	30-Sep-16
Term Loan B \| Interest rate cap agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Interest rate agreements, notional amount	2,735,000
Alliance and Product Supply Agreement liability
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	10 years
Funds on Deposit with Third Party
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Other current assets	$81,276
California Medical Group Insurance
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Equity interest owned	67.00%
Maximum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Percentage of management fees included in net operating revenues	1.00%
Maximum \| Term Loan B \| Interest rate cap agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Debt instrument, variable interest rate	3.50%
Maximum \| Customer relationships
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	20 years
Maximum \| Trade names
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	15 years
Maximum \| Provider network and practice management tools
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	15 years
Maximum \| Noncompetition and other agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	10 years
Maximum \| Buildings
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Useful lives of the assets	40 years
Maximum \| Equipment and Information Systems
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Useful lives of the assets	8 years
Minimum \| Customer relationships
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	10 years
Minimum \| Trade names
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	2 years
Minimum \| Provider network and practice management tools
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	2 years
Minimum \| Noncompetition and other agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amortization period	2 years
Minimum \| Buildings
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Useful lives of the assets	20 years
Minimum \| Equipment and Information Systems
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Useful lives of the assets	3 years
Dialysis And Related Lab Services \| Maximum
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Percentage of risk on revenue	1.00%
UNITED STATES
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Number of dialysis centers that the company operated or provided administrative services	2,179
Number of states that dialysis centers located	46
Number of patients served	173,000
Outside United States
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Number of dialysis centers that the company operated or provided administrative services	91

Reconciliations_of_Numerators_

Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Basic:
Income from continuing operations attributable to DaVita HealthCare Partners Inc.									$723,114		$620,197		$536,236
Discontinued operations attributable to DaVita HealthCare Partners Inc.											13,249		-219
Net income attributable to DaVita HealthCare Partners Inc. for basic earnings per share calculation									723,114		633,446		536,017
Weighted average shares outstanding during the period									214,496,000		212,128,000		192,396,000
Vested stock units											5,000		6,000
Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger									-2,194,000		-2,194,000		-366,000
Weighted average shares for basic earnings per share calculation									212,301,827		209,939,364		192,035,878
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.98	$0.87	$0.70	$0.87	$1.01	$0.65	$1.21	$0.08	$3.41		$2.95		$2.79
Basic income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.											$0.07
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$0.98	$0.87	$0.70	$0.87	$1.01	$0.65	$1.21	$0.14	$3.41		$3.02		$2.79
Diluted:
Income from continuing operations attributable to DaVita HealthCare Partners Inc.									723,114		620,197		536,236
Discontinued operations attributable to DaVita HealthCare Partners Inc.											13,249		-219
Net income attributable to DaVita HealthCare Partners Inc. for diluted earnings per share calculation									$723,114		$633,446		$536,017
Weighted average shares outstanding during the period									214,496,000		212,128,000		192,396,000
Vested stock units											5,000		6,000
Assumed incremental shares from stock plans									2,432,000		2,631,000		3,540,000
Weighted average shares for diluted earnings per share calculation									216,927,681		214,763,887		195,942,160
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.96	$0.85	$0.68	$0.85	$0.99	$0.64	$1.18	$0.08	$3.33		$2.89		$2.74
Diluted income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.											$0.06
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$0.96	$0.85	$0.68	$0.85	$0.99	$0.64	$1.18	$0.14	$3.33		$2.95		$2.74
Anti-dilutive stock-settled awards excluded from calculation									1,715,000	[1]	4,194,000	[1]	2,616,000	[1]

[1]	Shares associated with stock-settled stock appreciation rights and stock options excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts_Receivable_Additional

Accounts Receivable - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, percentage of balances more than six months old	12.00%	14.00%
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	100.00%
Account receivable outstanding, number of months	4 months
Increased (decreased) in allowance for doubtful accounts	$5,531	($7,979)
Government-based Programs, Medicare and Medicaid \| Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of accounts receivable due	80.00%
Health Care Patient \| Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of accounts receivable due	1.00%

Other_Receivables_Detail

Other Receivables (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Other Receivables, Net, Current [Abstract]
Other receivables	$400,916	$349,090
Supplier rebates and other non-trade receivables
Other Receivables, Net, Current [Abstract]
Other receivables	265,693	217,100
Medicare bad debt claims
Other Receivables, Net, Current [Abstract]
Other receivables	118,504	110,825
Operating advances under management and administrative services agreements
Other Receivables, Net, Current [Abstract]
Other receivables	$16,719	$21,165

Other_Current_Assets_Detail

Other Current Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$102,466	$93,877
Funds on deposit with third parties	81,276	79,317
Other	3,100	3,220
Other current assets	$186,842	$176,414

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]
Land	$35,885	$34,960
Buildings	157,550	157,998
Leasehold improvements	2,002,735	1,762,470
Equipment and information systems	2,066,775	1,839,981
New center and capital asset projects in progress	235,660	172,261
Property, Plant and Equipment, Gross, Total	4,498,605	3,967,670
Less accumulated depreciation	-2,029,506	-1,778,259
Property and equipment, net	$2,469,099	$2,189,411

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Abstract]
Depreciation and amortization expense on property and equipment	$428,309	$373,107	$299,810
Interest capitalized	$7,888	$6,408	$8,126

Amortizable_Intangible_Assets_

Amortizable Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite Lived Intangible Assets [Line Items]
Customer relationships	$1,575,865	$1,503,426
Trade names	171,168	170,994
Provider network and practice management tools	183,688	184,558
Noncompetition and other agreements	506,867	495,475
Deferred debt financing costs	101,001	121,872
Indefinite-lived assets	24,818	22,932
Intangible Assets, Gross (Excluding Goodwill), Total	2,571,389	2,508,146
Less accumulated amortization	-621,891	-483,773
Total intangible assets	1,949,498	2,024,373
Lease Agreements
Finite Lived Intangible Assets [Line Items]
Lease agreements	$7,982	$8,889

Intangibles_Additional_Informa

Intangibles - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense from amortizable intangible assets	$167,956	$160,960	$47,489
Amortization of lease agreement intangible assets and liabilities	-1,798	-1,447	103
Amortization benefit recognized from the alliance and product supply agreement	$5,330	$5,330	$5,330

Amortizable_Intangible_Liabili

Amortizable Intangible Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Alliance and product supply agreement commitment (See Note 18)	$68,200	$68,200
Less accumulated amortization	-64,203	-58,873
Net Alliance and product supply agreement	3,997	9,327
Lease agreements (net of accumulated amortization of $4,785 and $2,628)	10,407	12,563
Finite Lived Intangible Liabilities Net, Total	$14,404	$21,890

Amortizable_Intangible_Liabili1

Amortizable Intangible Liabilities (Parenthetical) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Lease agreements, accumulated amortization	$4,785	$2,628

Scheduled_Amortization_Charges

Scheduled Amortization Charges from Intangible Assets and Liabilities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Customer relationships
Expected Amortization Expense [Line Items]
2015	$82,619
2016	82,704
2017	82,686
2018	82,640
2019	82,407
Thereafter	991,862
Trade names
Expected Amortization Expense [Line Items]
2015	16,429
2016	16,429
2017	16,418
2018	16,364
2019	16,364
Thereafter	53,961
Provider network and practice management tools
Expected Amortization Expense [Line Items]
2015	26,229
2016	26,179
2017	26,243
2018	26,266
2019	22,542
Thereafter	526
Noncompetition and other agreements
Expected Amortization Expense [Line Items]
2015	40,482
2016	30,172
2017	28,563
2018	18,429
2019	13,984
Thereafter	39,242
Deferred debt financing costs
Expected Amortization Expense [Line Items]
2015	13,279
2016	13,129
2017	12,976
2018	12,683
2019	10,636
Thereafter	22,237
Lease agreements, net
Expected Amortization Expense [Line Items]
2015	-2,107
2016	-1,506
2017	-1,185
2018	-849
2019	-789
Thereafter	-3,971
Alliance and Product Supply Agreement liability
Expected Amortization Expense [Line Items]
2015	($3,997)

Recovered_Sheet2

Equity Investments and Other Investments - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Investment [Line Items]
Equity investments in non-consolidated businesses	$65,637	$40,686
Equity investment income	23,234	34,558	16,377
Cost-method Investments
Investment [Line Items]
Payment for purchase of preferred stock in a privately held company		5,000
HealthCare Partners (HCP)
Investment [Line Items]
Equity investment income	$9,480	$22,758

Investments_Detail

Investments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Certificates of deposit and money market funds due within one year	$335,975	$5,601
Investments in mutual funds and common stock	28,123	19,421
Total investment	364,098	25,022
Short-term investments	337,399	6,801
Long-term investments	26,699	18,221
Held to maturity
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Certificates of deposit and money market funds due within one year	335,975	5,601
Total investment	335,975	5,601
Short-term investments	335,975	5,601
Available for sale
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Investments in mutual funds and common stock	28,123	19,421
Total investment	28,123	19,421
Short-term investments	1,424	1,200
Long-term investments	$26,699	$18,221

Recovered_Sheet3

Investments in Debt and Equity Securities - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Investments Debt And Equity Securities [Abstract]
Available for sale investments gross pre-tax unrealized gain (loss)	$5,181	$5,096
Unrealized gain (loss) on investments, pre tax	425	3,752
Proceeds from sale of investments available-for-sale	1,262	4,158
Pre tax reclassification of net investment realized gain (loss) into net income	340	802
Reclassification of net investment realized gain (loss) into net income, net of tax	$207	$490	$75

Changes_in_Goodwill_by_Reporta

Changes in Goodwill by Reportable Segments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Beginning balance	$9,212,974	$8,952,750
Acquisitions	221,514	271,267
Divestitures	-1,851	-2,728
Other adjustments		-8,315
Foreign currency and other adjustments	-17,342
Ending balance	9,415,295	9,212,974
U.S. dialysis and related lab services
Goodwill [Line Items]
Beginning balance	5,469,473	5,309,152
Acquisitions	143,021	163,037
Divestitures	-1,851	-2,728
Other adjustments		12
Foreign currency and other adjustments
Ending balance	5,610,643	5,469,473
HealthCare Partners (HCP)
Goodwill [Line Items]
Beginning balance	3,516,162	3,506,571
Acquisitions	48,649	17,833
Divestitures
Other adjustments		-8,242
Foreign currency and other adjustments	-2,277
Ending balance	3,562,534	3,516,162
Other-Ancillary services and strategic initiatives
Goodwill [Line Items]
Beginning balance	227,339	137,027
Acquisitions	29,844	90,397
Divestitures
Other adjustments		-85
Foreign currency and other adjustments	-15,065
Ending balance	$242,118	$227,339

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]
Goodwill	$9,415,295	$9,212,974	$8,952,750
Goodwill impairment charge description	For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 2.5%, 2.8% and 3.0%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 5.3%, 5.9% and 6.3%, respectively.
Pre-tax goodwill impairment charge	0	0
HealthCare Partners (HCP)
Goodwill [Line Items]
Number of reporting units	3
Goodwill	3,562,534	3,516,162	3,506,571
HealthCare Partners (HCP) \| Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Decrease in operating income percentage used for assessment of fair values	3.00%
HealthCare Partners (HCP) \| Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Increase in discount rates used for assessment of fair values	1.00%
HealthCare Partners (HCP) \| California
Goodwill [Line Items]
Goodwill	2,511,477
Percentage of Fair value in excess of carrying amount	5.60%
HealthCare Partners (HCP) \| California \| Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-2.50%
HealthCare Partners (HCP) \| California \| Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-5.30%
HealthCare Partners (HCP) \| Nevada
Goodwill [Line Items]
Goodwill	517,618
Percentage of Fair value in excess of carrying amount	12.40%
HealthCare Partners (HCP) \| Nevada \| Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-2.80%
HealthCare Partners (HCP) \| Nevada \| Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-5.90%
HealthCare Partners (HCP) \| New Mexico
Goodwill [Line Items]
Goodwill	$72,130
Percentage of Fair value in excess of carrying amount	9.70%
HealthCare Partners (HCP) \| New Mexico \| Long-term Reduction of 3% Percent Operating Income
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-3.00%
HealthCare Partners (HCP) \| New Mexico \| Increase In Discount Rates By 100 Basis Points
Goodwill [Line Items]
Percentage of Fair value in excess of carrying amount	-6.30%

Other_Liabilities_Detail

Other Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Payor refunds and retractions	$125,435	$169,480
Contingent earn-out consideration	15,614	6,577
Insurance and self-insurance accruals	92,928	84,882
Accrued interest	87,224	45,662
Other medical payables	39,867	31,219
Accrued non-income tax liabilities	25,909	18,366
Interest rate swap agreements	1,457	12,069
Other	118,145	96,167
Other liabilities	$506,579	$464,422

Components_of_Changes_in_Healt

Components of Changes in Health Care Costs Payable (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Less: Claims paid
Health care costs payable, end of the year	$314,347	$287,452
Healthcare Cost
Medical Expense And Medical Claims Payable [Line Items]
Health care costs payable, beginning of the year	172,310	119,512
Acquisitions and other adjustments		26,575
Add: Components of incurred health care costs
Current year	1,572,723	1,329,887
Prior years	3,429	-16,587
Total incurred health care costs	1,576,152	1,313,300
Less: Claims paid
Current year	1,378,137	1,169,455
Prior years	155,920	117,622
Total claims paid	1,534,057	1,287,077
Health care costs payable, end of the year	$214,405	$172,310

Health_Care_Costs_Payable_Addi

Health Care Costs Payable - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Health Care Organizations [Abstract]
Increase (decrease) in prior year estimates of health care costs payable	$3,429	($16,587)

Components_of_Income_Tax_Expen

Components of Income Tax Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$188,302	$334,258	$239,232
State	30,789	68,715	49,178
International	1,687	1,764	660
Total current income tax	220,778	404,737	289,070
Deferred:
Federal	192,267	-6,695	64,195
State	32,360	-8,941	6,498
International	938	746
Total deferred income tax	225,565	-14,890	70,693
Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations, Total	$446,343	$389,847	$359,763

Allocation_of_Income_Tax_Expen

Allocation of Income Tax Expense (Benefit) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Continuing operations	$446,343	$381,013	$359,845
Discontinued operations		-84	-82
Gain on discontinued operations		8,918
Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations, Total	$446,343	$389,847	$359,763

Reconciliations_between_our_Ef

Reconciliations between our Effective Tax Rate from Continuing Operations and U.S Federal Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal income tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	3.50%	3.80%	4.00%
International rate differential	-0.20%	0.10%
Changes in deferred tax valuation allowances	0.60%	0.30%
Contingent earn-out adjustments		-2.60%
Other	-0.80%	1.40%	1.10%
Impact of noncontrolling interests primarily attributable to non-tax paying entities	-4.00%	-4.10%	-4.20%
Effective tax rate	34.10%	33.90%	35.90%

Deferred_Tax_and_Liabilities_A

Deferred Tax and Liabilities Arising from Temporary Differences (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Receivables	$42,973	$49,667
Accrued liabilities	253,158	252,008
Loss contingency reserve	1,423	139,844
Net operating loss carryforwards	100,768	96,212
Other	88,435	67,882
Deferred tax assets	486,757	605,613
Valuation allowance	-26,667	-13,860
Net deferred tax assets	460,090	591,753
Intangible assets	-835,816	-752,838
Property and equipment	-187,054	-183,059
Investments in partnerships	-78,618	-51,921
Other	-8,677	-6,913
Deferred tax liabilities	-1,110,165	-994,731
Net deferred tax liabilities	($650,075)	($402,978)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Increase in valuation allowance related to changes in the estimated tax benefit of federal and state operating losses of separate-return entities	$12,807
Liability for unrecognized tax benefits	31,877	60,538	67,546
Decrease in liability for unrecognized tax benefits	28,661
Unrecognized tax benefits due to change of accounting method	27,427
Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits	10,123	10,742
Domestic Tax Authority
Income Taxes [Line Items]
Net operating loss carryforwards	203,282
Net operating loss carryforwards, expiration beginning year	2028
Domestic Tax Authority \| Maximum
Income Taxes [Line Items]
Net operating loss carryforwards, expiration year	2034
State
Income Taxes [Line Items]
Net operating loss carryforwards	568,286
State \| Maximum
Income Taxes [Line Items]
Net operating loss carryforwards, expiration year	2034
Foreign Tax Authority
Income Taxes [Line Items]
Net operating loss carryforwards	$55,436

Reconciliation_of_Beginning_an

Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-than-not Threshold (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Balance beginning	$60,538	$67,546
Additions for tax positions related to current year	914	6,005
Reductions for tax positions related to prior years	-27,312	-3,901
Reductions related to lapse of applicable statute	-2,077	-8,480
Reductions related to settlements with taxing authorities	-186	-632
Balance ending	$31,877	$60,538

Long_Term_Debt_Detail

Long Term Debt (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Senior notes	$3,775,000	$2,800,000
Acquisition obligations and other notes payable	69,045	67,352
Capital lease obligations	218,097	152,751
Total debt principal outstanding	8,519,642	8,433,603
Discount on long-term debt	-16,208	-17,675
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	8,503,434	8,415,928
Less current portion	-120,154	-274,697
Long-term debt	8,383,280	8,141,231
Term Loan A
Debt Instrument [Line Items]
Senior Secured Credit Facilities	975,000	800,000
Term Loan A-3
Debt Instrument [Line Items]
Senior Secured Credit Facilities		1,282,500
Term Loan B
Debt Instrument [Line Items]
Senior Secured Credit Facilities	3,482,500	1,697,500
Term Loan B-2
Debt Instrument [Line Items]
Senior Secured Credit Facilities		$1,633,500

Scheduled_Maturities_of_Longte

Scheduled Maturities of Long-term Debt (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Debt Disclosure [Abstract]
2015	$120,154
2016	117,193
2017	144,161
2018	155,750
2019	730,084
Thereafter	$7,252,300

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Senior notes		$3,775,000	$2,800,000
Facility, aggregate principal amount	5,500,000
Maximum additional borrowing capacity	1,500,000
Long term borrowing annual principal payment, 2015		117,193
Long term borrowing annual principal payment, 2016		144,161
Long term borrowing annual principal payment, 2017		155,750
Long term borrowing annual principal payment, 2018		730,084
Thereafter		7,252,300
Proceeds from borrowings		60,038,508	66,286,097	43,248,175
Payment of total outstanding principal balances under existing Senior Secured Credit Facilities plus accrued interest		60,046,487	66,723,385	39,286,027
Debt refinancing charges		97,548		10,963
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	3,000
Debt expense		410,294	429,943	288,554
Debt refinancing charges		-97,548		-10,963
Debt expense recognized		385,750	401,140	270,107
Unrealized (losses) gain on interest rate swap and cap agreements		-10,059	169	-6,204
Overall weighted average effective interest rate on Senior Secured Credit Facilities			3.43%
Weighted average effective interest rate		4.68%
Overall weighted average effective interest rate		4.46%
Amortization of deferred financing costs		24,544	28,803	18,447
HealthCare Partners (HCP)
Debt Instrument [Line Items]
Outstanding letters of credit		1,000
Letter of Credit
Debt Instrument [Line Items]
Outstanding letters of credit		95,000
Revolving Credit Facility
Debt Instrument [Line Items]
Facility, aggregate principal amount	1,000,000
Facility, term	5 years
Interest rate cap agreements
Debt Instrument [Line Items]
Interest rate agreements, notional amount		3,500,000
Derivative, expiration date		30-Jun-18
Fair value of assets		12,340
Unrealized (losses) gain on interest rate swap and cap agreements		-2,147
Interest Rate Swap
Debt Instrument [Line Items]
Notional amount terminated	600,000
Debt refinancing charges	3,100
Debt expense		6,100
Debt refinancing charges	-3,100
Amortizing Swap
Debt Instrument [Line Items]
Notional amount terminated	1,137,500
Maximum
Debt Instrument [Line Items]
Senior secured leverage ratio	3.5
Maximum \| Interest rate cap agreements
Debt Instrument [Line Items]
Debt instrument Interest rate		3.50%
Minimum
Debt Instrument [Line Items]
Senior secured leverage ratio	1
Covenants factor leverage ratio	1
Term Loan A Term Loan B
Debt Instrument [Line Items]
Interest rate description		At December 31, 2014, the overall weighted average interest rate for the Term Loan A was determined based upon the LIBOR interest rates in effect for all of the individual tranches plus the interest rate margin.
Term Loan A Term Loan B \| Maximum
Debt Instrument [Line Items]
Term Loan A and Term Loan B maturity date range		12 months
Term Loan A Term Loan B \| Minimum
Debt Instrument [Line Items]
Term Loan A and Term Loan B maturity date range		1 month
Term Loan A
Debt Instrument [Line Items]
Debt instrument, annual principal payment		37,500	100,000
Term Loan A-3
Debt Instrument [Line Items]
Debt instrument, annual principal payment		16,875	67,500
Term Loan B
Debt Instrument [Line Items]
Debt instrument, annual principal payment		4,375	17,500
Term Loan B \| Interest rate cap agreements
Debt Instrument [Line Items]
Interest rate agreements, notional amount		2,735,000
Term Loan B \| Maximum \| Interest rate cap agreements
Debt Instrument [Line Items]
Debt instrument, variable interest rate		3.50%
LIBOR interest rate for interest cap		3.50%
Term Loan B \| Maximum \| Interest rate cap agreements \| Derivative Instrument 1
Debt Instrument [Line Items]
Debt instrument Interest rate		2.50%
Interest rate agreements, notional amount		2,735,000
Remaining outstanding debt		747,500
Derivative, Floor Interest Rate		0.75%
Term Loan B-2
Debt Instrument [Line Items]
Debt instrument, annual principal payment		4,125	16,500
New Term Loan A
Debt Instrument [Line Items]
Debt instrument, annual principal payment		25,000				25,000
Facility, aggregate principal amount	1,000,000
Facility, term	5 years
Long term borrowing annual principal payment, 2014	25,000
Long term borrowing annual principal payment, 2015	50,000
Long term borrowing annual principal payment, 2016	62,500
Long term borrowing annual principal payment, 2017	87,500
Long term borrowing annual principal payment, 2018	100,000
Thereafter	675,000
New Term Loan A \| Interest Rate Swap
Debt Instrument [Line Items]
Debt instrument, variable interest rate		1.75%
Interest rate agreements, notional amount		855,000
Fixed interest rate, lower limit		0.49%
Fixed interest rate, upper limit		0.52%
Weighted average effective interest rate		2.26%
Derivative, expiration date		30-Sep-16
Debt expense recognized		3,170
Fair value of assets		1,824
Unrealized pre-tax losses in other comprehensive income		1,457
New Term Loan A \| Interest Rate Swap \| Not Designated as Hedging Instrument
Debt Instrument [Line Items]
Debt instrument, variable interest rate		1.75%
Interest rate agreements, notional amount		120,000
New Term Loan B
Debt Instrument [Line Items]
Interest rate agreements, notional amount		2,735,000
LIBOR interest rate for interest cap		2.50%
Debt instrument, annual principal payment		17,500				17,500
Facility, aggregate principal amount	3,500,000
Facility, term	7 years
Long term borrowing annual principal payment, 2014	17,500
Long term borrowing annual principal payment, 2015	35,000
Long term borrowing annual principal payment, 2016	35,000
Long term borrowing annual principal payment, 2017	35,000
Long term borrowing annual principal payment, 2018	35,000
Long term borrowing annual principal payment, 2019	35,000
Long term borrowing annual principal payment, 2020	35,000
Long term borrowing annual principal payment, 2021	3,272,500
Derivative, expiration date		30-Sep-16
Debt expense recognized		2,439
Fair value of assets		1,594
Unrealized (losses) gain on interest rate swap and cap agreements		-5,972
New Term Loan B \| Interest rate cap agreements \| Derivative Instrument 2
Debt Instrument [Line Items]
Interest rate agreements, notional amount		1,250,000
Derivative, expiration date		30-Sep-14
Debt expense recognized		2,691
New Term Loan B \| Interest Rate Swap
Debt Instrument [Line Items]
Debt instrument, variable interest rate		2.75%
New Term Loan B \| Maximum
Debt Instrument [Line Items]
Covenants factor leverage ratio	3.5
New Term Loan B \| Maximum \| Interest rate cap agreements \| Derivative Instrument 2
Debt Instrument [Line Items]
Debt instrument Interest rate		4.00%
New Term Loan B \| Minimum
Debt Instrument [Line Items]
Debt instrument Interest rate	0.75%
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Undrawn revolving credit facilities		1,000,000
Payment of total outstanding principal balances under existing Senior Secured Credit Facilities plus accrued interest		5,362,400
Senior Notes 5.125 Percent Due 2024
Debt Instrument [Line Items]
Senior notes	1,750,000	1,750,000
Senior note, interest rate	5.13%	5.13%
Senior note, due date		2024
Senior notes interest payment period		The 5 1/8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015
Senior notes interest payment, first required payment date		15-Jan-15
Debt redemption end date		15-Jul-19
Proceeds from borrowings		1,750,000
Senior Notes 5.125 Percent Due 2024 \| Maximum
Debt Instrument [Line Items]
Debt redemption end date		15-Jul-17
Senior Notes 6.625 Percent Due 2020
Debt Instrument [Line Items]
Senior notes		775,000
Senior note, interest rate		6.63%
Senior note, due date		2020
Senior Notes 5.75 Percent Due 2022
Debt Instrument [Line Items]
Senior notes		1,250,000
Senior note, interest rate		5.75%
Senior note, due date		2022
New Term Loans and Senior Notes 5.125 Percent Due 2024
Debt Instrument [Line Items]
Proceeds from borrowings		6,250,000
New Term Loans and Senior Notes 5.125 Percent Due 2024 \| Maximum
Debt Instrument [Line Items]
Percentage of redemption	35.00%
New Term Loans
Debt Instrument [Line Items]
Proceeds from borrowings		4,500,000
Senior Notes 6.375 Percent Due 2018
Debt Instrument [Line Items]
Outstanding principal balances		483,100
Aggregate debt principal balances		775,000
Redemption of total amount of debt including principal and interest		512,400
Debt instrument, redemption price ratio		1,051.25
Cash tender premium for redemption		24,800
Fees, discounts and other professional expenses		81,600
Senior Notes 6.375 Percent Due 2018 \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Aggregate debt principal balances					188
Redemption of total amount of debt including principal and interest					194
Debt instrument, redemption price ratio					1,021.25
Cash tender premium for redemption					4
Senior Notes 6.375 Percent Due 2018 \| Derivative Instrument 2
Debt Instrument [Line Items]
Aggregate debt principal balances					291,719
Redemption of total amount of debt including principal and interest					309,954
Debt instrument, redemption price ratio					1,047.81
Cash tender premium for redemption					$13,947
London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable interest rate	1.75%
London Interbank Offered Rate (LIBOR) \| Term Loan A
Debt Instrument [Line Items]
Debt instrument, variable interest rate		1.75%
London Interbank Offered Rate (LIBOR) \| Term Loan B \| Maximum
Debt Instrument [Line Items]
Debt instrument, variable interest rate		2.75%
London Interbank Offered Rate (LIBOR) \| Term Loan B \| Minimum
Debt Instrument [Line Items]
Debt instrument, variable interest rate		2.75%
London Interbank Offered Rate (LIBOR) \| New Term Loan A
Debt Instrument [Line Items]
Debt instrument, variable interest rate			1.75%
London Interbank Offered Rate (LIBOR) \| New Term Loan A \| Maximum
Debt Instrument [Line Items]
Debt instrument, variable interest rate	2.00%
London Interbank Offered Rate (LIBOR) \| New Term Loan A \| Minimum
Debt Instrument [Line Items]
Debt instrument, variable interest rate	1.50%
London Interbank Offered Rate (LIBOR) \| New Term Loan B
Debt Instrument [Line Items]
Debt instrument, variable interest rate			2.75%

Derivative_Instruments_Detail

Derivative Instruments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Interest rate cap agreements
Derivative [Line Items]
Derivative assets, Fair value	$12,340
Designated as Hedging Instrument \| Interest rate swap agreements \| Other short-term liabilities
Derivative [Line Items]
Derivative liabilities, Fair value	1,457	12,069
Designated as Hedging Instrument \| Interest rate swap agreements \| Other long-term assets
Derivative [Line Items]
Derivative assets, Fair value	3,281	10,004
Designated as Hedging Instrument \| Interest rate cap agreements \| Other long-term assets
Derivative [Line Items]
Derivative assets, Fair value	$13,934	$7,567

Effects_of_Interest_Rate_Swap_

Effects of Interest Rate Swap Agreements (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	$3,000
Cash Flow Hedging
Derivative [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements		-10,059	169	-6,204
Amount of losses reclassified from accumulated OCI into income		10,608	12,889	-10,130
Cash Flow Hedging \| Interest rate swap agreements
Derivative [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements		-8,390	1,251	-8,838
Cash Flow Hedging \| Interest rate swap agreements \| Debt Expense
Derivative [Line Items]
Amount of losses reclassified from accumulated OCI into income		12,279	15,678	-12,989
Cash Flow Hedging \| Interest rate cap agreements
Derivative [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements		-8,119	-974	-1,316
Cash Flow Hedging \| Interest rate cap agreements \| Debt Expense
Derivative [Line Items]
Amount of losses reclassified from accumulated OCI into income		5,130	5,418	-3,589
Cash Flow Hedging \| Tax (expense) benefit
Derivative [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements		6,450	-108	3,950
Amount of losses reclassified from accumulated OCI into income		($6,801)	($8,207)	$6,448

Leases_Additional_Information_

Leases - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases Disclosure [Line Items]
Rent expense under all operating leases	$460,093	$424,096	$345,066
Net book value of property and equipment under capital leases	$197,344	$145,615
Minimum
Leases Disclosure [Line Items]
Facilities leased under non-cancellable operating leases term range, minimum	5 years
Facilities leased under non-cancellable operating leases renewal option range, minimum	5 years
Maximum
Leases Disclosure [Line Items]
Facilities leased under non-cancellable operating leases term range, minimum	15 years
Facilities leased under non-cancellable operating leases renewal option range, minimum	10 years

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments Under Non-cancelable Operating Leases and Capital Leases (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Operating leases
2015	$395,862
2016	370,920
2017	344,232
2018	302,752
2019	262,645
Thereafter	901,792
Operating Leases, Future Minimum Payments Due, Total	2,578,203
Capital leases
2015	21,011
2016	21,277
2017	21,552
2018	21,961
2019	22,615
Thereafter	202,245
Capital Leases, Future Minimum Payments Due, Total	310,661
Less portion representing interest	-92,564
Total capital lease obligations, including current portion	$218,097

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Nonqualified Deferred Compensation Plan \| All Trusts
Defined Benefit Plan Disclosure [Line Items]
Total fair value of assets held in trust	$27,899	$19,421
Nonqualified Deferred Compensation Plan \| DaVita Voluntary Deferral Plan
Defined Benefit Plan Disclosure [Line Items]
Voluntary compensation deferral plan description	The Company also maintains a voluntary compensation deferral plan, the DaVita Voluntary Deferral Plan. This plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company
Maximum percentage of employees' base salary to be maintained into deferral account	50.00%
Non-qualified deferred compensation plan, contributions	3,772	4,089	3,935
Deferred compensation arrangement, timing of payments	Deferred amounts are generally paid out in cash at the participantbs election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective
Non-qualified deferred compensation plan, distributions	1,111	4,158	1,324
Total fair value of assets held in trust	5,347	572
Nonqualified Deferred Compensation Plan \| DaVita Voluntary Deferral Plan \| Rabbi Trust
Defined Benefit Plan Disclosure [Line Items]
Total fair value of assets held in trust	21,208	17,419
Nonqualified Deferred Compensation Plan \| Executive Retirement Plan
Defined Benefit Plan Disclosure [Line Items]
Total fair value of assets held in trust	1,344	1,430
Executive Retirement Plan, distributions	152	0	226
Change of Control Protection Program
Defined Benefit Plan Disclosure [Line Items]
Cash bonuses to employees in the event of a change of control	646,000
HealthCare Partners (HCP)
Defined Benefit Plan Disclosure [Line Items]
Company matching contributions	7,400
HealthCare Partners (HCP) \| Nonqualified Deferred Compensation Plan \| Key Employees
Defined Benefit Plan Disclosure [Line Items]
Non-qualified deferred compensation plan, contributions	0	4,658
Cash surrender value of life insurance policies	57,700	56,300
Deferred compensation liabilities owed to participants	$60,400	$62,000
HealthCare Partners (HCP) \| Minimum
Defined Benefit Plan Disclosure [Line Items]
Multiple employer matching contributions rate	0.00%
HealthCare Partners (HCP) \| Maximum
Defined Benefit Plan Disclosure [Line Items]
Multiple employer matching contributions rate	6.00%

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2015
Legal Proceedings [Line Items]
Loss contingency reserve	$17,000	$17,000	$397,000	$85,837
Period of corporate integrity agreement		5 years
Subsequent Event
Legal Proceedings [Line Items]
Number of Subpoenas					6
Number of Medical Centers					6
2010 U.S. Attorney Physician Relationship Investigation
Legal Proceedings [Line Items]
Settlement payment before accrued interest		350,000
Settlement payment, civil forfeiture		39,000
Contingency reserve		414,000	397,000
Medicaid
Legal Proceedings [Line Items]
Settlement payment before accrued interest		$11,500

Recovered_Sheet4

Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Detail) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Nov. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
Commitments And Contingencies Disclosure [Line Items]
Other potential commitments to provide operating capital to several dialysis centers	$1,000
Schedule of Joint ventures to dissolve	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
HealthCare Partners (HCP)
Commitments And Contingencies Disclosure [Line Items]
Required minimum cash balance	65,400
Epogen
Commitments And Contingencies Disclosure [Line Items]
Long term purchase commitment, period		7 years
Long term purchase commitment, expiration date	31-Dec-13	31-Dec-18
Long term purchase commitment, origination date	1-Jan-13
Dialysis Equipment, Parts and Supplies
Commitments And Contingencies Disclosure [Line Items]
Long-term purchase commitment, time period	In January 2010, the Company entered into an agreement with Fresenius which committed the Company to purchase a certain amount of dialysis equipment, parts and supplies from Fresenius through 2013. However, this agreement has been extended through 2015.
Long term purchase commitment, expiration year	2013
Purchase commitment, purchase during the period	154,266		144,030	138,450
Dialysis Equipment, Parts and Supplies \| Extended Expiration
Commitments And Contingencies Disclosure [Line Items]
Long term purchase commitment, expiration year	2015
Hemodialysis Products, Supplies and Equipment
Commitments And Contingencies Disclosure [Line Items]
Long-term purchase commitment, time period	The Product Supply Agreement committed the Company to purchase a significant majority of its hemodialysis products, supplies and equipment at fixed prices through 2015.
Long term purchase commitment, expiration year	2015
Purchase commitment, purchase during the period	$112,645		$124,555	$147,639
Minimum
Commitments And Contingencies Disclosure [Line Items]
Scheduled dissolution term of joint ventures	10 years
Minimum \| Epogen
Commitments And Contingencies Disclosure [Line Items]
Long-term purchase commitment, percentage of quantity required		90.00%			90.00%
Maximum
Commitments And Contingencies Disclosure [Line Items]
Scheduled dissolution term of joint ventures	50 years

Longterm_incentive_compensatio2

Long-term incentive compensation and shareholders' equity - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 17, 2013	Jun. 11, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock split ratio	2
Stock-based compensation expense		$56,743	$59,998	$45,384
Aggregate intrinsic value of stock awards exercised		151,342	120,775	228,698
Aggregate intrinsic value of stock awards outstanding		310,351
Aggregate intrinsic value exercisable		84,129
Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits		698,475	603,013
Stock-based compensation expense		118,970	84,841	45,820
Tax benefit for stock-based Compensation		20,351	22,187	16,874
Unrecognized compensation cost related to outstanding LTIP awards		122,574
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans		73,585
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under performance-based cash component of LTIP costs, weighted average remaining period (in years)		1 year
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans, weighted average remaining period (in years)		1 year 3 months 18 days
Tax benefits from stock award exercises		59,119	46,898	88,964
Proceeds from stock option exercises		0	0	2,175
Common stock shares repurchased		0	0		0
Repurchase share authorized outstanding amount		358,200
Charter documents and Delaware law description		The Companybs charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.
Preferred stock authorized to be issued		5,000,000	5,000,000
Acquisition of additional ownership interests in several existing majority-owned joint ventures		17,876	3,569	26,761
Deferred purchase price obligations		136	209
Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		10,585,172	12,956,094
Weighted average fair value		$16.41	$13.47	$11.28
Liability-classified share awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		72,734
Stock-based compensation expense		1,774	338	175
Shares vested in period		10,625
Stock-based liability		1,242
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		836,421
Employee entitlement for purchase of the Company's common stock during each calendar year		25
Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits		$19,010	$12,817	$8,322
Stock issued for employee stock purchase plans		297,954	237,961	202,658
Expected volatility Rate		27.00%	28.00%	26.00%
Risk-free interest rate		0.20%	0.20%	0.10%
Weighted average fair value		$16.40	$14.24	$10.05
Employee stock purchase plan \| Beginning Of Period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price as percentage of fair market value		100.00%
Employee stock purchase plan \| End Of Period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price as percentage of fair market value		85.00%
Stock Incentive Plan 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares of common stock available for issuance						17,000,000	9,000,000
Award reduction rate		3					3.5
Shares available for future grants		33,687,881
Stock Incentive Plan 2011 \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		36 months
Stock Incentive Plan 2011 \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms of award (in years)		5 years
Vesting period		48 months
Stock Incentive Plan 2011 \| Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		10,585,172
Stock Incentive Plan 2011 \| Cash-settled stock appreciation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		65,000
Stock Incentive Plan 2011 \| Stock Settled Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		921,898
Stock Incentive Plan 2011 \| Cash Settled Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding balance		7,734

Summary_of_Status_of_Awards_Un

Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Appreciation Rights
Awards
Outstanding at beginning of year	12,956,094
Granted	1,553,829
Exercised	-3,473,804
Cancelled	-450,947
Outstanding at end of period	10,585,172	12,956,094
Exercisable at end of period	2,541,397
Weighted-average fair value of awards granted	$16.41	$13.47	$11.28
Weighted average exercise price
Outstanding at beginning of year	$45.44
Granted	$70.15
Exercised	$32.05
Cancelled	$51.49
Outstanding at end of period	$53.21	$45.44
Exercisable at end of period	$42.79
Weighted average remaining contractual life
Outstanding at end of period	2 years 8 months 12 days
Exercisable at end of period	1 year 7 months 6 days
Stock Unit
Awards
Outstanding at beginning of year	966,596
Granted	332,007
Exercised	-303,970
Cancelled	-72,735
Outstanding at end of period	921,898	966,596
Exercisable at end of period	496
Weighted-average fair value of awards granted	$72.24	$58.90	$54.85
Weighted average remaining contractual life
Outstanding at end of period	1 year 6 months
Exercisable at end of period	3 months 18 days

Summary_of_Range_of_Exercise_P

Summary of Range of Exercise Prices (Detail) (USD $)	12 Months Ended
Summary of Range of Exercise Prices (Detail) (USD $)	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Awards outstanding	10,585,172
Weighted average exercise price	$53.21
Awards exercisable	2,541,397
Weighted average exercise price	$42.79
Range 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$20.01
Range of exercise prices, upper range	$30
Awards outstanding	9,000
Weighted average exercise price	$29.90
Awards exercisable	9,000
Weighted average exercise price	$29.90
Range 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$30.01
Range of exercise prices, upper range	$40
Awards outstanding	893,976
Weighted average exercise price	$34.92
Awards exercisable	710,869
Weighted average exercise price	$34.65
Range 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$40.01
Range of exercise prices, upper range	$50
Awards outstanding	3,230,512
Weighted average exercise price	$43.02
Awards exercisable	1,545,204
Weighted average exercise price	$42.86
Range 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$50.01
Range of exercise prices, upper range	$60
Awards outstanding	4,577,354
Weighted average exercise price	$57.49
Awards exercisable	36,324
Weighted average exercise price	$55.03
Range 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$60.01
Range of exercise prices, upper range	$70
Awards outstanding	1,470,547
Weighted average exercise price	$68.06
Awards exercisable	240,000
Weighted average exercise price	$65.08
Range 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, lower range	$70.01
Range of exercise prices, upper range	$80
Awards outstanding	403,783
Weighted average exercise price	$73.07

Summary_of_Weighted_Average_Va

Summary of Weighted Average Valuation Inputs (Detail) (Stock Options And Stock Appreciation Rights)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options And Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	4 years 2 months 12 days	4 years 1 month 6 days	3 years 8 months 12 days
Expected volatility	25.80%	27.20%	28.00%
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	1.50%	0.70%	0.60%

Effects_of_Changes_in_DaVita_I

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net income attributable to DaVita HealthCare Partners Inc.	$208,020	$184,122	$147,683	$183,289	$212,278	$136,628	$254,376	$30,164	$723,114	$633,446	$536,017
Net transfer to noncontrolling interests									-5,002	-4,561	-19,630
Change from net income attributable to DaVita HealthCare Partners Inc. and transfers to noncontrolling interests									718,112	628,885	516,387
Additional paid-in capital
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Increase (decrease) in paid-in capital for sales of noncontrolling interest									355	-1,442	1,064
Decrease in paid-in capital for the purchase of a noncontrolling interest									($5,357)	($3,119)	($20,694)

Recovered_Sheet5

Other Comprehensive Income (loss) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Comprehensive Income (Loss) [Line Items]
Beginning balance	($2,645)
Unrealized (losses) gains	425	3,752
Unrealized (losses) gains net	238	2,300	1,541
Reclassification from accumulated other comprehensive losses (income) into net income	-340	-802
Reclassification from accumulated other	-207	-490	-75
Ending balance	-25,017	-2,645
Interest Rate Swaps and Interest Rate Cap Agreements
Comprehensive Income (Loss) [Line Items]
Beginning balance	-2,344	-15,402	-19,328
Unrealized (losses) gains	-16,509	277	-10,154
Related income tax	6,450	-108	3,950
Unrealized (losses) gains net	-10,059	169	-6,204
Reclassification from accumulated other comprehensive losses (income) into net income	17,409	21,096	16,578
Related income tax	-6,801	-8,207	-6,448
Reclassification from accumulated other	10,608	12,889	10,130
Ending balance	-1,795	-2,344	-15,402
Investment securities
Comprehensive Income (Loss) [Line Items]
Beginning balance	3,120	1,310	-156
Unrealized (losses) gains	425	3,752	2,524
Related income tax	-187	-1,452	-983
Unrealized (losses) gains net	238	2,300	1,541
Reclassification from accumulated other comprehensive losses (income) into net income	-340	-802	-123
Related income tax	133	312	48
Reclassification from accumulated other	-207	-490	-75
Ending balance	3,151	3,120	1,310
Foreign currency translation adjustments
Comprehensive Income (Loss) [Line Items]
Beginning balance	-3,421	-1,205
Unrealized (losses) gains	-22,952	-2,216	-1,205
Unrealized (losses) gains net	-22,952	-2,216	-1,205
Ending balance	-26,373	-3,421	-1,205
Accumulated other comprehensive income (loss)
Comprehensive Income (Loss) [Line Items]
Beginning balance	-2,645	-15,297	-19,484
Unrealized (losses) gains	-39,036	1,813	-8,835
Related income tax	6,263	-1,560	2,967
Unrealized (losses) gains net	-32,773	253	-5,868
Reclassification from accumulated other comprehensive losses (income) into net income	17,069	20,294	16,455
Related income tax	-6,668	-7,895	-6,400
Reclassification from accumulated other	10,401	12,399	10,055
Ending balance	($25,017)	($2,645)	($15,297)

Recovered_Sheet6

Acquisitions and Discontinued Operations - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 12, 2012	Apr. 03, 2013	Nov. 01, 2012
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives	10 years	14 years	17 years
Goodwill deductible for tax purposes associated with acquisitions	$175,247	$221,454	$491,457
Contingent earn-out obligation adjustment		-56,977
Additional cash consideration in the form of earn-out payments	15,614	6,577
Proceeds from sale of discontinued operations		62,258	3,559
Gain recorded on account of divestitures		13,375
Other Accrued Liabilities
Business Acquisition [Line Items]
Fair value of contingent earn-out consideration	15,614
Other long-term liabilities
Business Acquisition [Line Items]
Fair value of contingent earn-out consideration	23,515
Other companies
Business Acquisition [Line Items]
Additional cash consideration in the form of earn-out payments	134,321
Fair value of contingent earn-out consideration	39,129
Other companies \| EBITDA performance targets and quality margins
Business Acquisition [Line Items]
Earn out consideration payment period	2 years
Other companies \| Operating income targets
Business Acquisition [Line Items]
Earn out consideration payment period	3 years
Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives	10 years	17 years	18 years
Noncompetition agreements
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives	8 years	9 years	8 years
HomeChoice Partners
Business Acquisition [Line Items]
Proceeds from sale of discontinued operations				70,000
Performance amounts thresholds measurement period				2 years
Contingent receivable	0
Gain recorded on account of divestitures		13,375
HomeChoice Partners \| Maximum
Business Acquisition [Line Items]
Deferred purchase price obligations	9,000
Additional consideration if certain performance amounts exceed certain thresholds over the next two years				20,000
Approximate percentage of sale proceeds received.				90.00%
Other dialysis acquisitions
Business Acquisition [Line Items]
Cash paid to acquire business	272,094	310,394	648,318
Other dialysis acquisitions \| U.S. dialysis and related lab services
Business Acquisition [Line Items]
Number of businesses acquired	18	26	93
Other dialysis acquisitions \| Foreign Dialysis And Other Medical Businesses
Business Acquisition [Line Items]
Number of businesses acquired	7	38	13
Other dialysis acquisitions \| HomeChoice Partners \| Maximum
Business Acquisition [Line Items]
Deferred purchase price obligations	23,781	24,683	6,101
HealthCare Partners (HCP)
Business Acquisition [Line Items]
Cash paid to acquire business						3,645,759
Amortizable intangible assets acquired, weighted-average estimated useful lives						17 years 2 months 12 days
Goodwill deductible for tax purposes associated with acquisitions						2,426,986
Total consideration paid						4,701,231
Common stock share issued to acquire business						18,760,624
Approximate value of common stock share issued						1,055,472
Cash paid for post-closing working capital adjustment		5,251
Additional cash consideration in the form of earn-out payments						275,000
Amortizable intangible assets						1,882,818
Goodwill deductible period for tax purpose	14 years
Contingent consideration payment	68,750				136,954
Contingent earn-out obligation adjustment	56,977
HealthCare Partners (HCP) \| Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives						20 years
Amortizable intangible assets						1,453,410
HealthCare Partners (HCP) \| Noncompetition agreements
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives						5 years 8 months 12 days
Amortizable intangible assets						74,650
HealthCare Partners (HCP) \| Trade names
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives						10 years 7 months 6 days
Amortizable intangible assets						170,494
HealthCare Partners (HCP) \| Provider network and practice management tools
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives						7 years
Amortizable intangible assets						$184,264

Aggregate_Purchase_Cost_Alloca

Aggregate Purchase Cost Allocations for Acquisitions of DSI Renal Inc (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Goodwill	$9,415,295	$9,212,974	$8,952,750
Other dialysis acquisitions
Business Acquisition [Line Items]
Current assets	915	7,215	18,708
Property and equipment	5,999	23,760	41,741
Amortizable intangible and other long-term assets	95,293	80,646	90,296
Goodwill	221,514	271,267	554,685
Long-term deferred income taxes		-5,666	-1,838
Noncontrolling interests assumed	-25,963	-22,880	-21,962
Liabilities assumed	-1,883	-19,265	-27,211
Aggregate purchase cost	$295,875	$335,077	$654,419

Aggregate_Purchase_Cost_Alloca1

Aggregate Purchase Cost Allocations for Acquisitions of HCP (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 01, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 01, 2012
Business Acquisition [Line Items]
Goodwill	$9,415,295	$9,212,974	$8,952,750
HealthCare Partners (HCP)
Business Acquisition [Line Items]
Current assets, net of cash acquired				321,235
Property and equipment				102,382
Intangible assets				1,882,818
Other long-term assets				100,143
Goodwill				3,496,713
Current liabilities assumed				-559,180
Other long-term liabilities				-169,015
Long-term deferred income taxes				-184,015
Noncontrolling interests				-29,850
Aggregate purchase cost				$4,961,231

Reconciliation_of_Changes_in_C

Reconciliation of Changes in Contingent Earn-Out Obligations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Business Combinations [Abstract]
Beginning balance	$28,058
Contingent earn-out obligations associated with acquisitions	18,234
Remeasurement of fair value	-4,448
Payments of contingent earn-out obligations	-2,715
Ending balance	$39,129

Results_from_Discontinued_Oper

Results from Discontinued Operations Related to Homechoice (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations	($139)	($222)
HomeChoice Partners
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenues	6,351	67,990
Loss before income taxes	-223	-304
Income tax benefit	-84	-82
(Loss) income from discontinued operations	($139)	($222)

Net_Assets_of_Discontinued_Ope

Net Assets of Discontinued Operations Related to Homechoice (Detail) (HomeChoice Partners, USD $)	Feb. 01, 2013
In Thousands, unless otherwise specified	Feb. 01, 2013
HomeChoice Partners
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets	$17,039
Property and equipment, net	2,963
Long-term assets	28
Goodwill	31,853
Liabilities and noncontrolling interests	-8,998
Net assets from discontinued operations	$42,885

Pro_Forma_Summary_of_Results_o

Pro Forma Summary of Results of Operation (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]
Pro forma net revenues	$12,887,330	$12,160,749
Pro forma net income attributable to DaVita HealthCare Partners Inc.	733,490	651,204
Pro forma income from continuing operations attributable to DaVita HealthCare Partners Inc.	$733,490	$651,204
Pro forma basic net income per share attributable to DaVita HealthCare Partners Inc.	$3.45	$3.10
Pro forma diluted net income per share attributable to DaVita HealthCare Partners Inc.	$3.38	$3.03

Variable_Interest_Entities_Add

Variable Interest Entities - Additional Information (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Asset	$575,074
Liabilities	$311,148

Concentrations_Additional_Info

Concentrations - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Concentration risk, customer	There is no single payor that accounted for more than 10% of total consolidated accounts receivable at December 31, 2014 and 2013.
Accounts Receivable \| Government-based Programs, Medicare and Medicaid
Concentration Risk [Line Items]
Concentration Risk, Percentage	80.00%
Accounts Receivable \| Product Concentration Risk \| Minimum
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
U.S. dialysis and related lab services \| Sales Revenue, Services, Net \| Government-based Programs, Medicare and Medicaid
Concentration Risk [Line Items]
Concentration Risk, Percentage	67.00%	66.00%	66.00%
Accounts receivable, and other receivables, from Medicare and Medicaid-assigned plans	$705,532	$679,006
U.S. dialysis and related lab services \| Sales Revenue, Services, Net \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration Risk, Percentage	2.00%	2.00%
HealthCare Partners (HCP)
Concentration Risk [Line Items]
Number of health plans	3
HealthCare Partners (HCP) \| Sales Revenue, Services, Net \| Government-based Programs, Medicare and Medicaid
Concentration Risk [Line Items]
Concentration Risk, Percentage	71.00%	69.00%
HealthCare Partners (HCP) \| Sales Revenue, Services, Net \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration Risk, Percentage	64.00%	67.00%
HealthCare Partners (HCP) \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration Risk, Percentage	73.00%	69.00%

Assets_Liabilities_and_Tempora

Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Assets
Funds on deposit with third parties	$81,276	$79,317
Liabilities
Contingent earn-out obligations	39,129	28,058
Fair Value, Measurements, Recurring
Assets
Available for sale securities	28,123	19,421
Funds on deposit with third parties	81,276	79,317
Liabilities
Interest rate swap agreements	1,457	12,069
Contingent earn-out obligations	39,129	28,058
Temporary equity
Noncontrolling interests subject to put provisions	829,965	697,300
Fair Value, Measurements, Recurring \| Level 1
Assets
Available for sale securities	28,123	19,421
Funds on deposit with third parties	81,276	79,317
Fair Value, Measurements, Recurring \| Level 2
Liabilities
Interest rate swap agreements	1,457	12,069
Fair Value, Measurements, Recurring \| Level 3
Liabilities
Contingent earn-out obligations	39,129	28,058
Temporary equity
Noncontrolling interests subject to put provisions	829,965	697,300
Fair Value, Measurements, Recurring \| Interest rate cap agreements
Assets
Interest rate derivative agreements	13,934	7,567
Fair Value, Measurements, Recurring \| Interest rate cap agreements \| Level 2
Assets
Interest rate derivative agreements	13,934	7,567
Fair Value, Measurements, Recurring \| Interest rate swap agreements
Assets
Interest rate derivative agreements	3,281	10,004
Fair Value, Measurements, Recurring \| Interest rate swap agreements \| Level 2
Assets
Interest rate derivative agreements	$3,281	$10,004

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	$8,519,642	$8,433,603
Senior Secured Credit Facilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	4,441,292
Debt instrument, fair value	4,420,238
Senior Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument, carrying amount	3,775,000
Debt instrument, fair value	$3,924,715

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Segment
Segment Reporting [Abstract]
Number of Operating Segments	2

Summary_of_Segment_Net_Revenue

Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Patient service revenues	$3,328,017	$3,251,824	$3,172,489	$3,042,776	$3,063,209	$2,999,586	$2,871,673	$2,829,582	$8,868,338		$8,307,195		$7,351,902
Net patient service revenues									8,501,454		8,013,649		7,116,684
Other revenues									1,032,364		763,086		588,260
Total net operating revenues									12,795,106		11,764,050		8,186,280
Capitated revenues									3,261,288		2,987,315		481,336
Operating income	452,085	437,536	484,295	441,225	484,179	377,074	522,020	166,861	1,815,141		1,550,134		1,297,084
Contingent earn-out obligation adjustment											56,977
Corporate support costs									-13,012	[1]	-53,699	[1]	-46,481	[1]
Transaction expenses													-30,753
Operating income	452,085	437,536	484,295	441,225	484,179	377,074	522,020	166,861	1,815,141		1,550,134		1,297,084
Debt expense									-410,294		-429,943		-288,554
Debt refinancing charges									-97,548				-10,963
Other income, net									2,374		4,787		3,737
Consolidated income from continuing operations before income taxes	354,365	336,412	282,308	336,588	380,020	270,766	412,550	61,642	1,309,673		1,124,978		1,001,304
Operating Segments
Segment Reporting Information [Line Items]
Total net operating revenues									12,852,469		11,812,296		8,214,547
Operating income									1,828,153	[2]	1,546,856	[2]	1,374,318	[2]
Operating income									1,828,153	[2]	1,546,856	[2]	1,374,318	[2]
Operating Segments \| U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Patient service revenues									8,550,201		8,032,772		7,316,818
Less: Provision for uncollectible accounts									-353,028		-281,146		-233,580
Net patient service revenues									8,197,173		7,751,626		7,083,238
Other revenues									13,498	[3]	12,600	[3]	11,447	[3]
Total net operating revenues									8,210,671		7,764,226		7,094,685
Operating income									1,637,626	[2]	1,200,198	[2]	1,372,265	[2]
Operating income									1,637,626	[2]	1,200,198	[2]	1,372,265	[2]
Operating Segments \| U.S. dialysis and related lab services \| External Sources
Segment Reporting Information [Line Items]
Patient service revenues									8,513,089		7,998,692		7,299,032
Operating Segments \| U.S. dialysis and related lab services \| Intersegment Revenue
Segment Reporting Information [Line Items]
Patient service revenues									37,112		34,080		17,786
Operating Segments \| HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Net patient service revenues									219,306		220,251		34,407
Other revenues									91,374	[4]	55,723	[4]	23,552	[4]
Total net operating revenues									3,502,299		3,196,188		477,390
Capitated revenues									3,190,903		2,919,964		419,431
Operating income									214,983	[2]	385,253	[2]	66,930	[2]
Operating income									214,983	[2]	385,253	[2]	66,930	[2]
Operating Segments \| HealthCare Partners (HCP) \| Intersegment Revenue
Segment Reporting Information [Line Items]
Other revenues									716		250
Operating Segments \| Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Net patient service revenues									122,087		75,852		16,824
Other revenues									927,492		694,763		553,261
Total net operating revenues									1,139,499		851,882		642,472
Capitated revenues									70,385		67,351		61,906
Operating income									-24,456	[2]	-38,595	[2]	-64,877	[2]
Operating income									-24,456	[2]	-38,595	[2]	-64,877	[2]
Operating Segments \| Other-Ancillary services and strategic initiatives \| Intersegment Revenue
Segment Reporting Information [Line Items]
Total net operating revenues									19,535		13,916		10,481
Intersegment Elimination
Segment Reporting Information [Line Items]
Total net operating revenues									($57,363)		($48,246)		($28,267)

[1]	Corporate support costs in 2013 also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.
[2]	Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.
[3]	Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.
[4]	Other revenues primarily relate to providing medical consulting services.

Summary_of_Segment_Net_Revenue1

Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Corporate support costs, Adjustment to reduce tax	$13,012	[1]	$53,699	[1]	$46,481	[1]
Tax Adjustments
Segment Reporting Information [Line Items]
Corporate support costs, Adjustment to reduce tax			$7,721

[1]	Corporate support costs in 2013 also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.

Summary_of_Depreciation_and_Am

Summary of Depreciation and Amortization Expense by Segment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Depreciation and amortization	$590,935	$528,737	$341,969
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Depreciation and amortization	402,767	355,879	310,375
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Depreciation and amortization	169,485	158,356	24,544
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Depreciation and amortization	$18,683	$14,502	$7,050

Summary_of_Assets_by_Segment_D

Summary of Assets by Segment (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
ASSETS
Total assets	$17,942,715		$17,098,877
U.S. dialysis and related lab services
ASSETS
Total assets	10,959,096		10,248,993
HealthCare Partners (HCP)
ASSETS
Total assets	6,285,984		6,265,767
Other-Ancillary services and strategic initiatives
ASSETS
Total assets	$697,635	[1]	$584,117	[1]

[1]	Includes approximately $44,000 and $26,000 in 2014 and 2013, respectively, of net property and equipment related to the Companybs international operations.

Summary_of_Assets_by_Segment_P

Summary of Assets by Segment (Parenthetical) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Equity investments	$65,637	$40,686
Property and equipment, net	2,469,099	2,189,411
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Equity investments	28,138	27,009
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Equity investments	15,393	13,677
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Equity investments	22,106
Other-Ancillary services and strategic initiatives \| Outside United States
Segment Reporting Information [Line Items]
Property and equipment, net	$44,000	$26,000

Summary_of_Expenditures_for_Pr

Summary of Expenditures for Property and Equipment by Segment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$641,330	$617,597	$550,146
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Expenditures for property and equipment	560,610	554,345	524,180
HealthCare Partners (HCP)
Segment Reporting Information [Line Items]
Expenditures for property and equipment	27,885	31,582	7,464
Other-Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$52,835	$31,670	$18,502

Recovered_Sheet7

Supplemental Cash Flow Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash paid:
Income taxes	$238,615	$341,426	$322,018
Interest	351,967	405,030	257,640
Non-cash investing and financing activities:
Fixed assets under capital lease obligations	$72,389	$60,920	$55,813

Selected_quarterly_financial_d2

Selected quarterly financial data (unaudited) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$3,328,017	$3,251,824	$3,172,489	$3,042,776	$3,063,209	$2,999,586	$2,871,673	$2,829,582	$8,868,338	$8,307,195	$7,351,902
Operating income	452,085	437,536	484,295	441,225	484,179	377,074	522,020	166,861	1,815,141	1,550,134	1,297,084
Income from continuing operations before income taxes	354,365	336,412	282,308	336,588	380,020	270,766	412,550	61,642	1,309,673	1,124,978	1,001,304
Discontinued operations, net of tax.								13,236		13,236	-222
Net income attributable to DaVita HealthCare Partners Inc.	$208,020	$184,122	$147,683	$183,289	$212,278	$136,628	$254,376	$30,164	$723,114	$633,446	$536,017
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.98	$0.87	$0.70	$0.87	$1.01	$0.65	$1.21	$0.08	$3.41	$2.95	$2.79
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$0.98	$0.87	$0.70	$0.87	$1.01	$0.65	$1.21	$0.14	$3.41	$3.02	$2.79
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.96	$0.85	$0.68	$0.85	$0.99	$0.64	$1.18	$0.08	$3.33	$2.89	$2.74
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$0.96	$0.85	$0.68	$0.85	$0.99	$0.64	$1.18	$0.14	$3.33	$2.95	$2.74

Consolidating_Statements_of_In

Consolidating Statements of Income (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Patient service revenues	$3,328,017	$3,251,824	$3,172,489	$3,042,776	$3,063,209	$2,999,586	$2,871,673	$2,829,582	$8,868,338	$8,307,195	$7,351,902
Less: Provision for uncollectible accounts									-366,884	-293,546	-235,218
Net patient service revenues									8,501,454	8,013,649	7,116,684
Capitated revenues									3,261,288	2,987,315	481,336
Other revenues									1,032,364	763,086	588,260
Total net revenues									12,795,106	11,764,050	8,186,280
Operating expenses and charges									10,979,965	10,213,916	6,889,196
Operating income	452,085	437,536	484,295	441,225	484,179	377,074	522,020	166,861	1,815,141	1,550,134	1,297,084
Debt (expense) and refinancing charges									-507,842	-429,943	-299,517
Other income, net									2,374	4,787	3,737
Income tax expense									446,343	381,013	359,845
Income from continuing operations									863,330	743,965	641,459
Discontinued operations								13,236		13,236	-222
Net income									863,330	757,201	641,237
Less: Net income attributable to noncontrolling interests									-140,216	-123,755	-105,220
Net income attributable to DaVita HealthCare Partners Inc.	208,020	184,122	147,683	183,289	212,278	136,628	254,376	30,164	723,114	633,446	536,017
DaVita HealthCare Partners Inc.
Condensed Financial Statements, Captions [Line Items]
Other revenues									684,066	616,155	514,190
Total net revenues									684,066	616,155	514,190
Operating expenses and charges									443,951	434,776	365,680
Operating income									240,115	181,379	148,510
Debt (expense) and refinancing charges									-502,762	-427,141	-331,944
Other income, net									385,532	402,910	265,508
Income tax expense									46,856	59,716	32,912
Equity earnings in subsidiaries									647,085	536,014	486,855
Income from continuing operations										633,446	536,017
Net income									723,114	633,446	536,017
Net income attributable to DaVita HealthCare Partners Inc.									723,114	633,446	536,017
Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Patient service revenues									6,246,683	5,989,658	5,417,800
Less: Provision for uncollectible accounts									-238,600	-177,415	-124,592
Net patient service revenues									6,008,083	5,812,243	5,293,208
Capitated revenues									1,689,634	1,427,321	232,744
Other revenues									1,639,828	1,534,310	745,920
Total net revenues									9,337,545	8,773,874	6,271,872
Operating expenses and charges									8,276,991	7,843,476	5,479,531
Operating income									1,060,554	930,398	792,341
Debt (expense) and refinancing charges									-363,623	-366,188	-207,499
Other income, net									11,731	1,903	4,305
Income tax expense									397,268	303,603	320,267
Equity earnings in subsidiaries									335,691	260,268	218,197
Income from continuing operations										522,778	487,077
Net income									647,085	522,778	487,077
Net income attributable to DaVita HealthCare Partners Inc.									647,085	522,778	487,077
Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Patient service revenues									2,739,996	2,420,975	2,005,424
Less: Provision for uncollectible accounts									-128,284	-116,131	-110,626
Net patient service revenues									2,611,712	2,304,844	1,894,798
Capitated revenues									1,579,804	1,560,244	248,592
Other revenues									24,155	17,867	10,190
Total net revenues									4,215,671	3,882,955	2,153,580
Operating expenses and charges									3,701,199	3,444,598	1,797,347
Operating income									514,472	438,357	356,233
Debt (expense) and refinancing charges									-43,449	-39,413	-27,193
Other income, net									7,103	2,773	1,043
Income tax expense									2,219	17,694	6,666
Income from continuing operations										384,023	323,417
Discontinued operations										13,236	-222
Net income									475,907	397,259	323,195
Net income attributable to DaVita HealthCare Partners Inc.									475,907	397,259	323,195
Consolidating Adjustments
Condensed Financial Statements, Captions [Line Items]
Patient service revenues									-118,341	-103,438	-71,322
Net patient service revenues									-118,341	-103,438	-71,322
Capitated revenues									-8,150	-250
Other revenues									-1,315,685	-1,405,246	-682,040
Total net revenues									-1,442,176	-1,508,934	-753,362
Operating expenses and charges									-1,442,176	-1,508,934	-753,362
Debt (expense) and refinancing charges									401,992	402,799	267,119
Other income, net									-401,992	-402,799	-267,119
Equity earnings in subsidiaries									-982,776	-796,282	-705,052
Income from continuing operations										-796,282	-705,052
Net income									-982,776	-796,282	-705,052
Less: Net income attributable to noncontrolling interests									-140,216	-123,755	-105,220
Net income attributable to DaVita HealthCare Partners Inc.									($1,122,992)	($920,037)	($810,272)

Consolidating_Statements_of_Co

Consolidating Statements of Comprehensive Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Net income	$863,330	$757,201	$641,237
Other comprehensive income (losses)	-22,372	12,652	4,187
Total comprehensive income (losses)	840,958	769,853	645,424
Less: Comprehensive income attributable to noncontrolling interests	-140,216	-123,755	-105,220
Comprehensive income attributable to DaVita HealthCare Partners Inc.	700,742	646,098	540,204
DaVita HealthCare Partners Inc.
Condensed Financial Statements, Captions [Line Items]
Net income	723,114	633,446	536,017
Other comprehensive income (losses)	580	14,868	5,392
Total comprehensive income (losses)	723,694	648,314	541,409
Comprehensive income attributable to DaVita HealthCare Partners Inc.	723,694	648,314	541,409
Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income	647,085	522,778	487,077
Total comprehensive income (losses)	647,085	522,778	487,077
Comprehensive income attributable to DaVita HealthCare Partners Inc.	647,085	522,778	487,077
Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income	475,907	397,259	323,195
Other comprehensive income (losses)	-22,952	-2,216	-1,205
Total comprehensive income (losses)	452,955	395,043	321,990
Comprehensive income attributable to DaVita HealthCare Partners Inc.	452,955	395,043	321,990
Consolidating Adjustments
Condensed Financial Statements, Captions [Line Items]
Net income	-982,776	-796,282	-705,052
Total comprehensive income (losses)	-982,776	-796,282	-705,052
Less: Comprehensive income attributable to noncontrolling interests	-140,216	-123,755	-105,220
Comprehensive income attributable to DaVita HealthCare Partners Inc.	($1,122,992)	($920,037)	($810,272)

Consolidating_Balance_Sheets_D

Consolidating Balance Sheets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	$965,241	$946,249	$533,748	$393,752
Accounts receivable, net	1,525,849	1,485,163
Other current assets	1,385,707	1,040,866
Total current assets	3,876,797	3,472,278
Property and equipment, net	2,469,099	2,189,411
Intangible assets, net	1,949,498	2,024,373
Other long-term assets and investments	232,026	199,841
Goodwill	9,415,295	9,212,974	8,952,750
Total assets	17,942,715	17,098,877
Current liabilities	2,088,652	2,462,049
Long-term debt and other long-term liabilities	9,663,787	9,333,987
Noncontrolling interests subject to put provisions	829,965	697,300
Total DaVita HealthCare Partners Inc. shareholdersb' equity	5,170,513	4,432,479
Noncontrolling interests not subject to put provisions	189,798	173,062
Total equity	5,360,311	4,605,541
Total liabilities and equity	17,942,715	17,098,877
DaVita HealthCare Partners Inc.
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	698,876	602,188	195,037	365,276
Other current assets	362,672	27,910
Total current assets	1,061,548	630,098
Property and equipment, net	195,690	177,633
Intangible assets, net	85,338	77,531
Investments in subsidiaries	8,868,335	8,231,059
Intercompany receivables	3,723,454	3,983,214
Other long-term assets and investments	70,309	61,391
Total assets	14,004,674	13,160,926
Current liabilities	180,977	328,875
Long-term debt and other long-term liabilities	8,124,863	7,948,390
Noncontrolling interests subject to put provisions	528,321	451,182
Total DaVita HealthCare Partners Inc. shareholdersb' equity	5,170,513	4,432,479
Total equity	5,170,513	4,432,479
Total liabilities and equity	14,004,674	13,160,926
Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	77,921	175,004	166,107
Accounts receivable, net	915,851	939,543
Other current assets	930,093	904,852
Total current assets	1,923,865	2,019,399
Property and equipment, net	1,473,188	1,378,017
Intangible assets, net	1,811,218	1,882,685
Investments in subsidiaries	1,561,195	1,391,655
Other long-term assets and investments	60,385	70,728
Goodwill	7,958,221	7,850,910
Total assets	14,788,072	14,593,394
Current liabilities	1,493,243	1,776,419
Intercompany payables	3,105,173	3,426,433
Long-term debt and other long-term liabilities	1,321,321	1,159,483
Total DaVita HealthCare Partners Inc. shareholdersb' equity	8,868,335	8,231,059
Total equity	8,868,335	8,231,059
Total liabilities and equity	14,788,072	14,593,394
Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	188,444	169,057	172,604	28,476
Accounts receivable, net	609,998	545,620
Other current assets	92,942	108,104
Total current assets	891,384	822,781
Property and equipment, net	800,221	633,761
Intangible assets, net	52,942	64,157
Intercompany receivables	564,241	480,993
Other long-term assets and investments	101,332	67,722
Goodwill	1,457,074	1,362,064
Total assets	3,867,194	3,431,478
Current liabilities	414,432	356,755
Intercompany payables	1,182,522	1,037,774
Long-term debt and other long-term liabilities	217,603	226,114
Total DaVita HealthCare Partners Inc. shareholdersb' equity	1,561,195	1,391,655
Noncontrolling interests not subject to put provisions	491,442	419,180
Total equity	2,052,637	1,810,835
Total liabilities and equity	3,867,194	3,431,478
Consolidating Adjustments
Condensed Financial Statements, Captions [Line Items]
Investments in subsidiaries	-10,429,530	-9,622,714
Intercompany receivables	-4,287,695	-4,464,207
Total assets	-14,717,225	-14,086,921
Intercompany payables	-4,287,695	-4,464,207
Noncontrolling interests subject to put provisions	301,644	246,118
Total DaVita HealthCare Partners Inc. shareholdersb' equity	-10,429,530	-9,622,714
Noncontrolling interests not subject to put provisions	-301,644	-246,118
Total equity	-10,731,174	-9,868,832
Total liabilities and equity	($14,717,225)	($14,086,921)

Consolidating_Statements_of_Ca

Consolidating Statements of Cash Flows (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$863,330	$757,201	$641,237
Changes in operating assets and liabilities and non cash items included in net income	596,077	1,016,140	459,611
Net cash provided by operating activities	1,459,407	1,773,341	1,100,848
Cash flows from investing activities:
Additions of property and equipment, net	-641,330	-617,597	-550,146
Acquisitions	-272,094	-310,394	-4,294,077
Proceeds from asset sales	8,791	62,258	3,559
Purchase of investments and other items	-373,096	-11,149	8,214
Net cash used in investing activities	-1,277,729	-876,882	-4,832,450
Cash flows from financing activities:
Long-term debt and related financing costs, net	-7,989	-438,007	3,904,893
Other items	-156,990	-44,984	-32,509
Net cash (used in) provided by financing activities	-164,979	-482,991	3,872,384
Effect of exchange rate changes on cash	2,293	-967	-786
Net increase (decrease) in cash and cash equivalents	18,992	412,501	139,996
Cash and cash equivalents at beginning of the year	946,249	533,748	393,752
Cash and cash equivalents at end of the year	965,241	946,249	533,748
DaVita HealthCare Partners Inc.
Cash flows from operating activities:
Net income	723,114	633,446	536,017
Changes in operating assets and liabilities and non cash items included in net income	-597,992	-443,071	-383,619
Net cash provided by operating activities	125,122	190,375	152,398
Cash flows from investing activities:
Additions of property and equipment, net	-51,374	-55,252	-72,125
Acquisitions			-3,645,760
Proceeds from asset sales		60,650
Purchase of investments and other items	-333,803	-4,944	2,841
Net cash used in investing activities	-385,177	454	-3,715,044
Cash flows from financing activities:
Long-term debt and related financing costs, net	4,513	-421,739	3,909,760
Intercompany borrowing	410,437	585,441	-586,050
Other items	-58,207	52,620	68,697
Net cash (used in) provided by financing activities	356,743	216,322	3,392,407
Net increase (decrease) in cash and cash equivalents	96,688	407,151	-170,239
Cash and cash equivalents at beginning of the year	602,188	195,037	365,276
Cash and cash equivalents at end of the year	698,876	602,188	195,037
Guarantor Subsidiaries
Cash flows from operating activities:
Net income	647,085	522,778	487,077
Changes in operating assets and liabilities and non cash items included in net income	120,772	652,374	15,693
Net cash provided by operating activities	767,857	1,175,152	502,770
Cash flows from investing activities:
Additions of property and equipment, net	-312,191	-337,042	-305,885
Acquisitions	-228,569	-156,830	-564,499
Proceeds from asset sales	8,791	1,608	3,559
Purchase of investments and other items	-316	-3,502	-1,761
Net cash used in investing activities	-532,285	-495,766	-868,586
Cash flows from financing activities:
Long-term debt and related financing costs, net	-12,545	-11,061	-23,805
Intercompany borrowing	-306,011	-664,154	580,825
Other items	-14,099	4,726	-25,097
Net cash (used in) provided by financing activities	-332,655	-670,489	531,923
Net increase (decrease) in cash and cash equivalents	-97,083	8,897	166,107
Cash and cash equivalents at beginning of the year	175,004	166,107
Cash and cash equivalents at end of the year	77,921	175,004	166,107
Non-Guarantor Subsidiaries
Cash flows from operating activities:
Net income	475,907	397,259	323,195
Changes in operating assets and liabilities and non cash items included in net income	90,521	10,555	122,485
Net cash provided by operating activities	566,428	407,814	445,680
Cash flows from investing activities:
Additions of property and equipment, net	-277,765	-225,303	-172,136
Acquisitions	-43,525	-153,564	-83,818
Purchase of investments and other items	-38,977	-2,703	7,134
Net cash used in investing activities	-360,267	-381,570	-248,820
Cash flows from financing activities:
Long-term debt and related financing costs, net	43	-5,207	18,938
Intercompany borrowing	-104,426	78,713	5,225
Other items	-84,684	-102,330	-76,109
Net cash (used in) provided by financing activities	-189,067	-28,824	-51,946
Effect of exchange rate changes on cash	2,293	-967	-786
Net increase (decrease) in cash and cash equivalents	19,387	-3,547	144,128
Cash and cash equivalents at beginning of the year	169,057	172,604	28,476
Cash and cash equivalents at end of the year	188,444	169,057	172,604
Consolidating Adjustments
Cash flows from operating activities:
Net income	-982,776	-796,282	-705,052
Changes in operating assets and liabilities and non cash items included in net income	$982,776	$796,282	$705,052

Supplemental_Data_Condensed_Co

Supplemental Data - Condensed Consolidating Statements of Income (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Patient service revenues	$3,328,017	$3,251,824	$3,172,489	$3,042,776	$3,063,209	$2,999,586	$2,871,673	$2,829,582	$8,868,338		$8,307,195		$7,351,902
Less: Provision for uncollectible accounts									-366,884		-293,546		-235,218
Net patient service revenues									8,501,454		8,013,649		7,116,684
Capitated revenues									3,261,288		2,987,315		481,336
Other revenues									1,032,364		763,086		588,260
Total net revenues									12,795,106		11,764,050		8,186,280
Operating expenses and charges									10,979,965		10,213,916		6,889,196
Operating income	452,085	437,536	484,295	441,225	484,179	377,074	522,020	166,861	1,815,141		1,550,134		1,297,084
Debt (expense) and refinancing charges									-507,842		-429,943		-299,517
Other income, net									2,374		4,787		3,737
Income tax expense									446,343		381,013		359,845
Income from continuing operations									863,330		743,965		641,459
Discontinued operations								13,236			13,236		-222
Net income									863,330		757,201		641,237
Less: Net income attributable to noncontrolling interests									-140,216		-123,755		-105,220
Net income	208,020	184,122	147,683	183,289	212,278	136,628	254,376	30,164	723,114		633,446		536,017
Physician Groups
Condensed Financial Statements, Captions [Line Items]
Patient service revenues									121,929		122,873		20,052
Less: Provision for uncollectible accounts									-8,534		-6,602		-686
Net patient service revenues									113,395		116,271		19,366
Capitated revenues									1,511,000		1,560,244		248,592
Other revenues									6,630		5,239		487
Total net revenues									1,631,025		1,681,754		268,445
Operating expenses and charges									1,601,027		1,659,151		268,205
Operating income									29,998		22,603		240
Debt (expense) and refinancing charges									-11,113		-14,605		-1,386
Other income, net									238		6		54
Income tax expense									1,866		3,523
Income from continuing operations											4,481		-1,092
Net income									17,257		4,481		-1,092
Net income									17,257		4,481		-1,092
Unrestricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Operating expenses and charges									514		457		-1,372
Operating income									-514		-457		1,372
Income tax expense									-206		-183		549
Income from continuing operations											-274		823
Net income									-308		-274		823
Net income									-308		-274		823
Company and Restricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Patient service revenues									8,746,409	[1]	8,184,322	[1]	7,331,850	[1]
Less: Provision for uncollectible accounts									-358,350	[1]	-286,944	[1]	-234,532	[1]
Net patient service revenues									8,388,059	[1]	7,897,378	[1]	7,097,318	[1]
Capitated revenues									1,750,288	[1]	1,427,071	[1]	232,744	[1]
Other revenues									1,025,734	[1]	757,847	[1]	587,773	[1]
Total net revenues									11,164,081	[1]	10,082,296	[1]	7,917,835	[1]
Operating expenses and charges									9,378,424	[1]	8,554,308	[1]	6,622,363	[1]
Operating income									1,785,657	[1]	1,527,988	[1]	1,295,472	[1]
Debt (expense) and refinancing charges									-496,729	[1]	-415,338	[1]	-298,131	[1]
Other income, net									2,136	[1]	4,781	[1]	3,683	[1]
Income tax expense									444,683	[1]	377,673	[1]	359,296	[1]
Income from continuing operations											739,758	[1]	641,728	[1]
Discontinued operations											13,236	[1]	-222	[1]
Net income									846,381	[1]	752,994	[1]	641,506	[1]
Less: Net income attributable to noncontrolling interests									-140,216	[1]	-123,755	[1]	-105,220	[1]
Net income									$706,165	[1]	$629,239	[1]	$536,286	[1]

[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co1

Supplemental Data - Condensed Consolidating Statements of Comprehensive Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Net income (losses)	$863,330		$757,201		$641,237
Other comprehensive income (losses)	-22,372		12,652		4,187
Total comprehensive income (losses)	840,958		769,853		645,424
Less: Comprehensive income attributable to noncontrolling interests	-140,216		-123,755		-105,220
Comprehensive income attributable to DaVita HealthCare Partners Inc.	700,742		646,098		540,204
Physician Groups
Condensed Financial Statements, Captions [Line Items]
Net income (losses)	17,257		4,481		-1,092
Total comprehensive income (losses)	17,257		4,481		-1,092
Comprehensive income attributable to DaVita HealthCare Partners Inc.	17,257		4,481		-1,092
Unrestricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income (losses)	-308		-274		823
Total comprehensive income (losses)	-308		-274		823
Comprehensive income attributable to DaVita HealthCare Partners Inc.	-308		-274		823
Company and Restricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income (losses)	846,381	[1]	752,994	[1]	641,506	[1]
Other comprehensive income (losses)	-22,372	[1]	12,652	[1]	4,187	[1]
Total comprehensive income (losses)	824,009	[1]	765,646	[1]	645,693	[1]
Less: Comprehensive income attributable to noncontrolling interests	-140,216	[1]	-123,755	[1]	-105,220	[1]
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$683,793	[1]	$641,891	[1]	$540,473	[1]

[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co2

Supplemental Data - Condensed Consolidating Balance Sheets (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	$965,241		$946,249		$533,748		$393,752
Accounts receivable, net	1,525,849		1,485,163
Other current assets	1,385,707		1,040,866
Total current assets	3,876,797		3,472,278
Property and equipment, net	2,469,099		2,189,411
Amortizable intangibles, net	1,949,498		2,024,373
Other long-term assets	232,026		199,841
Goodwill	9,415,295		9,212,974		8,952,750
Total assets	17,942,715		17,098,877
Current liabilities	2,088,652		2,462,049
Long-term debt and other long-term liabilities	9,663,787		9,333,987
Noncontrolling interests subject to put provisions	829,965		697,300
Total DaVita HealthCare Partners Inc. shareholdersb' equity	5,170,513		4,432,479
Noncontrolling interests not subject to put provisions	189,798		173,062
Total equity	5,360,311		4,605,541
Total liabilities and equity	17,942,715		17,098,877
Physician Groups
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	112,448		127,309		132,362
Accounts receivable, net	255,953		235,463
Other current assets	18,450		35,640
Total current assets	386,851		398,412
Property and equipment, net	2,406		5,541
Amortizable intangibles, net	6,239		7,283
Other long-term assets	66,087		64,013
Goodwill	9,181		8,981
Total assets	470,764		484,230
Current liabilities	213,609		193,079
Payables to parent	178,371		194,958
Long-term debt and other long-term liabilities	61,895		94,727
Total DaVita HealthCare Partners Inc. shareholdersb' equity	16,889		1,466
Total equity	16,889		1,466
Total liabilities and equity	470,764		484,230
Unrestricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Other long-term assets	2,811		3,325
Total assets	2,811		3,325
Payables to parent	2,811		3,325
Total liabilities and equity	2,811		3,325
Company and Restricted Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Cash and cash equivalents	852,793	[1]	818,940	[1]	401,386	[1]	393,752	[1]
Accounts receivable, net	1,269,896	[1]	1,249,700	[1]
Other current assets	1,367,257	[1]	1,005,226	[1]
Total current assets	3,489,946	[1]	3,073,866	[1]
Property and equipment, net	2,466,693	[1]	2,183,870	[1]
Amortizable intangibles, net	1,943,259	[1]	2,017,090	[1]
Other long-term assets	163,128	[1]	132,503	[1]
Goodwill	9,406,114	[1]	9,203,993	[1]
Total assets	17,469,140	[1]	16,611,322	[1]
Current liabilities	1,875,043	[1]	2,268,970	[1]
Payables to parent	-181,182	[1]	-198,283	[1]
Long-term debt and other long-term liabilities	9,601,892	[1]	9,239,260	[1]
Noncontrolling interests subject to put provisions	829,965	[1]	697,300	[1]
Total DaVita HealthCare Partners Inc. shareholdersb' equity	5,153,624	[1]	4,431,013	[1]
Noncontrolling interests not subject to put provisions	189,798	[1]	173,062	[1]
Total equity	5,343,422	[1]	4,604,075	[1]
Total liabilities and equity	$17,469,140	[1]	$16,611,322	[1]

[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co3

Supplemental Data - Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Cash flows from operating activities:
Net income	$863,330		$757,201		$641,237
Changes in operating and intercompany assets and liabilities and non cash items included in net income	596,077		1,016,140		459,611
Net cash provided by operating activities	1,459,407		1,773,341		1,100,848
Cash flows from investing activities:
Additions of property and equipment	-641,330		-617,597		-550,146
Acquisitions and divestitures, net	-272,094		-310,394		-4,294,077
Proceeds from asset sales	8,791		62,258		3,559
Investments and other items	-373,096		-11,149		8,214
Net cash used in investing activities	-1,277,729		-876,882		-4,832,450
Proceeds from discontinued operations			62,258		3,559
Cash flows from financing activities:
Long-term debt and related financing costs, net	-7,989		-438,007		3,904,893
Other items	-156,990		-44,984		-32,509
Net cash (used in) provided by financing activities	-164,979		-482,991		3,872,384
Effect of exchange rate changes on cash	2,293		-967		-786
Net increase in cash and cash equivalents	18,992		412,501		139,996
Cash and cash equivalents at beginning of the year	946,249		533,748		393,752
Cash and cash equivalents at end of the year	965,241		946,249		533,748
Physician Groups
Cash flows from operating activities:
Net income	17,257		4,481		-1,092
Changes in operating and intercompany assets and liabilities and non cash items included in net income	1,048		4,343		-26,549
Net cash provided by operating activities	18,305		8,824		-27,641
Cash flows from investing activities:
Additions of property and equipment	2,058		-2,262		-4,794
Investments and other items	-16,745
Net cash used in investing activities	-14,687		-2,262		-4,794
Cash flows from financing activities:
Intercompany borrowing	-18,479		-11,615		164,797
Net cash (used in) provided by financing activities	-18,479		-11,615		164,797
Net increase in cash and cash equivalents	-14,861		-5,053		132,362
Cash and cash equivalents at beginning of the year	127,309		132,362
Cash and cash equivalents at end of the year	112,448		127,309		132,362
Unrestricted Subsidiaries
Cash flows from operating activities:
Net income	-308		-274		823
Changes in operating and intercompany assets and liabilities and non cash items included in net income	308		274		-823
Company and Restricted Subsidiaries
Cash flows from operating activities:
Net income	846,381	[1]	752,994	[1]	641,506	[1]
Changes in operating and intercompany assets and liabilities and non cash items included in net income	594,721	[1]	1,011,523	[1]	486,983	[1]
Net cash provided by operating activities	1,441,102	[1]	1,764,517	[1]	1,128,489	[1]
Cash flows from investing activities:
Additions of property and equipment	-643,388	[1]	-615,335	[1]	-545,352	[1]
Acquisitions and divestitures, net	-272,094	[1]	-310,394	[1]	-4,294,077	[1]
Proceeds from asset sales	8,791	[1]
Investments and other items	-356,351	[1]	-11,149	[1]	8,214	[1]
Net cash used in investing activities	-1,263,042	[1]	-874,620	[1]	-4,827,656	[1]
Proceeds from discontinued operations			62,258	[1]	3,559	[1]
Cash flows from financing activities:
Long-term debt and related financing costs, net	-7,989	[1]	-438,007	[1]	3,904,893	[1]
Intercompany borrowing	18,479	[1]	11,615	[1]	-164,797	[1]
Other items	-156,990	[1]	-44,984	[1]	-32,509	[1]
Net cash (used in) provided by financing activities	-146,500	[1]	-471,376	[1]	3,707,587	[1]
Effect of exchange rate changes on cash	2,293	[1]	-967	[1]	-786	[1]
Net increase in cash and cash equivalents	33,853	[1]	417,554	[1]	7,634	[1]
Cash and cash equivalents at beginning of the year	818,940	[1]	401,386	[1]	393,752	[1]
Cash and cash equivalents at end of the year	$852,793	[1]	$818,940	[1]	$401,386	[1]

[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts (Detail) (Allowance for uncollectible Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for uncollectible Accounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of year	$237,143	$245,122	$250,343
Acquisitions			7,752
Amounts charged to income	381,337	298,711	243,377
Amounts written off	375,806	306,690	256,350
Balance at end of year	$242,674	$237,143	$245,122